

**BARBARA VAN DER POL, PhD, MPH**  
**CURRICULUM VITAE**  
**University of Alabama at Birmingham**  
**School of Medicine**

*Barbara Van Der Pol*

16 July 2024

**RANK/TITLE**

Rank: Professor  
Department: Medicine – Division of Infectious Diseases  
Business Address: 238 Zeigler Research Building  
703 19<sup>th</sup> Street South  
Birmingham, AL 35294

**HOSPITAL AND OTHER (NON ACADEMIC APPOINTMENTS)**

July 2022 – Feb 2026 Chair, Microbiology Devices Panel of the Medical Devices Advisory Committee to the Food and Drug Administration (SGE)  
May 2019 – present Associate Scientist, Center for Women’s Reproductive Health  
Jan, 2018 – present Scholar, Sparkman Center for Global Health, UAB  
Aug 2016 – Aug 2023 Special Government Employee Advisor to the FDA Center for Devices & Radiological Health Microbiology Panel  
Feb, 2014 – present Director, Infectious Diseases STD Clinical Research Organization, UAB School of Medicine  
Aug, 2013 – present Director, Infectious Diseases STD Laboratory, UAB School of Medicine  
May, 2013 – present Affiliated Faculty, The Kinsey Institute  
Aug, 2012 –July, 2013 Director, Graduate Studies in Epidemiology & Biostatistics  
May, 2009 –July, 2013 Center for Sexual Health Promotion, Core Faculty  
July, 2007 –July, 2013 Director, Infectious Diseases Laboratory, Indiana University School of Medicine

**PROFESSIONAL CONSULTANTSHIPS**

Sep 2023 – Aug 2028 Chair, Johns Hopkins Center for Innovative Diagnostics for Infectious Diseases External Advisor Board

June 2023 – present	Abbott Rapid Diagnostics Advisory Board
Oct 2021 – present	Project Red Talon Working Group, Johns Hopkins Center for Indian Health
July 2020 – Dec 2020	Roche Diagnostics SARS-CoV-2 Advisory Board
July 2019 – present	Johns Hopkins POC Development External Advisory Board
Nov 2018 – Nov 2019	STD Clinic Initiative Advisory Board
June 2018 -	Abbott Molecular Diagnostics Medical Advisory Board
Mar 2018 – 2021	National Coalition of STD Directors, Advisor to Industry Advisory Board
June 2016 – June 2018	Consultant, African Society for Laboratory Medicine (Caribbean Region)
Mar 2016 – present	BD Diagnostics Advisory Board
Jul 2015 – present	External reviewer for Johns Hopkins Point of Care Developmental Applications
May 2014 –2015	Melinta Medical Advisory Board
Dec. 2013 – present	Consultant, AFENET/CDC (Caribbean Region)
Sept. 2013 – present	Roche Molecular Diagnostics Medical Advisory Board
Oct. 2013 – present	Atlas Genetics Clinical Advisory Board
Jan. 2012	Becton Dickinson Women’s Health Advisory Board
May 2010	Abbott TB Diagnostics Advisory Board
May 1999 – 2013	US Consultant, AMPATH Reference Laboratory, Eldoret, Kenya

## **EDUCATION**

### **Undergraduate**

Dec, 1980      BS, Biological Sciences, Honors Program      Indiana University, Bloomington, IN

### **Graduate**

May, 2000      Masters of Public Health, Epidemiology      Indiana University, Indianapolis, IN

Oct, 2007      Doctor of Philosophy, Health Behavior      Indiana University, Bloomington, IN

## **MILITARY SERVICE**

None

## **LICENSURE**

None

## **ACADEMIC APPOINTMENTS**

Oct 2019 – present	Professor of Medicine	UAB School of Medicine
Oct 2019 – present	Professor of Health Behaviors	UAB School of Public Health
Aug, 2013 – 2019	Associate Professor	UAB School of Medicine
May, 2013 – present	Affiliated Faculty	The Kinsey Institute, Indiana University
July, 2012 – July, 2013	Associate Professor	Indiana University School of Public Health
July, 2012 – July, 2013	Joint Appointment	Indiana University School of Medicine,
July, 2010 – July, 2013	Assistant Professor	Indiana University School of Public Health
July, 2010 – July, 2013	Joint Appointment	Indiana University School of Medicine,
July, 2010 – July, 2013	Joint Appointment	African Studies Program,
July, 2007 – June, 2010	Assoc Res Professor	Indiana University School of Medicine

## AWARDS/HONORS/ELECTED POSITIONS

2024 – Present	<b>Fellow</b> , American College of Epidemiology
2021 – 2025	<b>President</b> , International Society for STD Research
2021 – 2025	<b>Executive Committee Member</b> , International Union Against Sexually Transmitted Infections World
2021 – 2025	<b>Treasurer</b> , European Study Group for Mycoplasma and Chlamydia Executive Committee (a part of the European Society for Microbiology and Infectious Diseases)
2021 – 2023	<b>Past-President</b> , American STD Association
2021 – 2022	<b>Mentorship Project Award</b> , American Academy of Health Behaviors
2020	<b>Distinguished Alumnus</b> , Indiana University Fairbanks School of Public Health
2019 – 2021	<b>President-Elect</b> , International Society for STD Research
2018 – 2021	<b>President</b> , American STD Association
2015 – 2023	<b>Member</b> , ISSTDR Foundation
2014 – 2016	<b>Member</b> , American STD Association Executive Committee
2013 – 2019	<b>Secretary General</b> , International Society for STD Research
2009 - 2019	<b>Member</b> , International Society for STD Research Executive Board
2000	<b>Inductee</b> , Delta Omega Honorary Society in Public Health
2004 –2005	<b>President</b> , Indiana University Department of Public Health, Alumni Association

## PROFESSIONAL SOCIETIES

2017	European Society for Clinical Microbiology and Infectious Diseases
2017	National Coalition of STD Directors
2014	African Society for Laboratory Medicine
2011	American College of Epidemiology
2007	American Sexual Health Association
2006	American Academy of Health Behavior
2000	American Public Health Association
2000	International Union against Sexually Transmitted Infections
1989	American Sexually Transmitted Diseases Association
1984	American Society for Microbiology

## BOARDS/COUNCILS/COMMITTEES

2024 – 2025	<b>Member</b> , RIGHT Foundation Panel of Experts
2024 – 2025	<b>Consultant</b> , WHO Technical Specification Series for STI Diagnostics
2023 – 2028	<b>Chair</b> of the Johns Hopkins Center for Innovative Diagnostics for Infectious Diseases External Advisory Board
2023 – 2025	<b>Member</b> , National Sexual Health Conference (NSHC) Board of Directors
2023 – 2024	<b>Member</b> , CDC STD Laboratory Diagnostics Guidelines Advisory Panel
2022 – present	<b>Member</b> , CARBx Advisory and Grant Review Board

2021 – 2023	<b>Member</b> , World Health Organization Technical Advisory Group (TAG) on Sexually Transmitted Infection (STI) research priority setting
2020 – 2022	<b>Member</b> , International Symposium on Human Chlamydial Infections Steering Committee
2018 – 2021	<b>Chair</b> , North American Region, International Union Against STIs
2018 – 2020	<b>Member</b> , STD Clinic Advisory Board (National Coalition of STD Directors)
2018 – present	<b>Scholar</b> , Sparkman Center for Global Health
2014 – 2017	<b>Ad hoc member</b> , NIH Study Section ZRG1 IDM-W-(50) R
2014 – 2017	<b>Ad hoc member</b> , NIH Study Section ZRG1 IDM-V (81) A
2016	<b>Reviewer</b> , biennial African Society for Laboratory Medicine meeting
2014 – 2016	<b>Member</b> , NIH Study Section ZRG1 IDM-V (12)
2012-13	<b>Reviewer</b> , IU Collaborative Research Grants
2011– 2012	<b>Member</b> , CDC Advisory Committee for the 2012 National STD Prevention Meeting
2011	<b>Member</b> , NIH Study Section ZAI-FDS-M (S1)
2011 – 2014	<b>Chair</b> , Kinsey Institute Student Research Grant Review Committee
2011 – 2013	<b>Member</b> , Indiana University GLBT Advisory Board
2010 – 2013	<b>Member</b> , WHO Revision of Laboratory Diagnostics Manual Group
2010 – 2013	<b>Member</b> Expert Panel for Duration of CT Infection, University of Bristol, UK
2008 – 2014	<b>Core Leader</b> AMPATH Research Executive Committee
2010	<b>Member</b> , CDC National Action Plan for Prevention, Detection & Management of Infertility
2009	<b>Member</b> , CDC STD Diagnostic Guidelines Workgroup
2008	<b>Member</b> , CDC Chlamydia Immunology Expert Panel
2006 – 2009	<b>Volunteer</b> , Clinical Laboratory Standards Institute PEPFAR (Africa)
2005	<b>Subject Matter Expert</b> , CDC Region V Infertility Prevention Project

#### **PARTICIPATION AT NATIONAL & INTERNATIONAL MEETINGS**

2025	<b>Symposium Organizer:</b> Impact of including a measure of viability in molecular diagnostic tests. Presented at the ESCMID annual meeting, Vienna April 2025
2024	<b>Symposium Organizer:</b> Changing the Sexually Transmitted Infection Control Paradigm: Novel Diagnostic and Treatment Strategies. Presented at the Association for Diagnostic and Laboratory Medicine annual meeting. Chicago 31 July 2024
2023	<b>Symposium Organizer:</b> The Way Forward for Home Collection of STI Samples – Input from CDC, NIH and FDA. Presented at the International Society for STD Research 25 <sup>th</sup> biennial meeting [Chicago, 2023]
2021 – 2023	<b>Chair</b> , International Society for STD Research 25 <sup>th</sup> biennial meeting [Chicago, 2023]
2020 – 2022	<b>Organizer</b> , Julius Schachter International Symposium on Human Chlamydial Infections, June 2022
2021 – 2022	<b>Co-Chair</b> , Improving HIV/STI/Hepatitis Testing Conference, March 2022
2017 – 2022	<b>Organizer</b> , ASTDA Public Health/Industry/Academia Workshop [2018, 2019, 2020, 2021, 2022]
2021	<b>Talk Show Host</b> International Society for STD Research biennial meeting, Amsterdam, July 2021

- 2021 **Judge:** Poster & Oral presentation judge at the International Society for STD Research biennial meeting, Amsterdam, July 2021
- 2021 – 2022 **Co-Chair,** ASTDA/CDC HIV Diagnostics Conference [Atlanta March 2022]
- 2020 – 2022 **Organizer,** International Symposium on Human Chlamydial Infections [San Antonio, 2022]
- 2020 – 2021 **Member,** Sexual Health Conference Organizing Committee
- 2019 – 2021 **Member,** 2021 ISSTDR Fundraising Committee
- 2019 – 2021 **Member,** 2021 ISSTDR Scholarship Committee
- 2019 **Symposium organizer:** ISSTDR Special Symposium. The impact of advances in diagnostic technology on policy at the International Society for STD Research biennial meeting, Vancouver, July 2019
- 2019 **Judge:** Poster presentation judge at the International Society for STD Research biennial meeting, Vancouver, July 2019
- 2018 – 2020 **Co-Chair,** ASTDA/CDC STD Prevention meeting [Atlanta 2020]
- 2018 – 2019 **Co-Chair,** ASTDA/CDC HIV Diagnostics Conference [Atlanta March 2019]
- 2018 – 2019 **Reviewer,** 2019 ISSTDR Behavioral Track
- 2018 – 2019 **Member,** 2019 ISSTDR Scholarship Committee
- 2018 – 2019 **Member,** 2019 ISSTDR Fundraising Committee
- 2018 **Reviewer:** Abstracts for the biennial meeting of the African Society for Laboratory Medicine
- 2018 **Plenary Moderator:** Defining the Future of STD Prevention & Care: Past, Present & Future at the STD Engage Meeting of the National Coalition of STD Directors, Orlando, FL Nov 2018
- 2018 **Symposium Chair:** The Role of the Laboratory in Controlling STIs at the IUSTI Asia Pacific Sexual Health Congress, Auckland Nov 2018
- 2018 **Organizer & Judge:** Poster and Oral Presentations Awards. ASTDA/CDC STD Prevention Conference. Washington, DC Aug 2018
- 2018 **Symposium Chair:** From Bench To Bedside: Advances In Laboratory Diagnostics at the ASTDA/CDC STD Prevention Conference Washington, DC Aug 2018
- 2018 **Plenary Moderator:** Opioids and STDs at the ASTDA/CDC STD Prevention Conference Washington, DC August 2018
- 2017 – 2018 **Scientific Track Chair,** ASTDA/CDC STD Prevention Meeting [Washington, DC 2018]
- 2017 – 2018 **Organizer,** International Symposium on Human Chlamydial Infections [Zeist, The Netherlands, 2018]
- 2017 – 2018 **Member,** IDSA Diagnostic Committee
- 2017 **Chair:** New technologies for diagnosis, characterization and control of STIs/HIV Symposium. STI & HIV World Congress. Rio de Janeiro July 2017
- 2016 – 2018 **President Elect,** American STD Association
- 2016 – 2017 **Chair,** ISSTDR Scholarship Committee 2016
- 2016 **Symposium Chair:** Bacterial Vaginosis, IUSTI Asia Pacific Conference, Okyama, Japan Dec 2016
- 2016 **Commentator:** Poster Grand Rounds Presentation. 2016 STD Prevention Conference. Atlanta Sep 2016

- 2016 **Judge:** Poster and Panel Presentations. 2016 STD Prevention Conference. Atlanta Sep 2016
- 2016 **Reviewer:** Abstract reviewer for the biennial meeting of the African Society for Laboratory Medicine
- 2016 **Session Moderator:** Diagnostics. 8<sup>th</sup> Meeting of the European Society for Chlamydia Research. Oxford, UK. Sep 2016
- 2016 **Session Panelist:** Surviving & Thriving: ASTDA Workshop for Young Investigators. IUSTI World Meeting. Marrakech. May 2016
- 2016 **Session Chair:** Advancing Prevention of STI through Innovations in Diagnostic Technology: Opportunities and New Horizons. IUSTI World Meeting, Marrakech. May 2016
- 2016 **Session Moderator:** STI POC Policy Research Priorities. 2016 STAR STI-CTG Programmatic Meeting for POC STI Diagnostics, Silver Springs, MD Apr 2016
- 2015 **Session Moderator:** Molecular Detection of Antimicrobial Resistance. 21<sup>st</sup> Biennial meeting of the ISSTD, Brisbane Australia Sep 2015
- 2014 – 2016 **International Organizer,** 8<sup>th</sup> Meeting of the European Society for Chlamydia Research [Oxford, UK, 2016]
- 2014 – 2016 **Member,** Scientific Organizing Committee, 8<sup>th</sup> Meeting of the European Society for Chlamydia Research [Oxford, UK, 2016]
- 2014 **Session Moderator:** Chlamydia Diagnostics Session. 13<sup>th</sup> International Symposium on Human Chlamydial Infections. Pacific Grove June 2014
- 2013 **Session Moderator & Presenter:** STI & AIDS World Congress Roche Symposium. Next Generation CT/NG Screening: Results from the VENUS Clinical Trial. Presented at the 20<sup>th</sup> Biennial meeting of the ISSTD, Vienna Austria July 2013
- 2013 **Session Moderator:** Alternative Screening Tools and Screening Sites. 20<sup>th</sup> Biennial meeting of the ISSTD, Vienna Austria July 2013
- 2011 **Rapporteur:** Clinical & Basic Sciences Tracks, Biennial meeting of the International Society for STD Research, Quebec City, Canada, July 2011
- 2011 – 2013 **Co- Chair,** ISSTD/IUSTI Congress Unification Committee
- 2010 – 2011 **Chair,** ISSTD Early Career Development Committee
- 2008 **Session Moderator:** NIH Microbicide Workshop, 2008
- 2006 **Member,** Organizing Committee, NIH Self-Obtained Vaginal Swab Workshop

#### UNIVERSITY SERVICE ACTIVITIES

- 2021 – 2024 UAB DOM Appointment, Promotions & Tenure Committee, **Member**
- 2018 – 2021 UAB Research Administration Network Group **Member**
- 2018 UAB DOM Clinical Trials Task Force **Member**
- 2018 – 2020 UAB DOM Research Development Group **Chair**
- 2016 – 2018 UAB DOM Research Development Group **Member**
- 2016 - 2018 UAB DOM Restructuring Research Incentives & Rewards Committee **Chair**
- 2016 - UAB DOM Scientific Review Committee Clinical **Reviewer and Vice-Chair**
- 2016 - 2018 UAB DOM Mentorship Assessment Task Force **Chair**
- 2016 UAB DOM Medicine Trainee Research Symposium **Judge**
- 2015 – UASOM Admissions Committee **Member**

2015 UAB DOM Medicine Trainee Research Symposium **Judge**  
2014 UAB DOM Strategic Planning PhD Working Group **Member**  
2013 – UASOM Department of Medicine Research Strategic Planning Committee **Member**  
2014 – UASOM/UAB Undergraduate Health Professional Mentoring Program **Member**  
2012-2013 Indiana University School of Public Health Promotion & Tenure Committee  
2012-2013 Indiana University School of Public Health MPH Concentration Coordinators' Committee  
2012-2013 Indiana University School of Public Health Research Committee  
2012-2013 Indiana University School of Public Health Graduate Studies Committee  
2012-2013 Indiana University School of Public Health Epidemiology & Biostatistics Faculty Search Committee  
2012 Indiana University Women in Science Competition Judge  
2012 Indiana University School of Public Health Reviewer, Faculty Research Support Program  
2012-2013 Indiana University Internal Review Board, Behavioral Research  
2011 Indiana University HPER Global Advisory Committee  
2011-2012 Indiana University Epidemiology Chair Search Committee  
2011-2012 Indiana University Community & Urban Health Project Development Team  
2011 Indiana University Women in Science Competition Judge  
2010-2012 Indiana University MPH Leadership Committee for School of HPER  
2010-2011 Indiana University Epidemiology Faculty Search Committee

## **EDITORIAL BOARD MEMBERSHIPS**

### **Associate Editor**

Sexually Transmitted Diseases

### **Editorial & Review Boards**

Journal of Clinical Microbiology

Expert Review of Molecular Diagnostics

American Journal of Health Behavior Review Board Member

### **Ad Hoc Reviewer**

American Journal of Public Health

Antimicrobial Agents & Chemotherapy

Clinical Infectious Diseases Journal of Clinical Microbiology

Clinical & Vaccine Immunology

Expert Review of Molecular Diagnostics

Infection & Immunology

Journal of Adolescent Health

Journal of the American Medical Association

Journal of Infectious Diseases

Journal of Mathematical Analysis and Application

Journal of Sex Research

Journal of Sexual Medicine

Microbes & Infection

PLOS One

Retrovirology: Research & Treatment

Sexual Health  
WHO/STD Diagnostics Initiative

**MAJOR RESEARCH INTERESTS**

I have been involved in laboratory-based epidemiologic and behavioral research in the field of sexually transmitted infections (STI) and HIV for more than 35 years. I have extensive experience with development and evaluation of molecular diagnostic assays and I have spent 2 decades working in sub-Saharan Africa and the Caribbean region providing technology transfer, capacity building and quality improvement training. My research and service interests align as I try to assess how to best use new diagnostic tools to provide increased access to and utilization of sexual health care.

**TEACHING EXPERIENCE**

**Invited Guest Lectures**

Spring	2019	E605	Epidemiology of HPV
Spring	2019	E605	Vaccine Ethics
Spring	2018	E605	Epidemiology of HPV
Spring	2018	E605	Vaccine Ethics
Spring	2017	E605	Epidemiology of HPV
Spring	2017	E605	Vaccine Ethics
Spring	2016	E605	Epidemiology of HPV
Spring	2015	E698	Epidemiology of HPV

**Courses Taught**

Spring	2024	ESCMID Post-Graduate Workshop on Intracellular Pathogens	
Spring	2024	ESGMAC Early Career Workshop:	
Fall	2023	Managing Quality in Clinical Labs, week long course in 2 countries	
Spring	2013	E624	Social Epidemiology
Spring	2013	E698	MPH Culminating Experience in Epi
Fall	2012	C650	MPH Culminating Experience in Epidemiology
Fall	2012	Y619	Infectious Diseases Epidemiology
Spring	2012	C624	Social Epidemiology
Fall	2011	T590	Introduction to Research Methods
Fall	2010	T590	Introduction to Research Methods
Spring	2010	H594	Program Evaluation

**Curriculum Development**

***MPH Epidemiology Concentration – Indiana University 2010-2011***

Development of required competencies  
 Development of required course content for Introduction to Research, Introduction to Epidemiology, Infectious Diseases Epidemiology & Social Epidemiology  
 Development of Core Culminating Examination

***PhD in Epidemiology – Indiana University 2010-2011***

Development of program requirements



## Development of required competencies

**Graduate Advising**

2018	Clarisse Engowei	PhD – Epidemiology
2013	Randy Hubach	PhD – Health Behaviors
2013	Margo Mullinax	PhD – Health Behaviors
2013	Kristen Gillett-Heacock	MPH – Epidemiology
2013	Gauri Desai	MPH – Epidemiology
2012	Emily McDonald	MPH – Epidemiology
2012	Jake Hunnicutt	MPH – Epidemiology
2012	Chanelle Wactor	MPH – Epidemiology
2011	Sarah Mae Hizon	MPH – Epidemiology
2011	Phillip Aka	MPH – Epidemiology
2011	Stephanie Flemming	MPH - Epidemiology
2010	Veronica Halsema	MPH – Epidemiology
2010	Michael Mannell	MPH - Epidemiology
2010	Rickie Marker-Hoffman	MPH – Epidemiology

***Graduate Thesis/Dissertation Committees***

Alison Footman	University of Alabama at Birmingham, School of Public Health. Committee co-Chair
Steven G. Badman	University of New South Wales, Graduate Research School / Kirby Institute. Dissertation examiner
Riona Matadin	University of KwaZulu-Natal, School of Laboratory Medicine and Medical. Dissertation examiner Sciences
Lisa Natoli	University of New South Wales, Graduate Research School. Dissertation examiner
Alissa Davis	Indiana University Department of Epi/Biostats; Member, Qualifying Exam Committee
April Bell	Indiana University Department of Epi/Biostats; Chair, Qualifying Exam Committee
Samantha Scott	Indiana University Department of Kinesiology, Master's Thesis Committee
Chris Robbins	Indiana University Department of Applied Health Sciences, Doctoral Dissertation Committee
Daniel Yeung	Indiana University Department of Epi/Biostats, Qualifying Exam Committee
Andreia Alexander	Indiana University Department of Applied Health Sciences, Doctoral Dissertation Committee
Josh Rosenberger	Indiana University Department of Applied Health Sciences, Doctoral Dissertation Committee
Jasmine Newman	Indiana University Department of Biology, Doctoral Dissertation Committee; Chair, Qualifying Exam Committee
Emily Hamilton	Indiana University Department of Kinesiology, Master's Thesis Committee
Leah Tanen	Indiana University Department of Kinesiology, Master's Thesis Committee
Rose Ayikukwei	Indiana University Department of Applied Health Sciences, Doctoral Dissertation Committee

Alexis Roth Indiana University Department of Applied Health Sciences, Doctoral Dissertation Committee

***Other Mentoring***

Stacey Griner	University of North Texas Health Sciences Center
Casey Pinto	Penn State University – Hershey Campus
Brandie Taylor	Temple University
Latesha Eloppe	UAB SOM Fellow/Early Career
Nathan Stupiansky	IU Adolescent Medicine Post-Doctoral Fellow
Juanita Brand	Marion County Health Department/Ball State University, early career development mentee
Sue Mavedzenge	London School of Hygiene and Tropical Medicine Doctoral student
Simon Mates	Howard Medical Student Summer Internship Program
Andrew Smith	IU Department of Public Health Master’s Project Preceptor
Valerie Suggs	IU Department of Public Health Master’s Project Preceptor
Aneesh Tosh	IU Adolescent Medicine Fellow
Ryan Ly	IU Department of Public Health Master’s Project Preceptor
Emily Jarvis	IU Department of Public Health Master’s Project Preceptor
Michael Hogan	Howard Medical Student Summer Internship Program
Katrina Samuels	Howard Medical Student Summer Internship Program
Amanda Army	Indiana University School of Medicine
Colleen Kendrick	Indiana University School of Medicine 3rd & 4th year Student Rotations
Greg Dawkins	Howard Medical Student Summer Internship Program
Vivian Ghindi	Howard Medical Student Summer Internship Program

**INVITED LECTURES – International**

- 2024 STI Diagnostic Options Now and in the Future. Presented at the Technical consultation on WHO prequalification performance study requirements for IVDs for *Neisseria gonorrhoeae*, *Chlamydia trachomatis* and *Trichomonas vaginalis* NAT (TSS-24), *Neisseria gonorrhoeae* and *Chlamydia trachomatis* RDTs (TSS-25 & TSS-26) and self-testing requirements for syphilis RDTs (TSS-27). 20 August 2024
- 2024 The STI Diagnostic Landscape: A US-Centric Update. Presented at the WHO Mobilize for action on STI in collaboration with IAS & IUSTI. 21 July 2024
- 2024 How to Diagnose Human *Chlamydia trachomatis* Infections. Presented at the ESCMID Post-graduate Course in Lausanne, Switzerland. 27 May 2024
- 2024 Where are we with STI POC testing? Presented at the European Society for Clinical Microbiology & Infectious Diseases, April 27, 2024
- 2023 Moderator & Speaker: Building the Road to Remote Collection & Testing. Presented at International Society for STD Research biennial meeting, July 24, 2023
- 2022 Keynote: Update on *Chlamydia* Diagnostics. Presented at the Julius Schachter International Symposium on Human Chlamydial Infections, June 22, 2022
- 2021 Comprehensive Diagnosis of Genital Discharge in Women. Presented at the Japanese Society for STI Annual Meeting. 26 Nov 2021
- 2016 Advances in *Trichomonas vaginalis* diagnostics and research. Mini-Plenary session at the 17<sup>th</sup> IUSTI World Congress. Marrakech. May 2016
- 2013 Results for **Today**: Screening women quickly for CT/GC using the Xpert assay. Presented at the 20<sup>th</sup> Biennial meeting of the ISSTD, Vienna Austria July 2013
- 2013 Molecular Testing: The Newest Technology to Diagnose Vaginitis caused by STIs. Presented at the 20<sup>th</sup> Biennial meeting of the ISSTD, Vienna Austria July 2013
- 2013 New WHO STI Guidelines: Introduction and scaling up implementation, what does it take? Presented at the 20<sup>th</sup> Biennial meeting of the ISSTD, Vienna Austria July 2013
- 2012 Moving Forward with Self-Obtained Samples. Presented at the British Association for Sexual Health & HIV and American STD Association joint meeting. Brighton, UK June 2012.
- 2011 A Major Advancement in the Molecular Diagnosis and Typing of Herpes Simplex Virus Infections using the BD HSV Qx Assays on the BD Viper System. Presented at the biennial meeting of the International Society for STD Research, Quebec City, Canada, July 2011
- 2011 Performance of the cobas® 4800 System for Detection of *Chlamydia* & *Gonorrhea* in Women. Presented at the biennial meeting of the International Society for STD Research, Quebec City, Canada, July 2011
- 2011 HSV, *Trichomonas* and HIV: The Perfect Storm. Presented as a part of “Translating New Research Findings in STIs into Sexual Health and Clinical Practice”. New Delhi, India. November 2011 [Continuing Medical Education (CME) credits given]
- 2010 To Pee or Not to Pee? What is the Best STD Test for ME? Presented at Society for Adolescent Health & Medicine Annual Meeting, Toronto, Ontario, April 2010
- 2010 Global TB Epidemiology Update. Presented at the Abbott TB Diagnostic Advisory Board Meeting, London May 2010
- 2010 Time Motion Analysis of *Chlamydia*/*Gonorrhea* Diagnostic Systems. Presented at the Rotkreuz Symposium 2010, Rotkreuz, Switzerland, Nov 2010
- 2010 Interpreting Clinical Trial Data for US FDA Submissions. Keynote Lecture. Presented at the Rotkreuz Symposium 2010, Rotkreuz, Switzerland, Nov 2010

- 2009 Vaginal Swabs: The Recommended Specimen Type for CT/GC Screening in Women. Presented at the 18th International Society for STD Research Bi-annual Meeting, London, June 2009
- 2009 Expanding the Horizons of Chlamydia and Gonorrhea Screening (session Moderator). Expanding Opportunities: A Variety of Sample Collection Possibilities for CT/GC Screening. Presented at the 18th International Society for STD Research Bi-annual Meeting, London, June 2009

### **INVITED LECTURES – National**

- 2024 Changing Access to STI Diagnostics: Improving Reach with New Technologies & Applications. Presented at the Association for Diagnostics and Laboratory Medicine annual meeting, Chicago 31 July 2024
- 2024 Keynote Plenary: Can we get there from here: remote testing for STIs. Presented at the STI ENGAGE Annual Meeting, June 5, 2024
- 2023 Pan American Clinical Virology Society Annual meeting: What's New with Non-Viral STI Testing?
- 2022 Strategies for Detection of *Mycoplasma genitalium*. Presented at the Infectious Diseases Society of Obstetrics and Gynecology. 5 August 2022
- 2022 Direct to Consumer STI Testing Services. Presented at the American Society for Microbiology. 12 June 2022
- 2022 Improved Options for Vaginal and Sexual Healthcare. Presented at the American College of Obstetrics and Gynecology Annual Meeting, 6 May 2022
- 2022 Highlights of the 2022 Advancing HIV/STI/Hepatitis Diagnostic Conference, at the American Public Health Laboratories Annual Conference, 20 May 2022
- 2022 STD Diagnostics 101: STI Testing Technology. Presented at the CDC/ASHA/ASTDA/APHL sponsored HIV, STI and Hepatitis Meeting. 29 Mar 2022
- 2021 Testing Technologies as Enhancers of DIS Activities: Lessons from COVID-19 and Beyond. Presented at the CDC Disease Intervention Specialist Conference. 10 Sep 2021
- 2018 What's on the Way and Where Will It Take Us? Presented at the STD Prevention Meeting, Aug 2018, Washington DC
- 2017 Strange Bedfellows: The value of public/private partnerships. Presented at the National Coalition of STD Directors Annual Meeting, Nov 2017, Washington DC
- 2016 Reducing missed opportunities: Reconnecting HIV & STI screening. Presented at the 2016 HIV Diagnostics Conference. Atlanta. Mar 2016
- 2016 Running amok: When technology outpaces the regulatory framework. Presented at the STAR STI Clinical Trials Group Programmatic Meeting for Diagnostics. Washington DC. Apr 2016
- 2016 Use of cell phones to collect daily diary data in studies of sexual behaviors. Presented at the Innovative Uses of Technology in HIV Clinical Trials Workshop. Newark. Apr 2016
- 2016 Incorporating trichomonas screening with CT/GC testing using the BD MAX Multi-Plex assay. Presented at the 32<sup>nd</sup> annual Clinical Virology Symposium, Daytona Beach, FL May 2016
- 2015 Update on the CDC STD Diagnostic Guidelines. UAB STD Training Center Presentation to California Department of Health Laboratory Directors Annual Meeting, San Diego, CA. Oct 2015
- 2014 The CDC STD laboratory guidelines: what's new and how does it impact you? Presented at the Clinical Virology Symposium Pre-Symposium meeting for American Public Health Laboratories. Daytona Beach, 26 April 2014.

- 2014 Update on the CDC STD Diagnostic Guidelines. Roche Molecular Centers of Excellence Conference. 12 June 2014
- 2014 Update on the CDC STD Diagnostic Guidelines. Southern California American Society for Microbiology Annual meeting. 23 October 2014
- 2013 TV or not TV? Should screening for *T. vaginalis* be routine? Presented at the Clinical Virology Symposium. Daytona Beach, FL Apr 2013.
- 2012 Current Recommendations for Chlamydia & Gonorrhea Screening in the US. Presented at the Association of Public Health Laboratories Annual meeting. Seattle, WA May 2012
- 2012 Current Guidelines for Chlamydia & Gonorrhea Screening. Presented at the American Society for Microbiology 112<sup>th</sup> Annual meeting. San Francisco, CA June 2012
- 2011 Evaluation of the cobas 4800 for Detection of Chlamydia and Gonorrhea. Presented at the 111th annual meeting of the Society for Microbiology. New Orleans, May, 2011
- 2009 Changing the Culture of Sample Collection for Chlamydia & Gonorrhea Diagnostics: Vaginal Swabs are In! Presented at the Clinical Virology Symposium, Apr 2009

**INVITED LECTURES – Regional**

- 2023 Southern California American Association for Clinical Chemistry: Breaking the Condom: Reducing Barriers to STI Test Access
- 2022 Using Improved STI Diagnostics to Improve Clinical Care. Presented as the Indiana University Class of '47 STD Lectureship. 8 Apr 2022
- 2022 What's New in STI Diagnostics. Presented to the University of Florida Department of Environmental & Global Health. 30 Mar 2022
- 2016 The changing landscape of Infectious Diseases diagnostics presented at ID Grand Rounds, Feb, 2016
- 2016 Sexual Health Panel: STD diagnostic and treatment guidelines review. Presented at the Transforming Molecular Testing Workshop. Mystic, CN Mar 2016
- 2015 Update on the CDC STD Diagnostic Guidelines. UAB STD Training Center Presentation to Florida Department of Health Laboratories, Jacksonville, FL. Feb 2015
- 2014 Racial Disparities in Knowledge, STI Screening History & Infection Rates. Presented at the UAB Health Disparities Research Symposium. 20 Mar 2014
- 2014 What's New with the CDC Chlamydia & Gonorrhea Laboratory Diagnostic Guidelines? Presented at UAB Infectious Diseases Grand Rounds. 24 April 2014
- 2014 Update on the CDC STD Diagnostic Guidelines. UAB STD Training Center Annual STD Update Conference. 29 October 2014
- 2013 Further Outside the Box: Where is STD Screening Going? Presentation for BD Marketing and R&D. Sparks, MD Jan 2013
- 2012 Chlamydia & Gonorrhea Testing using non-Genital Samples. NAATwork Café sponsored by BD Diagnostics. Atlanta, GA March 2012
- 2012 *Trichomonas vaginalis* & HIV: Exacerbating Risk in sub-Saharan African Women. Chester A. Darling Distinguished Lectureship. Allegheny College. March 2012.
- 2012 Update on Chlamydia & Gonorrhea Screening in the US. Presented at the South Central Association for Clinical Microbiology annual meeting. Indianapolis, IN March 2012
- 2012 Chlamydia & Gonorrhea Testing using non-Genital Samples. NAATwork Café sponsored by BD Diagnostics. Chicago, IL, May 2012

- 2012 The Role of Laboratories in Global Health Research. Keynote Lecture. Indiana Global Health Research Working Conference. Turkey Run State Park, IN October 2012
- 2012 Chlamydia/Gonorrhea Screening: Moving Farther Outside the Box! Illinois Society for Microbiology Fall Meeting, Des Plaines, IL November 2012
- 2011 Chlamydia and Gonorrhea: Are They Passé? Presented at Roche Lunch & Learn, Pleasanton, CA Feb 2011
- 2011 IU Student Health Staff Update on the CDC STD Treatment & Diagnosis Guidelines, Mar 2011
- 2011 Findings about the Male Urethral Microbiome. Presented at the Clinical Translational Sciences Institute Annual Meeting, Indianapolis, Apr 2011
- 2010 STD course for IU Infectious Disease Fellows, July 2010
- 2010 Advancements in Molecular Automation for the Clinical Laboratory. Keynote Lecture. Presented at the American Society for Clinical Laboratory Science Annual meeting, Los Angeles, July 2010.
- 2010 Using Organism Load as a Marker of Vaccine Effectiveness. Presented at Glaxo-Smith Kline Chlamydia Vaccine Advisory Board Meeting, Atlanta, Sep 2010
- 2010 Understanding the Male Urethral Microbiome. Presented at the Clinical Translational Sciences Institute Bloomington Retreat, Nov 2010
- 2010 The Male Urethral Microbiome and STIs. Presented at the Clinical Translational Sciences Institute Lafayette Retreat, Dec 2010
- 2009 STD course for IU Infectious Disease Fellows, July 2009
- 2009 Beyond the Result: Enhancing CT/GC Amplification Testing. Presented at Association for Molecular Pathology Annual Meeting, Kissimmee FL, Nov 2009
- 2008 Abstinence State Changes in Adolescent Women. Presented at Society for Research on Adolescence Development and Risk Symposium, May 2008
- 2008 Confirmation of Chlamydia and Gonorrhea Results: Why, When & How? Roche VIP Workshop, Indianapolis June 2008
- 2007 Global Epidemiology of STD and Application of Molecular Diagnostics. Presented at Digene Corporation, July 2007
- 2007 Utilization of Molecular Diagnostics in Resource Rich and Resource Constrained Settings. Presented at Roche Molecular Systems, Sep 2007
- 2007 State-of-the-Market Molecular Diagnostics: Effect of Molecular Diagnostics on Chlamydia Epidemiology. Presented at Abbott Molecular Diagnostics, June 2007

### **Webinars**

- 2024 European Study group on Mycoplasma & Chlamydia Webinar Moderator: Debate – Chlamydia screening of asymptomatic people should be discontinued. June 2024
- 2024 National STI Prevention & Training Center: Where are we with STI POC testing?, April 2024
- 2024 LabRoots series: Breaking Barriers in STI Clinical Management, March 2024
- 2023 Managing Quality in Clinical Laboratories – Week long series of 4 hour sessions, Sep 2023
- 2023 LabRoots series: Moving toward more comprehensive sexual health care for women and men. Sep 2023
- 2022 HIV Diagnostics in the PrEP Era. Dec 2022
- 2022 Trichomonas: What is it and Why Should I Care. For American Sexual Health Association, May 10, 2022
- 2022 Highlights of the 2022 Advancing HIV/STI/Hepatitis Diagnostic Conference, for American Public Health Laboratories, May 5, 2022

- 2022 Redditt Science Series: Ask Me Anything About STIs, January 2022
- 2021 STI – Why can't we get rid of them? Leveraging newer diagnostic tools to make a difference. Presented 18 Aug 2021 for American Society for Microbiology
- 2019 STI Pipeline – What's on the way for diagnostics?. Hosted by the National Coalition of STD Directors. Presented live on 9 December 2019
- 2019 Resistance Guided Therapy for *Mycoplasma genitalium*: Application of Macrolide Resistance Testing Results. Hosted by the Center for Infectious Diseases Research and Policy. Presented live on 14 Oct 2019
- 2019 Considerations for Point-of-Care Tests. Hosted by the University of Washington STD Prevention Training Center. Presented live on 22 July 2019
- 2019 Non-viral STIs in the Age of PrEP. Hosted by the Pan American Society for Clinical Virology. Presented live on 24 June 2019
- 2018 Increasing STI Screening Coverage by Focusing on the End Users: Clinicians and Patients Sponsored by Roche Molecular. Presented Sep 2018.
- 2014 The CDC STD laboratory guidelines: What's new and how does it impact you?
- 2014 Keynote Address. BioConference Live. 28-30 May 2014
- 2013 TV or Not TV: Should Screening for *Trichomonas vaginalis* be Routine? Sponsored by BD Diagnostics. Webinar presented June 2013
- 2013 We've Come a Long Way Baby! Sponsored by Cepheid. Presented Dec 2013
- 2012 Understanding Clinical Trial Evaluations Data. Sponsored by Roche Diagnostics. Webinar presented July, 2012.

**FEDERAL & FOUNDATION CONTRACT & GRANTS (CURRENT)**

**75D30123D15974 (Van Der Pol) 08/2023-08/2024 [\$713,585] CDC**  
 Sexually Transmitted Infections Impact Research Consortium (STIIRC), Request for Task Order 002, Monkeypox Research  
 Role: PI

**5 NU62PS924587-04-00 (Van Wagoner) 04/2020-03/2025 [\$3,860,000] CDC**  
 Alabama/North Carolina Regional STD/HIV Prevention Training Center  
 Role: PTC Faculty

**FEDERAL & FOUNDATION CONTRACT & GRANTS (PAST)**

**1U19AI113212-01 (Hook) 06/2018-05/2020 [\$134,899]**  
 The UAB Sexually Transmitted Infections Cooperative Research Centers (STI CRC) - CRC Project 1  
 Role: co-I

**1U19AI113212-01 (Hook) 6/2014-6/2019 [\$1,768,423] NIH-NIAID**  
 The UAB STI CRC: DiSCIS Laboratory Core  
 The Laboratory Core supports all projects in the U19 program with diagnostic and experimental laboratory testing as well as biorepository maintenance.  
 Role: Core Leader

**1U19AI113212-01 (Hook)**                      **6/2014-6/2019**                      **[\$809,869]**                      **NIH-NIAID**  
 The UAB STI CRC: Project 1 “Determining the Origins of NGU in Men through Evaluation of Sexual Partnerships

This project is attempting to understand the relationship between the shared microbiota within a sexual dyad and the influence of those organisms on the presence of non-gonococcal urethritis in men.

Role: Co-Director

**5U19AI113173 (Marrazzo)**                      **02/16-06/19**                      **[\$181,952]**                      **NIH-NIAID**

University of Washington Sexually Transmitted Infections Cooperative Research Center

The Genital Microbiome as a Determinant of Sexual Health & Local Immunity

This project is intended to develop and assess standardized techniques that will facilitate cross-intuitional comparisons of microbiome studies.

Role: Site PI

**1R21DA043417 (Roth)**                      **12/1/16 – 11/30/18**                      **[\$27,369]**                      **NIH-NIDA**

Drexel University College of Medicine

Packaging Pre-Exposure Prophylaxis to Prevent HIV Transmission Among Women who Inject Drugs

This project will improve our understanding of the ability of programs to provide PrEP services to marginalized populations

Role: Co-Investigator

**Robert Wood Johnson (Elopre)**                      **01/2018-12/2021**                      **[\$420,000]**

Increasing Uptake of Prep in Urban and Rural Black Women in the South

This project will improve our understanding of the barriers and facilitators of PrEP service provision to women living in the rural South

Role: Mentor/Investigator

**HHSN272201300012I (Hook)**                      **9/2014-5/2015**                      **NIH-NIAID**

Task Area 2 Task Order 2 “Case Control Study Implementation”

Role: Investigator

**HHSN277201300121I (Hook)**                      **9/2014-3/2015**                      **NIH-NIAID**

Task Area 1 Task Order 5 “Clearance Time of Gonococcal Nucleic Acid by Nucleic Acid Amplification Testing (NAAT)”

Role: Task Principal Investigator

**1U48DP005037-01 (Michael)**                      **9/2014-9/2017**                      **DHHS-CDC**

CITY Health II Center for the Study of Community Health

Role: Investigator

**National Institute of Allergy and Infectious Diseases/NIH/DHHS**                      **06/14-05/20**                      **[\$1,503,783]**

The UAB STI CRC - DiSCIS Laboratory Core

Role: PI

**National Institute of Allergy and Infectious Diseases/NIH/DHHS**                      **06/14-05/20**                      **[\$674,970]**



The UAB STI CRC - Project 1: Determining the Origins of NGU in Men Through Evaluation of Sexual Partnerships

Role: PI

**UH3- AI083980-01**

Urethral Microbiome of Adolescent Males

Principal Investigator JD Fortenberry

Roles: Laboratory Director, Co-Investigator

Agency: NIH (HMP)

Project Period: 7/2011-8/2013

**UH2- DK083980-01**

Urethral Microbiome of Adolescent Males

Principal Investigator JD Fortenberry

Roles: Laboratory Director,

Agency: NIH (HMP)

Project Period: 6/2010-5/2011

**1R56AI090393-01**

STRONG Project

Principal Investigator MA Ott

Role: Co-Investigator , Site PI

Agency: NIH (NIAID)

Project Period: 7/2011-6/2012

**HD059494-02**

Sexual Health Among Bisexual Men

Principal Investigator BM Dodge

Role: Co-Investigator

Agency: NIH (NICHD)

Project Period: 2/2010-4/2011

**623-A-00-0-08-00**

AMPATH, controlling and preventing HIV/AIDS in western Kenya

Principal Investigator R Einterz

Roles: Co-Investigator, US Director, Laboratory Core

Agency: USAID

Project Period: 10/2012-7/2013\*

\*This project is still funded (through 2017), but my role has become unclear since changing institutions in August

**Altering our lens for the detection of cervical cancer: implementing HPV DNA testing among women at an urban STD clinic**

Co-Principal Investigator Barbara Van Der Pol

Agency: NIH CTSA through the Indiana Clinical & Translational Sciences Institute

Project Period: 2/2012-4/2014

**Comparison of urogenital microbiome in urine and urethral swabs**

Co-Principal Investigator Barbara Van Der Pol  
 Agency: NIH CTSA through the Indiana Clinical & Translational Sciences Institute  
 Project Period: 7/2009-2/2011

**Women’s reactions following serologic diagnosis of HSV-2 infection.**

Principal Investigator Barbara Van Der Pol  
 Agency: NIH CTSA through the Indiana Clinical & Translational Sciences Institute  
 Project Period: 3/2009-2/2011

**INDUSTRY SPONSORED (ACTIVE)**

**Abbott Molecular (iProcess) 2/22-2/24 [\$24,227]**

Collection and Distribution of Urine Specimen for Research Purposes

Role: PI

**Becton Dickinson 08/2023-08/2024 [\$41,609]**

Becton Dickinson Program for Collection of Biospecimens to Support Sexually Transmitted Infection

Assay Development of Testing

Role: PI

**Becton Dickinson 08/2023-08/2024 [\$151,846]**

Becton Dickinson Program for Collection of Biospecimens to Support Sexually Transmitted Infection

Assay Development of Testing (Quicksilver #2)

Role: PI

**Becton Dickinson 09/2023-09/2024 [\$18,934]**

IDS-QSCTGCClinicalStudy Clinical Validation of the BD Elience™ POC CT/GC Assay

Role: PI

**Becton Dickinson 12/2023-12/2024 [\$23,009]**

Testing Contrived Specimens Using BD MAX Vaginal Panel and Aptima BV Assay (FFS)

Role: PI

**Becton Dickinson 08/2023-08/2024 [\$530,467]**

Clinical Validation of the BD Respiratory Viral Panel for BD COR™ System

Role: PI

**Becton Dickinson 08/2023-08/2024 [\$530,467]**

Clinical Validation of the BD Respiratory Viral Panel for BD COR™ System

Role: PI

**BioFire 12/20-12/2024 [\$998,397]**

Pilot Clinical Evaluation of The Sexually Transmitted Infection/Vaginitis(STI/V) Panel DX-SDY-047600

Role: PI

**BioFire** 03/2023-02/2024 [\$16,295]  
Evaluation of Accuracy and Ease of Use of the BioFire Sexually Transmitted Infection Panel on the BioFire SpotFire System in a Near-Patient Setting  
Role: PI

**BioFire** 03/2023-03/2024 [\$138,991]  
Pilot Clinical Evaluation of the BioFire Vaginitis Panel, BFDX Study DX-SDY-119342  
Role: PI

**Cepheid** 4/21-4/24 [\$224,861]  
Protocol 274C3 Clinical Evaluation of the Xpert Xpress CoV-2/Flu/RSV XC Test on GeneXpert Dx and Infinity Systems in Laboratory and Near-Patient Testing Environment  
Role: PI

**Foundation for Innovative New Diagnostics (FIND)** 07/2021-6/2024 [\$297,770]  
A Cross Sectional Study Among Sexually Active Women To Support The Clinical Performance Evaluation Of Two Novel Point Of Care Diagnostic STI Tests Detecting Genital Neisseria Gonorrhoea And Chlamydia Trachomatis Infection  
Role: PI

**Cue Health** 03/2023-03/2024 [\$18,200]  
Clinical Study of the Cue® Chlamydia + Gonorrhoea Molecular Test with Female Lay Users Self-Testing in a Simulated Home Use Setting and Untrained Operators Testing in a CLIA Waived Environment  
Role: PI

**Detect, Inc** 07/2023-03/2024 [\$76,661]  
A Clinical Study to Support the Development of the Detect STI Test  
Role: PI

**Hologic** 04/2023-02/20254 [\$72,914]  
Clinical Performance of the Aptima® SARS-CoV-2 Assay on the Panther® System in Nasopharyngeal Swab Specimens from Symptomatic Individuals  
Role: PI

**Magic LifeSciences** 09/2022-11/2025 [\$16,250]  
Point-of Care Molecular Diagnostic testing for Sexually Transmitted Infections using Giant Magnetoresistive Biosensors  
Role: PI

**Rheonix, Inc** 11/2023-11/2024 [\$379,908]  
Clinical Study Protocol for the Trial Sites RHEONIX COVID-19 FLU RSV Assay and The RHEONIX COVID-19 MDx ASSAY  
Role: PI

**INDUSTRY SPONSORED (PAST)**

<b>Abbott Molecular</b>	<b>2/22-2/24</b>	<b>[\$24,882]</b>
Clinical Laboratory Services Agreement Role: PI		
<b>Iprocess Global</b>	<b>2/22-2/24</b>	<b>[\$103,350]</b>
Collection and Distribution of Urine Specimen for Research Purposes Role: PI		
<b>Cepheid</b>	<b>10/21-12/23</b>	<b>[\$876,850]</b>
Clinical Evaluation of The Xpert Xpress CT/NG Test in Male Urine and Extragenital Specimens Protocol 248C1 Role: PI		
<b>Cepheid</b>	<b>10/21-12/23</b>	<b>[\$249,600]</b>
Clinical Evaluation of the Xpert Xpress CT/NG Test in Female Extragenital Specimens Role: PI		
<b>Cepheid</b>	<b>10/21-12/23</b>	<b>[\$363,350]</b>
Clinical Evaluation of the Xpert Xpress CT/NG Test in Female Urogenital Specimens Role: PI		
<b>Cepheid</b>	<b>10/21-10/23</b>	<b>[\$249,600]</b>
Clinical Evaluation of the Xpert Xpress CT/NG in Female Urogenital Specimens Role: PI		
<b>binx health</b>	<b>9/21-9/23</b>	<b>[\$67,145]</b>
io mSTI Negative Cut-off Study Role: PI		
<b>binx health</b>	<b>9/21-9/23</b>	<b>[\$33,573]</b>
io mSTI Negative Cut-Off Study Role: PI		
<b>Hologic</b>	<b>8/21-8/23</b>	<b>[\$853,530]</b>
Prospective Collection of First-catch Urine, Vaginal Swab, and Penile Meatal Swab Specimens for Testing With the Aptima Assays Role: PI		
<b>Hologic</b>	<b>8/21-8/23</b>	<b>[\$345,888]</b>
Prospective Collection of First-catch Urine, Vaginal Swab, and Penile Meatal Swab Specimens for Testing With the Aptima Assays Role: PI		
<b>Hologic</b>	<b>8/21-8/23</b>	<b>[\$2,430,276]</b>

Prospective Collection of First-catch Urine, Vaginal Swab, and Penile Meatal Swab Specimens for Testing With the Aptima Assays

Role: PI

**Hologic** 7/21-7/23 [\$283,400]

Prospective Collection of First-catch Urine, Vaginal Swab, and Penile Meatal Swab Specimens for Testing With the Aptima Assays

Role: PI

**Hologic** 7/21-7/23 [\$141,700]

Prospective Collection of First-catch Urine, Vaginal Swab, and Penile Meatal Swab Specimens for Testing With the Aptima Assays

Role: PI

**Hologic** 7/21-7-23 [\$55,466]

Prospective Collection of First-catch Urine, Vaginal Swab, and Penile Meatal Swab Specimens for Testing With the Aptima Assays

07/2021-07/2023 \$55,466

**Hologic** 7/21-7/23 [\$128,543]

Prospective Collection of First-catch Urine, Vaginal Swab, and Penile Meatal Swab Specimens for Testing With the Aptima Assays

Role: PI

**Hologic** 7/21-7/23 [\$459,830]

Prospective Collection of First-catch Urine, Vaginal Swab, and Penile Meatal Swab Specimens for Testing With the Aptima Assays

Role: PI

**Becton Dick**

**inson** 1/22-1/23 [\$2,042,503]

Clinical Validation of the BD Respiratory Viral Panel for BD MAX System

Role: PI

**Becton Dickinson** 1/22-1/23 [\$336,432]

Clinical Validation of the BD Respiratory Viral Panel for BD Max System

Role: PI

**Becton Dickinson** 1-22-1/23 [\$1,706,071]

Clinical Validation of the BD Respiratory Viral Panel for BD Max System

Role: PI

**Becton Dickinson** 1/22-1/23 [\$188,760]

Mycoplasma Genitalium (MG) Collection for Testing of BD Mycoplasma Genitalium (MG) Reagents for BD COR System

Role: PI

**Becton Dickinson** 1/21-1/23 [\$94,380]  
Mycoplasma Genitalium (MG) Collection for Testing of BD Mycoplasma Genitalium (MG) Reagents for BD MAX System  
Role: PI

**Biofire Diagnostics** 12/20-12/2023 [\$42,265]  
Pilot Clinical Evaluation of the Spotfire Sexually Transmitted Infection/Vaginitis(STI/V) Panel  
Role: PI

**Becton Dickinson** 4/21-4/22 [\$10,000]  
Becton Dickinson Program for Collection of BioSpecimens CT/GC collection for project Quicksilver BDx-GSCP01 IDS-21QuickSilver CTGC  
Role: PI

**Becton Dickinson** 4/21-4/22 [\$231,175]  
Testing Protocol for the BD SARS-CoV-2/Flu for BD MAX™ System Post Market Clinical Study  
Role: PI

**Abbott Molecular** 12/21-12/22 [\$546,567]  
Alinity m BV/CV Scientific Study Specimen Collection and Testing Protocol  
Role: PI

**Hologic** 07/21-07/23 [\$17,350]  
Prospective Collection of First-catch Urine, Vaginal Swab, and Penile Meatal Swab Specimens for Testing with the Aptima® Assays  
Role: PI

**SpeeDx** 06/19-06/23 [\$577,590]  
Comparison of Current Standard of Care Versus the Australian Guidelines for Management of Mycoplasma Genitalium Infections Among Men being Treated for Non-Gonococcal Urethritis  
Role: PI

**Hologic** 06/20-07/23 [\$5,367]  
Prospective Collection of First-catch Urine, Vaginal Swab, and Penile Meatal Swab Specimens for Testing with the Aptima Assays  
Role: PI

**Cepheid** 10/21-12/22 [\$12,000]  
Clinical Evaluation of the Xpert Xpress CT/NG Test (Protocols 248C1, 248C2, and 248C3)  
Role: PI

**Cepheid** 10/21-12/22 [\$12,000]  
Clinical Evaluation of the Xpert Xpress CT/NG Test in Female Urogenital Specimens Protocol 248C  
Role: PI

**Cepheid** 10/21-12/22 [\$12,000]

Clinical Evaluation of the Xpert Xpress CT/NG Test in Female Extragenital Specimens Protocol 248C3  
 Role: PI

**binx health** 07/21-06/22 [\$157,287]  
 A cross sectional study among sexually active women to support the clinical performance evaluation of two novel point of care diagnostic STI tests detecting genital Neisseria gonorrhoeae and Chlamydia trachomatis infection  
 Role: PI

**Cepheid** 04/21-04/22 [\$172,970]  
 Protocol 274C Clinical Evaluation of the Xpert Xpress CoV-2/Flu/RSV XC Test on the GeneXpert Xpress System in a CLIA-Waived Environment and Protocol 274C3 Clinical Evaluation of the Xpert Xpress CoV-2/Flu/RSV XC Test on GeneXpert  
 Role: PI

**Becton Dickinson and Company** 04/21-04/22 [\$703,118]  
 Testing Protocol for the BD SARS-CoV-2/Flu for BD MAX™ System Post Market Clinical Study  
 Role: PI

**Becton Dickinson and Company** 04/21-04/22 [\$114,953]  
 Becton Dickinson Program for Collection of BioSpecimens; CT/GC collection for project Quicksilver BDX-GSCP01 / IDS-21QuickSilver CTGC  
 Role: PI

**Starpharma** 01/20-01/22 [\$447,308]  
 Starpharma FFS Reference Lab  
 Role: PI

**American Sexually Transmitted Disease Association** 06/2020-06/2022 [\$2,300]  
 ASTDA Small Project Assistance - Chlamydia Vaccine Acceptability  
 Role: PI

**Cepheid** 10/21-12/21 [\$751,584]  
 Clinical Evaluation of The Xpert CT/NG Test in Male Urine and Extragenital Specimens Protocol 248C1  
 Role: PI

**Cepheid** 10/21-12/21 [\$213,942]  
 Clinical Evaluation of the Xpert Xpress CT/NG in Female Extragenital Specimens  
 Role: PI

**Hologic** 10/20-10/21 [\$119,393]  
 Retrospective Specimen Characterization and Agreement Study  
 Role: PI

**Hologic** 10/20-10/21 [\$119,393]  
 Retrospective Specimen Characterization and Agreement Study

Role: PI

**Becton Dickinson and Company** 10/20-10/22 [\$207,127]

Retrospective Specimen Characterization and Agreement Study

Role: PI

**Cepheid** 07/20-12/21 [\$510,250]

PROTOCOL 233C Clinical Evaluation of the Xpert Xpress MVP Test

Role: PI

**Abbott Laboratories** 08/19-08/20 [\$1,093,534]

HSV US Clinical Reference Testing

Role: PI

**Cepheid** 11/18-11/19 [\$66,950]

Pre-Clinical Study of the Xpert Xpress MVP Test

Role: PI

**Cepheid** 10/18-12/21 [\$31,417]

PROTOCOL 233C Clinical Evaluation of the Xpert Xpress MVP Test

Role: PI

**Abbott Molecular** 10/18-09/19 [\$598,706]

Specimen Collection Protocol for the USA Assay Method Comparison

Role: PI

**Atlas Genetics** 09/18-08/19 [\$1,851,648]

IO-CTNG: A Multi-Centre Evaluation of the Atlas Genetics io CTNG System used in Centralised and Point of Care Settings

Role: PI

**Luminex Corporation** 05/18-05/19 [\$120,405]

Sample Processing for Research Study ARI-VAG-02-CS-001

Role: PI

**Speedx** 05/18-05/19 [\$490,726]

Prospective Multi Site Method Comparison Clinical Study of the Resistance Plus MG Diagnostic Accuracy in Detecting M. Genitalium and Mutations Associated with Azithromycin Resistance

Role: PI

**Speedx Pty.** 05/18-06/22 [\$106,470]

Prospective, Multi-Site, Method Comparison Clinical Study of the ResistancePlus™ MG Diagnostic Accuracy in Detecting M. Genitalium and Mutations Associated with Azithromycin Resistance

Role: PI



<b>Abbott Molecular</b>	<b>04/18-04/19</b>	<b>[\$72,950]</b>
Specimen Collection Protocol for the (CE) Assay Method Comparison		
Role: PI		
<b>University of California - San Francisco</b>	<b>03/18-03/22</b>	<b>[\$838,079]</b>
Rectal and Oropharyngeal Swabs to Diagnose Gonococcal and Chlamydial Infection in Men and Women		
Role: PI		
<b>Luminex Corporation</b>	<b>03/18-03/19</b>	<b>[\$85,455]</b>
A Multi-Site, Research Study to Evaluate Patient Populations Symptomatic or Asymptomatic for Bacterial Vaginosis for the Development of a Vaginitis In Vitro Diagnostic Assay		
Role: PI		
<b>University of California -San Francisco</b>	<b>03/18-03/19</b>	<b>[\$788,079]</b>
Rectal and Oropharyngeal Swabs to Diagnose Gonococcal and Chlamydial Infection in Men and Women		
Role: PI		
<b>Becton Dickinson And Company</b>	<b>02/18-02/19</b>	<b>[\$4,485]</b>
Work Order 1- XGen Benchmarking Study		
Role: PI		
<b>Hologic, Inc.</b>	<b>02/18-02/19</b>	<b>[151,800]</b>
Clinical Evaluation of the Aptima Combo 2® Assay Using the Panther® System in Female Urine Samples		
Role: PI		
<b>Becton Dickinson And Company</b>	<b>01/18-12/18</b>	<b>[\$6,210]</b>
FFS- Work: BD Onclarity HPV Assay on the BD Viper LT System: Workflow Study		
Role: PI		
<b>Roche Molecular Systems, Inc.</b>	<b>12/17-12/18</b>	<b>[\$115,931]</b>
Evaluation of the Performance of cobas® TV/MG for use on the cobas® 6800/8800 Systems for the Detection of Trichomonas vaginalis (TV) and Mycoplasma genitalium (MG) in Male and Female Urine, Male Penile Meatal Swabs, and in Female Vaginal and Endocervical Swabs, all Collected in cobas® PCR Media, and Cervical Samples Collected in PreservCyt® Solution		
Role: PI		
<b>Roche Molecular Systems, Inc.</b>	<b>11/17-11/18</b>	<b>[426,075]</b>
FFS-cX8-TVMG-441 testing		
Role: PI		
<b>binx healthcare</b>	<b>01/17-06/23</b>	<b>[\$204,851]</b>
Laboratory Agreement with Atlas Genetics		
Role: PI		
<b>Roche Molecular Systems</b>	<b>11/16-11/18</b>	<b>[\$542,006]</b>

Evaluation of the Performance of the Cobas CT/NG Test for use on the Cobas 6800/8800 Systems for the Detection of Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG) in Male and Female Urine, and in Female Vaginal and Endocervical Swabs, all Collected in Cobas PCR Media, and Cervical Samples Collected in PreservCyt Solution

Role: PI

**Rheonix**

**10/14-06/22**

**[\$22,898]**

Clinical Specimen Collection Protocol for the Rheonix STI TRI-Plex Assay and Rheonix EncompassMDx Workstation

Role: PI

**Rheonix, Inc.**

**10/14-09/19**

**[\$1,012,891]**

Clinical Specimen Collection Protocol for the Rheonix STI TRI-Plex Assay and Rheonix EncompassMDx Workstation

Role: PI

**Roche**

**10/16-10/17**

Evaluation of the Performance of the Cobas CT/NG Test for use on the Cobas 6800/8800 Systems for the Detection of Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG) in Male and Female Urine, and in Female Vaginal and Endocervical Swabs, all Collected in Cobas PCR Media, and Cervical Samples Collected in PreservCyt Solution

Role: PI

**Click Diagnostics**

**09/16-08/17**

UAB ClickDx Custom Vaginal Swab Collection

Role: PI

**Becton Dickinson**

**07/16-12/16**

Clinical Evaluation of the BD MAX™ STI Plus Assay, when tested with the BD MAX System

Role: PI

**Atlas**

**04/16-12/16**

Atlas Genetics Clinical Acceptability Study

**Beckman Coulter**

**06/15-05/16**

Multi-Specimen Procurement for VERIS Trichomonas Vaginalis (TV) and Chlamydia Trachomatis/Neisseria Gonorrhoeae (CTNG) Assay Evaluation

Role: PI

**Becton Dickinson**

**10/14-10/17**

Longitudinal Clinical Evaluation of the HPV Assay on the BD Viper LT System with Cervical Specimens

Role: PI

**Roche**

**06/14-05/15**

Rectal Gonorrhea Screening in an HIV Clinic

Role: PI

<b>Melinta</b>	<b>12/13- 12/14</b>	<b>[\$580,325]</b>
Central Reference Laboratory for Phase 3 GC Treatment Trial		
Role: PI		
<b>Qiagen</b>	<b>12/13-11/14</b>	<b>[\$71,910]</b>
Prospective Collection of Urogenital Samples for IVD Product Development		
Role: PI		
<b>BD Diagnostics</b>	<b>01/13-01/16</b>	<b>[\$811.040]</b>
Viper LT HPV Cobas-Athena Testing		
Role: co- PI		
<b>BD Diagnostics</b>	<b>8/12-7/14</b>	<b>[\$217,946]</b>
Clinical Evaluation of the BD MAX CT/GC/TV Assay, when tested with the BD MAX System		
Role: co-PI		
<b>Roche Molecular Systems</b>	<b>4/12-7/14</b>	<b>[\$159,575]</b>
Evaluation of the Performance of the cobas HSV Assay		
Role: co-PI		
<b>BD Diagnostics</b>	<b>5/12-8/13</b>	<b>[\$72,863]</b>
Clinical Agreement between the Viper LT System and the Viper XTR System using the BD CTQx and GCQx Amplified Assays		
Role: PI		
<b>Roche Molecular Systems</b>	<b>4/12-4/13</b>	<b>[\$359,965]</b>
Evaluation of the Performance of the cobas CT/NG Test for Detection of <i>Chlamydia trachomatis</i> (CT) and <i>Neisseria gonorrhoeae</i> (NG) in Urogenital Swabs and Urine, and Cervical Samples Collected in PreservCyt Solution		
Role: PI		

## BIBLIOGRAPHY

### MANUSCRIPTS

#### Peer-Reviewed, Published

1. Jones RB, Katz BP, **Van Der Pol B**, Caine VA, Batteiger BE, Newhall WJ. Effect of blind passage and multiple sampling on recovery of *Chlamydia trachomatis* from urogenital specimens. J Clin Microbiol. 1986;24(6):1029-33. Epub 1986/12/01. doi: 10.1128/jcm.24.6.1029-1033.1986. PMID: 3536994; PMCID: PMC269092.

2. Laughon BE, Ehret JM, Tanino TT, **Van Der Pol B**, Handsfield HH, Jones RB, Judson FN, Hook EW, 3rd. Fluorescent monoclonal antibody for confirmation of *Neisseria gonorrhoeae* cultures. J Clin Microbiol. 1987;25(12):2388-90. Epub 1987/12/01. PMID: 3123514; PMCID: PMC269495.
3. Smith JW, Rogers RE, Katz BP, Brickler JF, Lineback PL, **Van Der Pol B**, Jones RB. Diagnosis of chlamydial infection in women attending antenatal and gynecologic clinics. J Clin Microbiol. 1987;25(5):868-72. Epub 1987/05/01. doi: 10.1128/jcm.25.5.868-872.1987. PMID: 3294888; PMCID: PMC266106.
4. Jones RB, **Van Der Pol B**, Katz BP. Effect of differences in specimen processing and passage technique on recovery of *Chlamydia trachomatis*. J Clin Microbiol. 1989;27(5):894-8. Epub 1989/05/01. doi: 10.1128/jcm.27.5.894-898.1989. PMID: 2745697; PMCID: PMC267450.
5. Jones RB, **Van Der Pol B**, Martin DH, Shepard MK. Partial characterization of *Chlamydia trachomatis* isolates resistant to multiple antibiotics. J Infect Dis. 1990;162(6):1309-15. Epub 1990/12/01. doi: 10.1093/infdis/162.6.1309. PMID: 2230260.
6. **Van Der Pol BJ**, Jones RB. Comparison of immunotyping of *Chlamydia trachomatis* by indirect fluorescent-antibody staining and radioimmunoassay. J Clin Microbiol. 1992;30(4):1014-5. Epub 1992/04/01. doi: 10.1128/jcm.30.4.1014-1015.1992. PMID: 1572957; PMCID: PMC265205.
7. Byrne GI, Stephens RS, Ada G, Caldwell HD, Su H, Morrison RP, **Van Der Pol B**, Bavoil P, Bobo L, Everson S, et al. Workshop on in vitro neutralization of *Chlamydia trachomatis*: summary of proceedings. J Infect Dis. 1993;168(2):415-20. Epub 1993/08/01. doi: 10.1093/infdis/168.2.415. PMID: 8335979.
8. **Van Der Pol B**, Williams JA, Jones RB. Rapid antigen detection assay for identification of *Chlamydia trachomatis* infection. J Clin Microbiol. 1995;33(7):1920-1. Epub 1995/07/01. doi: 10.1128/jcm.33.7.1920-1921.1995. PMID: 7665671; PMCID: PMC228300.
9. Batteiger BE, Lin PM, Jones RB, **Van Der Pol BJ**. Species-, serogroup-, and serovar-specific epitopes are juxtaposed in variable sequence region 4 of the major outer membrane proteins of some *Chlamydia trachomatis* serovars. Infect Immun. 1996;64(7):2839-41. Epub 1996/07/01. doi: 10.1128/iai.64.7.2839-2841.1996. PMID: 8698520; PMCID: PMC174151.
10. Katz BP, Blythe MJ, **Van Der Pol B**, Jones RB. Declining prevalence of chlamydial infection among adolescent girls. Sex Transm Dis. 1996;23(3):226-9. Epub 1996/05/01. doi: 10.1097/00007435-199605000-00011. PMID: 8724513.

11. Ortiz L, Demick KP, Petersen JW, Polka M, Rudersdorf RA, **Van Der Pol B**, Jones R, Angevine M, DeMars R. *Chlamydia trachomatis* major outer membrane protein (MOMP) epitopes that activate HLA class II-restricted T cells from infected humans. *J Immunol.* 1996;157(10):4554-67. Epub 1996/11/15. PMID: 8906834.
12. Jones RB, **Van Der Pol B**, Johnson RB. Susceptibility of *Chlamydia trachomatis* to trovafloxacin. *J Antimicrob Chemother.* 1997;39 Suppl B:63-5. Epub 1997/06/01. doi: 10.1093/jac/39.suppl\_2.63. PMID: 9222072.
13. Schachter J, Jones RB, Butler RC, Rice B, Brooks D, **Van Der Pol B**, Gray M, Moncada J. Evaluation of the Vidas Chlamydia test to detect and verify *Chlamydia trachomatis* in urogenital specimens. *J Clin Microbiol.* 1997;35(8):2102-6. Epub 1997/08/01. doi: 10.1128/jcm.35.8.2102-2106.1997. PMID: 9230390; PMCID: PMC229911.
14. Steingrimsson O, Pawlak C, **Van Der Pol B**, Turner BP, Hjaltalin Olafsson J, Dolphin L, Williams JE, Peyton CE, Klepper RE, Jones RB, Anderson GD, Rashti N, Weissfeld AS, Pronovost A. Multicenter comparative evaluation of two rapid immunoassay methods for the detection of *Chlamydia trachomatis* antigen in endocervical specimens. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.* 1997;3(6):663-7. Epub 1997/02/01. doi: 10.1111/j.1469-0691.1997.tb00475.x. PMID: 11864210.
15. Arno JN, Xie C, Jones RB, **Van Der Pol B**. Identification of T cells that respond to serovar-specific regions of the *Chlamydia trachomatis* major outer membrane protein in persons with serovar E infection. *J Infect Dis.* 1998;178(6):1713-8. Epub 1998/11/17. doi: 10.1086/314478. PMID: 9815224.
16. Stothard DR, **Van Der Pol B**, Smith NJ, Jones RB. Effect of serial passage in tissue culture on sequence of omp1 from *Chlamydia trachomatis* clinical isolates. *J Clin Microbiol.* 1998;36(12):3686-8. Epub 1998/11/18. doi: 10.1128/JCM.36.12.3686-3688.1998. PMID: 9817897; PMCID: PMC105264.
17. Stothard DR, Williams JA, **Van Der Pol B**, Jones RB. Identification of a *Chlamydia trachomatis* serovar E urogenital isolate which lacks the cryptic plasmid. *Infect Immun.* 1998;66(12):6010-3. Epub 1998/11/24. doi: 10.1128/IAI.66.12.6010-6013.1998. PMID: 9826386; PMCID: PMC108762.
18. Martin DH, Cammarata C, **Van Der Pol B**, Jones RB, Quinn TC, Gaydos CA, Crotchfelt K, Schachter J, Moncada J, Jungkind D, Turner B, Peyton C. Multicenter evaluation of AMPLICOR and automated COBAS AMPLICOR CT/NG tests for *Neisseria gonorrhoeae*. *J Clin Microbiol.* 2000;38(10):3544-9. Epub 2000/10/04. doi: 10.1128/JCM.38.10.3544-3549.2000. PMID: 11015361; PMCID: PMC87434.

19. **Van Der Pol B**, Quinn TC, Gaydos CA, Crotchfelt K, Schachter J, Moncada J, Jungkind D, Martin DH, Turner B, Peyton C, Jones RB. Multicenter evaluation of the AMPLICOR and automated COBAS AMPLICOR CT/NG tests for detection of *Chlamydia trachomatis*. J Clin Microbiol. 2000;38(3):1105-12. Epub 2000/03/04. doi: 10.1128/JCM.38.3.1105-1112.2000. PMID: 10699004; PMCID: PMC86350.
20. Zydlewski AW, Stothard DR, **Van Der Pol B**, Jones RB, Filo RS, Hasbargen JA. Is there a role for *Chlamydia pneumoniae* in hemodialysis vascular access thrombosis? Am J Kidney Dis. 2000;36(6):1122-5. Epub 2000/11/30. doi: 10.1053/ajkd.2000.19813. PMID: 11096035.
21. **Van Der Pol B**, Ferrero DV, Buck-Barrington L, Hook E, 3rd, Lenderman C, Quinn T, Gaydos CA, Lovchik J, Schachter J, Moncada J, Hall G, Tuohy MJ, Jones RB. Multicenter evaluation of the BDProbeTec ET System for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in urine specimens, female endocervical swabs, and male urethral swabs. J Clin Microbiol. 2001;39(3):1008-16. Epub 2001/03/07. doi: 10.1128/JCM.39.3.1008-1016.2001. PMID: 11230419; PMCID: PMC87865.
22. **Van Der Pol B**, Martin DH, Schachter J, Quinn TC, Gaydos CA, Jones RB, Crotchfelt K, Moncada J, Jungkind D, Turner B, Peyton C, Kelly JF, Weiss JB, Rosenstraus M. Enhancing the specificity of the COBAS AMPLICOR CT/NG test for *Neisseria gonorrhoeae* by retesting specimens with equivocal results. J Clin Microbiol. 2001;39(9):3092-8. Epub 2001/08/30. doi: 10.1128/JCM.39.9.3092-3098.2001. PMID: 11526134; PMCID: PMC88302.
23. **Van Der Pol B**. COBAS Amplicor: an automated PCR system for detection of *C. trachomatis* and *N. gonorrhoeae*. Expert Rev Mol Diagn. 2002;2(4):379-89. Epub 2002/07/26. doi: 10.1586/14737159.2.4.379. PMID: 12138503.
24. **Van Der Pol B**, Williams JA, Smith NJ, Batteiger BE, Cullen AP, Erdman H, Edens T, Davis K, Salim-Hammad H, Chou VW, Searce L, Blutman J, Payne WJ. Evaluation of the Digene Hybrid Capture II Assay with the Rapid Capture System for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. J Clin Microbiol. 2002;40(10):3558-64. Epub 2002/10/02. doi: 10.1128/JCM.40.10.3558-3564.2002. PMID: 12354846; PMCID: PMC130850.
25. Schachter J, McCormack WM, Chernesky MA, Martin DH, **Van Der Pol B**, Rice PA, Hook EW, 3rd, Stamm WE, Quinn TC, Chow JM. Vaginal swabs are appropriate specimens for diagnosis of genital tract infection with *Chlamydia trachomatis*. J Clin Microbiol. 2003;41(8):3784-9. Epub 2003/08/09. doi: 10.1128/JCM.41.8.3784-3789.2003. PMID: 12904390; PMCID: PMC179798.
26. Alvarez-Olmos MI, Barousse MM, Rajan L, **Van Der Pol B**, Fortenberry D, Orr D, Fidel PL, Jr. Vaginal lactobacilli in adolescents: presence and relationship to local and systemic immunity, and to

- bacterial vaginosis. *Sex Transm Dis.* 2004;31(7):393-400. Epub 2004/06/25. doi: 10.1097/01.olq.0000130454.83883.e9. PMID: 15215693.
27. Barousse MM, **Van Der Pol B**, Fortenberry D, Orr D, Fidel PL, Jr. Vaginal yeast colonisation, prevalence of vaginitis, and associated local immunity in adolescents. *Sex Transm Infect.* 2004;80(1):48-53. Epub 2004/02/03. doi: 10.1136/sti.2002.003855. PMID: 14755036; PMCID: PMC1758371.
  28. **Van Der Pol B**, Williams JA, Orr DP, Batteiger BE, Fortenberry JD. Prevalence, incidence, natural history, and response to treatment of *Trichomonas vaginalis* infection among adolescent women. *J Infect Dis.* 2005;192(12):2039-44. Epub 2005/11/17. doi: 10.1086/498217. PMID: 16288365.
  29. Raymond EG, Stewart F, Weaver M, Monteith C, **Van Der Pol B**. Impact of increased access to emergency contraceptive pills: a randomized controlled trial. *Obstet Gynecol.* 2006;108(5):1098-106. Epub 2006/11/02. doi: 10.1097/01.AOG.0000235708.91572.db. PMID: 17077230.
  30. Smith-McCune KK, Tuveson JL, Rubin MM, Da Costa MM, Darragh TM, Shiboski SC, **Van Der Pol B**, Moscicki AB, Palefsky JM, Sawaya GF. Effect of Replens gel used with a diaphragm on tests for human papillomavirus and other lower genital tract infections. *Journal of lower genital tract disease.* 2006;10(4):213-8. Epub 2006/10/03. doi: 10.1097/01.lgt.0000225889.13916.c6. PMID: 17012985.
  31. **Van Der Pol B**, Kraft CS, Williams JA. Use of an adaptation of a commercially available PCR assay aimed at diagnosis of chlamydia and gonorrhea to detect *Trichomonas vaginalis* in urogenital specimens. *J Clin Microbiol.* 2006;44(2):366-73. Epub 2006/02/04. doi: 10.1128/JCM.44.2.366-373.2006. PMID: 16455885; PMCID: PMC1392661.
  32. Barousse MM, Theall KP, **Van Der Pol B**, Fortenberry JD, Orr DP, Fidel PL, Jr. Susceptibility of middle adolescent females to sexually transmitted infections: impact of hormone contraception and sexual behaviors on vaginal immunity. *Am J Reprod Immunol.* 2007;58(2):159-68. Epub 2007/07/17. doi: 10.1111/j.1600-0897.2007.00504.x. PMID: 17631009.
  33. Morrison CS, Wang J, **Van Der Pol B**, Padian N, Salata RA, Richardson BA. Pregnancy and the risk of HIV-1 acquisition among women in Uganda and Zimbabwe. *AIDS.* 2007;21(8):1027-34. Epub 2007/04/26. doi: 10.1097/QAD.0b013e3280f00fc4. PMID: 17457097.
  34. Tosh AK, **Van Der Pol B**, Fortenberry JD, Williams JA, Katz BP, Batteiger BE, Orr DP. *Mycoplasma genitalium* among adolescent women and their partners. *J Adolesc Health.* 2007;40(5):412-7. Epub 2007/04/24. doi: 10.1016/j.jadohealth.2006.12.005. PMID: 17448398; PMCID: PMC1899169.

35. **Van Der Pol B.** *Trichomonas vaginalis* infection: the most prevalent nonviral sexually transmitted infection receives the least public health attention. Clin Infect Dis. 2007;44(1):23-5. Epub 2006/12/05. doi: 10.1086/509934. PMID: 17143810.
36. Hobbs MM, **Van Der Pol B**, Totten P, Gaydos CA, Wald A, Warren T, Winer RL, Cook RL, Deal CD, Rogers ME, Schachter J, Holmes KK, Martin DH. From the NIH: proceedings of a workshop on the importance of self-obtained vaginal specimens for detection of sexually transmitted infections. Sex Transm Dis. 2008;35(1):8-13. Epub 2007/12/25. doi: 10.1097/OLQ.0b013e31815d968d. PMID: 18157061; PMCID: PMC3836284.
37. van de Wijgert JH, Morrison CS, Cornelisse PG, Munjoma M, Moncada J, Awio P, Wang J, **Van Der Pol B**, Chipato T, Salata RA, Padian NS. Bacterial vaginosis and vaginal yeast, but not vaginal cleansing, increase HIV-1 acquisition in African women. J Acquir Immune Defic Syndr. 2008;48(2):203-10. Epub 2008/06/04. doi: 10.1097/QAI.0b013e3181743936. PMID: 18520679.
38. **Van Der Pol B**, Kwok C, Pierre-Louis B, Rinaldi A, Salata RA, Chen PL, van de Wijgert J, Mmiro F, Mugerwa R, Chipato T, Morrison CS. *Trichomonas vaginalis* infection and human immunodeficiency virus acquisition in African women. J Infect Dis. 2008;197(4):548-54. Epub 2008/02/16. doi: 10.1086/526496. PMID: 18275275.
39. Fife KH, **Van Der Pol B**, Roth AM, Brand J, Arno JN, Madlem J, Juliar BE, Katz BP, Williams JA, Zimet GD, Fortenberry JD. Implementation of routine access to herpes simplex virus type 2 antibody testing in a public health sexually transmitted disease clinic. Sex Transm Dis. 2009;36(11):724-8. Epub 2009/10/08. doi: 10.1097/OLQ.0b013e3181bc9a2f. PMID: 19809384.
40. Tu W, Batteiger BE, Wiehe S, Ofner S, **Van Der Pol B**, Katz BP, Orr DP, Fortenberry JD. Time from first intercourse to first sexually transmitted infection diagnosis among adolescent women. Arch Pediatr Adolesc Med. 2009;163(12):1106-11. Epub 2009/12/10. doi: 10.1001/archpediatrics.2009.203. PMID: 19996047; PMCID: PMC3018688.
41. van de Wijgert JH, Morrison CS, Brown J, Kwok C, **Van Der Pol B**, Chipato T, Byamugisha JK, Padian N, Salata RA. Disentangling contributions of reproductive tract infections to HIV acquisition in African Women. Sex Transm Dis. 2009;36(6):357-64. Epub 2009/05/13. doi: 10.1097/OLQ.0b013e3181a4f695. PMID: 19434010.
42. Batteiger BE, Tu W, Ofner S, **Van Der Pol B**, Stothard DR, Orr DP, Katz BP, Fortenberry JD. Repeated *Chlamydia trachomatis* genital infections in adolescent women. J Infect Dis. 2010;201(1):42-51. Epub 2009/11/26. doi: 10.1086/648734. PMID: 19929379; PMCID: PMC2791188.



43. Dodge B, **Van Der Pol B**, Rosenberger JG, Reece M, Roth AM, Herbenick D, Fortenberry JD. Field collection of rectal samples for sexually transmitted infection diagnostics among men who have sex with men. *Int J STD AIDS*. 2010;21(4):260-4. Epub 2010/04/10. doi: 10.1258/ijsa.2009.009056. PMID: 20378897.
44. Lovvorn AE, Patnaik P, Walker CJ, Kwok C, **Van Der Pol B**, Chipato T, Byamugisha JK, Salata RA, Morrison CS. Variations in CD4 cell counts among HIV-uninfected and infected women in Uganda and Zimbabwe. *Int J STD AIDS*. 2010;21(5):342-5. Epub 2010/05/26. doi: 10.1258/ijsa.2009.009020. PMID: 20498104; PMCID: PMC5172453.
45. Mavedzenge SN, **Van Der Pol B**, Cheng H, Montgomery ET, Blanchard K, de Bruyn G, Ramjee G, Straten A. Epidemiological synergy of *Trichomonas vaginalis* and HIV in Zimbabwean and South African women. *Sex Transm Dis*. 2010;37(7):460-6. Epub 2010/06/22. doi: 10.1097/OLQ.0b013e3181cfcc4b. PMID: 20562586.
46. Morrison CS, Demers K, Kwok C, Bulime S, Rinaldi A, Munjoma M, Dunbar M, Chipato T, Byamugisha J, **Van Der Pol B**, Arts E, Salata RA. Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. *AIDS*. 2010;24(4):573-82. Epub 2010/02/16. doi: 10.1097/QAD.0b013e32833433df. PMID: 20154581; PMCID: PMC3148071.
47. Nelson DE, **Van Der Pol B**, Dong Q, Revanna KV, Fan B, Easwaran S, Sodergren E, Weinstock GM, Diao L, Fortenberry JD. Characteristic male urine microbiomes associate with asymptomatic sexually transmitted infection. *PLoS One*. 2010;5(11):e14116. Epub 2010/12/03. doi: 10.1371/journal.pone.0014116. PMID: 21124791; PMCID: PMC2991352.
48. **Van Der Pol B**. Diagnosing Vaginal Infections: It's Time to Join the 21st Century. *Current infectious disease reports*. 2010;12(3):225-30. Epub 2011/02/11. doi: 10.1007/s11908-010-0096-1. PMID: 21308534.
49. Dong Q, Nelson DE, Toh E, Diao L, Gao X, Fortenberry JD, **Van Der Pol B**. The microbial communities in male first catch urine are highly similar to those in paired urethral swab specimens. *PLoS One*. 2011;6(5):e19709. Epub 2011/05/24. doi: 10.1371/journal.pone.0019709. PMID: 21603636; PMCID: PMC3094389.
50. Martinez O, Dodge B, Reece M, Schnarrs PW, Rhodes SD, Goncalves G, Munoz-Laboy M, Malebranche D, **Van Der Pol B**, Nix R, Kelle G, Fortenberry JD. Sexual health and life experiences: voices from behaviourally bisexual Latino men in the Midwestern USA. *Cult Health Sex*. 2011;13(9):1073-89. Epub 2011/08/06. doi: 10.1080/13691058.2011.600461. PMID: 21815839; PMCID: PMC3158839.

51. Morrison CS, Chen PL, Nankya I, Rinaldi A, **Van Der Pol B**, Ma YR, Chipato T, Mugerwa R, Dunbar M, Arts E, Salata RA. Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe. *J Acquir Immune Defic Syndr.* 2011;57(2):157-64. Epub 2011/03/02. doi: 10.1097/QAI.0b013e318214ba4a. PMID: 21358412; PMCID: PMC3164299.
52. Nowak RG, Gravitt PE, Morrison CS, Gange SJ, Kwok C, Oliver AE, Howard R, **Van Der Pol B**, Salata RA, Padian NS, Chipato T, Munjoma M, Celentano DD. Increases in human papillomavirus detection during early HIV infection among women in Zimbabwe. *J Infect Dis.* 2011;203(8):1182-91. Epub 2011/04/01. doi: 10.1093/infdis/jiq172. PMID: 21451006; PMCID: PMC3068021.
53. Rosenberger JG, Dodge B, **Van Der Pol B**, Reece M, Herbenick D, Fortenberry JD. Reactions to self-sampling for ano-rectal sexually transmitted infections among men who have sex with men: a qualitative study. *Arch Sex Behav.* 2011;40(2):281-8. Epub 2009/10/23. doi: 10.1007/s10508-009-9569-4. PMID: 19847636.
54. Rosenberger JG, Reece M, Schick V, Herbenick D, Novak DS, **Van Der Pol B**, Fortenberry JD. Sexual behaviors and situational characteristics of most recent male-partnered sexual event among gay and bisexually identified men in the United States. *The journal of sexual medicine.* 2011;8(11):3040-50. Epub 2011/09/03. doi: 10.1111/j.1743-6109.2011.02438.x. PMID: 21883941.
55. Roth A, **Van Der Pol B**, Dodge B, Fortenberry JD, Zimet G. Future chlamydia screening preferences of men attending a sexually transmissible infection clinic. *Sex Health.* 2011;8(3):419-26. Epub 2011/08/20. doi: 10.1071/SH10017. PMID: 21851785.
56. Roth AM, Dodge BM, **Van Der Pol B**, Reece M, Zimet GD. Low acceptance of HSV-2 testing among high-risk women. *Int J STD AIDS.* 2011;22(6):329-31. Epub 2011/06/18. doi: 10.1258/ijsa.2010.010399. PMID: 21680668.
57. Roth AM, Williams JA, Ly R, Curd K, Brooks D, Arno J, **Van Der Pol B**. Changing sexually transmitted infection screening protocol will result in improved case finding for trichomonas vaginalis among high-risk female populations. *Sex Transm Dis.* 2011;38(5):398-400. Epub 2011/01/11. doi: 10.1097/OLQ.0b013e318203e3ce. PMID: 21217417.
58. Stupiansky NW, **Van Der Pol B**, Williams JA, Weaver B, Taylor SE, Fortenberry JD. The natural history of incident gonococcal infection in adolescent women. *Sex Transm Dis.* 2011;38(8):750-4. Epub 2011/02/15. doi: 10.1097/OLQ.0b013e31820ff9a4. PMID: 21317686.
59. Taylor SN, **Van Der Pol B**, Lillis R, Hook EW, 3rd, Lebar W, Davis T, Fuller D, Mena L, Fine P, Gaydos CA, Martin DH. Clinical evaluation of the BD ProbeTec *Chlamydia trachomatis* Qx amplified DNA assay on the BD Viper system with XTR technology. *Sex Transm Dis.*

2011;38(7):603-9. Epub 2011/02/09. doi: 10.1097/OLQ.0b013e31820a94d2. PMID: 21301389; PMCID: PMC3763498.

60. Dodge B, Schnarrs PW, Goncalves G, Malebranche D, Martinez O, Reece M, Rhodes SD, **Van Der Pol B**, Nix R, Fortenberry JD. The significance of privacy and trust in providing health-related services to behaviorally bisexual men in the United States. *AIDS Educ Prev.* 2012;24(3):242-56. Epub 2012/06/09. doi: 10.1521/aeap.2012.24.3.242. PMID: 22676463; PMCID: PMC3375875.
61. Dodge B, Schnarrs PW, Reece M, Goncalves G, Martinez O, Nix R, Malebranche D, **Van Der Pol B**, Murray M, Fortenberry JD. Community involvement among behaviourally bisexual men in the Midwestern USA: experiences and perceptions across communities. *Cult Health Sex.* 2012;14(9):1095-110. Epub 2012/09/18. doi: 10.1080/13691058.2012.721136. PMID: 22978551; PMCID: PMC3463651.
62. Dodge B, Schnarrs PW, Reece M, Martinez O, Goncalves G, Malebranche D, **Van Der Pol B**, Nix R, Fortenberry JD. Individual and Social Factors Related to Mental Health Concerns among Bisexual Men in the Midwestern United States. *Journal of bisexuality.* 2012;12(2):223-45. Epub 2012/06/30. doi: 10.1080/15299716.2012.674862. PMID: 22745591; PMCID: PMC3383005.
63. Dodge B, **Van Der Pol B**, Reece M, Malebranche D, Martinez O, Goncalves G, Schnarrs P, Nix R, Fortenberry JD. Rectal self-sampling in non-clinical venues for detection of sexually transmissible infections among behaviourally bisexual men. *Sex Health.* 2012;9(2):190-1. Epub 2012/04/14. doi: 10.1071/SH11068. PMID: 22498165; PMCID: PMC3334864.
64. Martinez O, Dodge B, Goncalves G, Schnarrs P, Munoz-Laboy M, Reece M, Malebranche D, **Van Der Pol B**, Kelle G, Nix R, Fortenberry JD. Sexual Behaviors and Experiences among Behaviorally Bisexual Latino Men in the Midwestern United States: Implications for Sexual Health Interventions. *Journal of bisexuality.* 2012;12(2):283-310. Epub 2012/06/12. doi: 10.1080/15299716.2012.674865. PMID: 22685383; PMCID: PMC3368508.
65. Mavedzenge SN, **Van Der Pol B**, Weiss HA, Kwok C, Mambo F, Chipato T, Van der Straten A, Salata R, Morrison C. The association between *Mycoplasma genitalium* and HIV-1 acquisition in African women. *AIDS.* 2012;26(5):617-24. Epub 2012/01/03. doi: 10.1097/QAD.0b013e32834ff690. PMID: 22210630.
66. Meyerson BE, Crosby RA, **Van Der Pol B**, Zimet GD. Thinking differently about cervical cancer screening in high-risk populations. *Am J Prev Med.* 2012;43(2):221-4. Epub 2012/07/21. doi: 10.1016/j.amepre.2012.04.021. PMID: 22813689.
67. Montgomery ET, **Van Der Pol B**, van der Straten A, Ramjee G, de Bruyn G, Chipato T, Blanchard K, Padian NS, Team M. Discrepancies in diagnosis of incident HIV infection between antibody- and

DNA-based tests in a phase III prevention trial in southern Africa. *Int J STD AIDS*. 2012;23(9):649-52. Epub 2012/10/04. doi: 10.1258/ijsa.2009.009124. PMID: 23033520.

68. Nelson DE, Dong Q, **Van Der Pol B**, Toh E, Fan B, Katz BP, Mi D, Rong R, Weinstock GM, Sodergren E, Fortenberry JD. Bacterial communities of the coronal sulcus and distal urethra of adolescent males. *PLoS One*. 2012;7(5):e36298. Epub 2012/05/19. doi: 10.1371/journal.pone.0036298. PMID: 22606251; PMCID: PMC3350528.
69. Rosenberger JG, Reece M, Schick V, Herbenick D, Novak DS, **Van Der Pol B**, Fortenberry JD. Condom use during most recent anal intercourse event among a U.S. sample of men who have sex with men. *The journal of sexual medicine*. 2012;9(4):1037-47. Epub 2012/02/23. doi: 10.1111/j.1743-6109.2012.02650.x. PMID: 22353190.
70. Roth A, Fortenberry JD, **Van Der Pol B**, Rosenberger J, Dodge B, Arno J, Waters J, Certo D, Reece M. Court-based participatory research: collaborating with the justice system to enhance sexual health services for vulnerable women in the United States. *Sex Health*. 2012;9(5):445-52. Epub 2012/10/06. doi: 10.1071/SH11170. PMID: 23036783.
71. Roth AM, Rosenberger JG, Reece M, **Van Der Pol B**. A methodological approach to improve the sexual health of vulnerable female populations: incentivized peer-recruitment and field-based STD testing. *J Health Care Poor Underserved*. 2012;23(1):367-75. Epub 2012/05/31. doi: 10.1353/hpu.2012.0011. PMID: 22643484.
72. Schnarrs PW, Dodge B, Reece M, Goncalves G, Martinez O, **Van Der Pol B**, Malebranche D, Murray M, Nix R, Fortenberry JD. Subjective Sexual Experiences of Behaviorally Bisexual Men in the Midwestern United States: Sexual Attraction, Sexual Behaviors, & Condom Use. *Journal of bisexuality*. 2012;12(2):246-82. Epub 2012/06/30. doi: 10.1080/15299716.2012.674863. PMID: 22745592; PMCID: PMC3382978.
73. Taylor SN, Liesenfeld O, Lillis RA, Body BA, Nye M, Williams J, Eisenhut C, Hook EW, 3rd, **Van Der Pol B**. Evaluation of the Roche cobas(R) CT/NG test for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in male urine. *Sex Transm Dis*. 2012;39(7):543-9. Epub 2012/06/19. doi: 10.1097/OLQ.0b013e31824e26ff. PMID: 22706217.
74. **Van Der Pol B**, Liesenfeld O, Williams JA, Taylor SN, Lillis RA, Body BA, Nye M, Eisenhut C, Hook EW, 3rd. Performance of the cobas CT/NG test compared to the Aptima AC2 and Viper CTQ/GCQ assays for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. *J Clin Microbiol*. 2012;50(7):2244-9. Epub 2012/04/21. doi: 10.1128/JCM.06481-11. PMID: 22518864; PMCID: PMC3405604.

75. **Van Der Pol B**, Taylor SN, Lebar W, Davis T, Fuller D, Mena L, Fine P, Gaydos CA, Martin DH, Hook EW, 3rd. Clinical evaluation of the BD ProbeTec *Neisseria gonorrhoeae* Qx amplified DNA assay on the BD Viper system with XTR technology. *Sex Transm Dis.* 2012;39(2):147-53. Epub 2012/01/18. doi: 10.1097/OLQ.0b013e3182372fd8. PMID: 22249304; PMCID: PMC3725734.
76. **Van Der Pol B**, Warren T, Taylor SN, Martens M, Jerome KR, Mena L, Lebed J, Ginde S, Fine P, Hook EW, 3rd. Type-specific identification of anogenital herpes simplex virus infections by use of a commercially available nucleic acid amplification test. *J Clin Microbiol.* 2012;50(11):3466-71. Epub 2012/08/10. doi: 10.1128/JCM.01685-12. PMID: 22875892; PMCID: PMC3486267.
77. Dize L, West S, Williams JA, **Van Der Pol B**, Quinn TC, Gaydos CA. Comparison of the Abbott m2000 RealTime CT assay and the Cepheid GeneXpert CT/NG assay to the Roche Amplicor CT assay for detection of *Chlamydia trachomatis* in ocular samples from Tanzania. *J Clin Microbiol.* 2013;51(5):1611-3. Epub 2013/03/15. doi: 10.1128/JCM.00519-13. PMID: 23486714; PMCID: PMC3647953.
78. Dodge B, Schnarrs PW, Reece M, Martinez O, Goncalves G, Malebranche D, **Van Der Pol B**, Nix R, Fortenberry JD. Sexual behaviors and experiences among behaviorally bisexual men in the midwestern United States. *Arch Sex Behav.* 2013;42(2):247-56. Epub 2011/12/22. doi: 10.1007/s10508-011-9878-2. PMID: 22187027; PMCID: PMC3310970.
79. Gaydos CA, **Van Der Pol B**, Jett-Goheen M, Barnes M, Quinn N, Clark C, Daniel GE, Dixon PB, Hook EW, 3rd, Group CNS. Performance of the Cepheid CT/NG Xpert Rapid PCR Test for Detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. *J Clin Microbiol.* 2013;51(6):1666-72. Epub 2013/03/08. doi: 10.1128/JCM.03461-12. PMID: 23467600; PMCID: PMC3716060.
80. Hook EW, **Van Der Pol B**. Evolving gonococcal antimicrobial resistance: research priorities and implications for management. *Sex Transm Infect.* 2013;89 Suppl 4:iv60-2. Epub 2013/11/28. doi: 10.1136/sextrans-2013-051021. PMID: 24243882.
81. Martens MG, Fine P, Fuller D, Ginde SY, Hook EW, 3rd, Lebed J, Mena L, Taylor SN, **Van Der Pol B**. Clinical evaluation of a new Pap test-based method for screening of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* using liquid-based cytology media. *South Med J.* 2013;106(9):506-12. Epub 2013/09/05. doi: 10.1097/SMJ.0b013e3182a5f113. PMID: 24002555.
82. O'Neill CE, Seth-Smith HMB, **Van Der Pol B**, Harris SR, Thomson NR, Cutcliffe LT, Clarke IN. *Chlamydia trachomatis* clinical isolates identified as tetracycline resistant do not exhibit resistance in vitro: whole-genome sequencing reveals a mutation in porB but no evidence for tetracycline resistance genes. *Microbiology (Reading).* 2013;159(Pt 4):748-56. Epub 2013/02/05. doi: 10.1099/mic.0.065391-0. PMID: 23378575.

83. Roth AM, Rosenberger JG, Reece M, **Van Der Pol B**. Expanding sexually transmitted infection screening among women and men engaging in transactional sex: the feasibility of field-based self-collection. *Int J STD AIDS*. 2013;24(4):323-8. Epub 2013/08/24. doi: 10.1177/0956462412472791. PMID: 23970665; PMCID: PMC3970701.
84. Roth AM, **Van Der Pol B**, Fortenberry JD, Reece M, Dodge B, Certo D, Zimet GD. Herpes simplex virus type 2 serological testing at a community court: predictors of test acceptance and seropositivity among female defendants. *Int J STD AIDS*. 2013;24(3):169-74. Epub 2013/03/08. doi: 10.1177/0956462412472442. PMID: 23467289.
85. **Van Der Pol B**. Cobas(R) 4800: a fully automated system for the detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. *Expert Rev Mol Diagn*. 2013;13(2):131-40. Epub 2013/03/13. doi: 10.1586/erm.12.141. PMID: 23477553.
86. **Van Der Pol B**. Laboratory support of global health research. *J Gen Intern Med*. 2013;28 Suppl 3:S654-9. Epub 2013/06/26. doi: 10.1007/s11606-013-2458-5. PMID: 23797915; PMCID: PMC3744279.
87. **Van Der Pol B**. *Trichomonas vaginalis*: reviewing the available diagnostic testing options. *MLO Med Lab Obs*. 2013;45(8):18, 20. Epub 2013/11/12. PMID: 24205535.
88. **Van Der Pol B**, Taylor SN, Liesenfeld O, Williams JA, Hook EW, 3rd. Vaginal swabs are the optimal specimen for detection of genital *Chlamydia trachomatis* or *Neisseria gonorrhoeae* using the Cobas 4800 CT/NG test. *Sex Transm Dis*. 2013;40(3):247-50. Epub 2013/02/15. doi: 10.1097/OLQ.0b013e3182717833. PMID: 23407470.
89. Won H, Ramachandran P, Steece R, **Van Der Pol B**, Moncada J, Schachter J, Gaydos C. Is there evidence of the new variant *Chlamydia trachomatis* in the United States? *Sex Transm Dis*. 2013;40(5):352-3. Epub 2013/04/17. doi: 10.1097/OLQ.0b013e3182841786. PMID: 23588122; PMCID: PMC3744364.
90. Alemnji G, Fonjongo P, **Van Der Pol B**, Peter T, Kantor R, Nkengasong J. The centrality of laboratory services in the HIV treatment and prevention cascade: The need for effective linkages and referrals in resource-limited settings. *Aids Patient Care STDS*. 2014;28(5):268-73. Epub 2014/04/20. doi: 10.1089/apc.2013.0356. PMID: 24742299; PMCID: PMC4826026.
91. Hubach RD, Dodge B, Davis A, Smith AD, Zimet GD, **Van Der Pol B**. Preferred methods of sexually transmitted infection service delivery among an urban sample of underserved midwestern men. *Sex Transm Dis*. 2014;41(2):129-32. Epub 2014/01/15. doi: 10.1097/OLQ.0000000000000082. PMID: 24413494; PMCID: PMC4148079.

92. Hubach RD, Dodge B, Goncalves G, Malebranche D, Reece M, **Van Der Pol B**, Martinez O, Schnarrs PW, Nix R, Fortenberry JD. Gender matters: condom use and nonuse among behaviorally bisexual men. *Arch Sex Behav*. 2014;43(4):707-17. Epub 2013/08/06. doi: 10.1007/s10508-013-0147-4. PMID: 23912775; PMCID: PMC3912218.
93. Ma L, Mancuso M, Williams JA, **Van Der Pol B**, Fortenberry JD, Jia Q, Myers L, Martin DH. Extensive variation and rapid shift of the MG192 sequence in *Mycoplasma genitalium* strains from patients with chronic infection. *Infect Immun*. 2014;82(3):1326-34. Epub 2014/01/08. doi: 10.1128/IAI.01526-13. PMID: 24396043; PMCID: PMC3958013.
94. Papp JR, Schachter J, Gaydos CA, **Van Der Pol B**. Recommendations for the Laboratory-Based Detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*-2014. *MMWR Recommendations and Reports*. 2014;63(2):1-19. PMID: WOS:000333752400001.
95. Tanen L, Docherty CL, **Van Der Pol B**, Simon J, Schrader J. Prevalence of chronic ankle instability in high school and division I athletes. *Foot & ankle specialist*. 2014;7(1):37-44. Epub 2013/11/30. doi: 10.1177/1938640013509670. PMID: 24287210.
96. **Van Der Pol B**. Chlamydia point-of-care diagnostics: caveat emptor. *Sex Transm Infect*. 2014;90(3):176-7. Epub 2014/04/11. doi: 10.1136/sextrans-2013-051445. PMID: 24719031.
97. **Van Der Pol B**. Sexually transmitted infections in women. *Scand J Clin Lab Invest Suppl*. 2014;244:68-74; discussion 3. Epub 2014/08/02. doi: 10.3109/00365513.2014.936691. PMID: 25083897.
98. **Van Der Pol B**, Williams JA, Taylor SN, Cammarata CL, Rivers CA, Body BA, Nye M, Fuller D, Schwebke JR, Barnes M, Gaydos CA. Detection of *Trichomonas vaginalis* DNA by use of self-obtained vaginal swabs with the BD ProbeTec Qx assay on the BD Viper system. *J Clin Microbiol*. 2014;52(3):885-9. Epub 2014/01/07. doi: 10.1128/JCM.02966-13. PMID: 24391200; PMCID: PMC3957762.
99. Williams JA, Eddleman L, Pantone A, Martinez R, Young S, **Van Der Pol B**. Time-Motion Analysis of Four Automated Systems for the Detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* by Nucleic Acid Amplification Testing. *J Lab Autom*. 2014;19(4):423-6. Epub 2013/11/08. doi: 10.1177/2211068213511245. PMID: 24196751.
100. Williams JA, Ofner S, Batteiger BE, Fortenberry JD, **Van Der Pol B**. Duration of polymerase chain reaction-detectable DNA after treatment of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Trichomonas vaginalis* infections in women. *Sex Transm Dis*. 2014;41(3):215-9. Epub 2014/02/14. doi: 10.1097/OLQ.0000000000000102. PMID: 24521729.

101. Davis A, Best J, Wei C, Luo J, **Van Der Pol B**, Meyerson B, Dodge B, Aalsma M, Tucker J, Group SefSHR. Intimate partner violence and correlates with risk behaviors and HIV/STI diagnoses among men who have sex with men and men who have sex with men and women in China: a hidden epidemic. *Sexually transmitted diseases*. 2015;42(7):387.
  
102. Hickey RJ, Zhou X, Settles ML, Erb J, Malone K, Hansmann MA, Shew ML, **Van Der Pol B**, Fortenberry JD, Forney LJ. Vaginal microbiota of adolescent girls prior to the onset of menarche resemble those of reproductive-age women. *MBio*. 2015;6(2):e00097-15.
  
103. Meyerson B, Sayegh M, Davis A, Arno J, Zimet G, LeMonte A, Williams J, Barclay L, **Van Der Pol B**. Cervical cancer screening in an STD clinic: Adoption experiences from a Midwestern Clinic. *Am J Public Health Nations Health*. 2015;in press.
  
104. Roth AM, **Van Der Pol B**, Fortenberry JD, Dodge B, Reece M, Certo D, Zimet GD. The impact of brief messages on HSV-2 screening uptake among female defendants in a court setting: a randomized controlled trial utilizing prospect theory. *J Health Commun*. 2015;20(2):230-6. Epub 2014/12/17. doi: 10.1080/10810730.2014.920062. PMID: 25494832; PMCID: PMC4356496.
  
105. Schick V, Dodge B, **Van Der Pol B**, Baldwin A, Fortenberry JD. Sexual behaviours, sex toy and sexual safety methods reported by women who have sex with women and men. *Sex Health*. 2015;12(4):287-99. Epub 2015/06/02. doi: 10.1071/SH14045. PMID: 26028062.
  
106. Schick V, **Van Der Pol B**, Dodge B, Baldwin A, Fortenberry JD. A mixed methods approach to assess the likelihood of testing for STI using self-collected samples among behaviourally bisexual women. *Sex Transm Infect*. 2015;91(5):329-33. Epub 2015/02/01. doi: 10.1136/sextrans-2014-051842. PMID: 25637328.
  
107. Schick VR, Baldwin A, Bay-Cheng LY, Dodge B, **Van Der Pol B**, Fortenberry JD. “First, I... then, we...”: exploring the sequence of sexual acts and safety strategies reported during a sexual encounter using a modified timeline followback method. *Sexually Transmitted Infections*. 2015.
  
108. Scott SA, Simon JE, **Van Der Pol B**, Docherty CL. Risk factors for sustaining a lower extremity injury in an army reserve officer training corps cadet population. *Military medicine*. 2015;180(8):910-6.
  
109. **Van Der Pol B**, Hook EW, 3rd, Williams JA, Smith B, Taylor SN. Performance of the BD CTQx and GCQx Amplified Assays on the BD Viper LT Compared With the BD Viper XTR System. *Sex Transm Dis*. 2015;42(9):521-3. Epub 2015/08/14. doi: 10.1097/OLQ.0000000000000313. PMID: 26270114.



110. Davis A, Best J, Luo J, **Van Der Pol B**, Dodge B, Meyerson B, Aalsma M, Wei C, Tucker JD, Social Entrepreneurship for Sexual Health Research Group. Differences in risk behaviours, HIV/STI testing and HIV/STI prevalence between men who have sex with men and men who have sex with both men and women in China. *Int J STD AIDS*. 2016;27(10):840-9. Epub 2015/07/18. doi: 10.1177/0956462415596302. PMID: 26185041; PMCID: PMC4714950.
111. Davis A, Roth A, Brand JE, Zimet GD, **Van Der Pol B**. Coping strategies and behavioural changes following a genital herpes diagnosis among an urban sample of underserved Midwestern women. *Int J STD AIDS*. 2016;27(3):207-12. Epub 2015/03/21. doi: 10.1177/0956462415578955. PMID: 25792549; PMCID: PMC5008844.
112. Pfeiffer EJ, McGregor KA, **Van Der Pol B**, Hardy Hansen C, Ott MA. Willingness to Disclose Sexually Transmitted Infection Status to Sex Partners Among College-Aged Men in the United States. *Sex Transm Dis*. 2016;43(3):204-6. Epub 2016/02/10. doi: 10.1097/OLQ.0000000000000420. PMID: 26859810; PMCID: PMC4748392.
113. Roth AM, Goldshear JL, Martinez-Donate AP, Welles S, Chavis M, **Van Der Pol B**. Reducing Missed Opportunities: Pairing Sexually Transmitted Infection Screening With Syringe Exchange Services. *Sex Transm Dis*. 2016;43(11):706-8. Epub 2016/11/29. doi: 10.1097/OLQ.0000000000000516. PMID: 27893601.
114. Schillinger JA, Katz BP, Markowitz LE, Braslins PG, Shrier LA, Madico G, **Van Der Pol B**, Orr DP, Rice PA, Batteiger BE. Genotype-Specific Concordance of *Chlamydia trachomatis* Genital Infection Within Heterosexual Partnerships. *Sex Transm Dis*. 2016;43(12):741-9. Epub 2016/11/12. doi: 10.1097/OLQ.0000000000000525. PMID: 27835626; PMCID: PMC5113142.
115. **Van Der Pol B**. Clinical and Laboratory Testing for *Trichomonas vaginalis* Infection. *J Clin Microbiol*. 2016;54(1):7-12. Epub 2015/10/23. doi: 10.1128/JCM.02025-15. PMID: 26491181; PMCID: PMC4702717.
116. **Van Der Pol B**. Type-specific detection of herpes simplex virus type 1 and type 2 using the cobas(R) HSV 1 and 2 test on the cobas(R) 4800 platform. *Expert Rev Mol Diagn*. 2016;16(11):1145-54. Epub 2016/10/30. doi: 10.1080/14737159.2016.1243473. PMID: 27687862.
117. Venner CM, Nankya I, Kyeyune F, Demers K, Kwok C, Chen P-L, Rwambuya S, Munjoma M, Chipato T, Byamugisha J, **Van Der Pol B**, Mugenyi P, Salata R, Morrison C, Arts E.. Infecting HIV-1 subtype predicts disease progression in women of sub-Saharan Africa. *EBioMedicine*. 2016;13:305-14.
118. Andriesen J, Bull S, Dietrich J, Haberer JE, **Van Der Pol B**, Voronin Y, Wall KM, Whalen C, Priddy F. Using Digital Technologies in Clinical HIV Research: Real-World Applications and

Considerations for Future Work. *J Med Internet Res.* 2017;19(7):e274. Epub 2017/08/02. doi: 10.2196/jmir.7513. PMID: 28760729; PMCID: PMC5556256.

119. Baldwin A, Schick VR, Dodge B, **Van Der Pol B**, Herbenick D, Sanders SA, Fortenberry JD. Variation in Sexual Identification Among Behaviorally Bisexual Women in the Midwestern United States: Challenging the Established Methods for Collecting Data on Sexual Identity and Orientation. *Arch Sex Behav.* 2017;46(5):1337-48. Epub 2016/08/05. doi: 10.1007/s10508-016-0817-0. PMID: 27488307.
120. Chatterji S, Bay-Cheng LY, Schick V, Dodge B, Baldwin A, **Van Der Pol B**, Fortenberry JD. The year's best: Interpersonal elements of bisexual women's most satisfying sexual experiences in the past year. *J Sex Res.* 2017;54(7):887-98.
121. Cristillo AD, Bristow CC, Peeling R, **Van Der Pol B**, de Cortina SH, Dimov IK, Pai NP, Jin Shin D, Chiu RY, Klapperich C, Madhivanan P, Morris SR, Klausner JD. Point-of-Care Sexually Transmitted Infection Diagnostics: Proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Group Programmatic Meeting. *Sex Transm Dis.* 2017;44(4):211-8. Epub 2017/03/11. doi: 10.1097/OLQ.0000000000000572. PMID: 28282646; PMCID: PMC5347466.
122. Jordan SJ, Schwebke JR, Aaron KJ, **Van Der Pol B**, Hook EW, 3rd. Meatal Swabs Contain Less Cellular Material and Are Associated with a Decrease in Gram Stain Smear Quality Compared to Urethral Swabs in Men. *J Clin Microbiol.* 2017;55(7):2249-54. Epub 2017/05/12. doi: 10.1128/JCM.00423-17. PMID: 28490486; PMCID: PMC5483927.
123. Muzny CA, Harbison HS, Austin EL, Schwebke JR, **Van Der Pol B**, Hook EW, 3rd. Sexually Transmitted Infection Risk among Women Is Not Fully Explained by Partner Numbers. *South Med J.* 2017;110(3):161-7. Epub 2017/03/04. doi: 10.14423/SMJ.0000000000000621. PMID: 28257539.
124. **Van Der Pol B**. Profile of the triplex assay for detection of chlamydia, gonorrhoea and trichomonas using the BD MAX™ System. *Expert Rev Mol Diagn.* 2017;17(6):539-47.
125. **Van Der Pol B**, Williams JA, Fuller D, Taylor SN, Hook EW, 3rd. Combined Testing for Chlamydia, Gonorrhoea, and Trichomonas by Use of the BD Max CT/GC/TV Assay with Genitourinary Specimen Types. *J Clin Microbiol.* 2017;55(1):155-64. Epub 2016/11/01. doi: 10.1128/JCM.01766-16. PMID: 27795343; PMCID: PMC5228226.
126. Dionne-Odom J, Geisler WM, Aaron KJ, Waites KB, Westfall AO, **Van Der Pol B**, Xiao L. High Prevalence of Multidrug-Resistant *Mycoplasma genitalium* in Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in Alabama. *Clin Infect Dis.* 2018;66(5):796-8. Epub 2017/10/14. doi: 10.1093/cid/cix853. PMID: 29028993; PMCID: PMC5850425.

127. Dionne-Odom J, Westfall AO, **Van Der Pol B**, Fry K, Marrazzo J. Sexually Transmitted Infection Prevalence in Women With HIV: Is There a Role for Targeted Screening? *Sex Transm Dis*. 2018;45(11):762-9. Epub 2018/04/12. doi: 10.1097/OLQ.0000000000000852. PMID: 29642121; PMCID: PMC6179909.
128. Gupta K, Bakshi RK, **Van Der Pol B**, Daniel G, Brown L, Press CG, Gorwitz R, Papp J, Lee JY, Geisler WM. Repeated *Chlamydia trachomatis* infections are associated with lower bacterial loads. *Epidemiol Infect*. 2018;147:e18. Epub 2018/10/05. doi: 10.1017/S0950268818002704. PMID: 30284525; PMCID: PMC6447480.
129. Jordan SJ, Aaron KJ, Schwebke JR, **Van Der Pol BJ**, Hook EW, 3rd. Defining the Urethritis Syndrome in Men Using Patient Reported Symptoms. *Sex Transm Dis*. 2018;45(7):e40-e2. Epub 2018/02/22. doi: 10.1097/OLQ.0000000000000790. PMID: 29465655; PMCID: PMC5995624.
130. Roth A, Tran NK, Chavis M, **Van Der Pol B**. Examining unmet needs: a cross-sectional study exploring knowledge, attitudes and sexually transmitted infection screening preferences among persons who inject drugs in Camden, New Jersey. *Sexually Transmitted Infections*. 2018;94(8):598-603. doi: 10.1136/sextrans-2017-053498. PMID: WOS:000452793400016.
131. Roth AM, Aumaier BL, Felsher MA, Welles SL, Martinez-Donate AP, Chavis M, **Van Der Pol B**. An Exploration of Factors Impacting Preexposure Prophylaxis Eligibility and Access Among Syringe Exchange Users. *Sexually Transmitted Diseases*. 2018;45(4):217-21. doi: 10.1097/Olq.0000000000000728. PMID: WOS:000428028200004.
132. **Van Der Pol B**, Daniel G, Kodsí S, Paradis S, Cooper CK. Molecular-based Testing for Sexually Transmitted Infections Using Samples Previously Collected for Vaginitis Diagnosis. *Clinical Infectious Diseases*. 2018.
133. Xiao L, Waites KB, Wang H, **Van Der Pol B**, Ratliff AE, Geisler WM. Evaluation of a real-time PCR assay for detection of *Mycoplasma genitalium* and macrolide resistance-mediating mutations from clinical specimens. *Diagn Microbiol Infect Dis*. 2018;91(2):123-5. Epub 2018/03/08. doi: 10.1016/j.diagmicrobio.2018.02.002. PMID: 29510884; PMCID: PMC5970045.
134. Aaron KJ, **Van Der Pol B**, Jordan SJ, Schwebke JR, Hook EW, 3rd. Delay in Seeking Health Care Services After Onset of Urethritis Symptoms in Men. *Sex Transm Dis*. 2019;46(5):317-20. Epub 2019/04/16. doi: 10.1097/OLQ.0000000000000976. PMID: 30985634; PMCID: PMC6481179.
135. Craig-Kuhn MC, Granade C, Muzny CA, **Van Der Pol B**, Lillis R, Taylor SN, Schmidt N, Martin DH, Kissinger P. Optimal Timing for *Trichomonas vaginalis* Test of Cure Using Nucleic Acid Amplification Testing. *Sex Transm Dis*. 2019;46(5):312-6. Epub 2019/01/03. doi: 10.1097/OLQ.0000000000000968. PMID: 30601374; PMCID: PMC6465101.

136. Harrison SA, Olson KM, Ratliff AE, Xiao L, **Van Der Pol B**, Waites KB, Geisler WM. *Mycoplasma genitalium* Coinfection in Women With *Chlamydia trachomatis* Infection. Sex Transm Dis. 2019;46(10):e101-e4. Epub 2019/09/14. doi: 10.1097/OLQ.0000000000001028. PMID: 31517808; PMCID: PMC7457732.
137. Nye MB, Osiecki J, Lewinski M, Liesenfeld O, Young S, Taylor SN, Lillis RA, Body BA, Eisenhut C, Hook Iii EW, **Van Der Pol B**. Detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* with the cobas CT/NG v2.0 test: performance compared with the BD ProbeTec CT Q(x) and GC Q(x) amplified DNA and Aptima AC2 assays. Sex Transm Infect. 2019;95(2):87-93. Epub 2018/08/22. doi: 10.1136/sextrans-2018-053545. PMID: 30126947; PMCID: PMC6580769.
138. Shaw MK, Porterfield HS, Favaloro S, Dehon PM, **Van Der Pol B**, Quayle AJ, McGowin CL. Prevalence and cervical organism burden among Louisiana women with *Trichomonas vaginalis* infections. PLoS One. 2019;14(6):e0217041. Epub 2019/06/21. doi: 10.1371/journal.pone.0217041. PMID: 31220094; PMCID: PMC6586396.
139. **Van Der Pol B**. Making the most of point-of-care testing for sexually transmitted diseases. Clinical Infectious Diseases. 2019.
140. **Van Der Pol B**, Fife K, Taylor SN, Nye MB, Chavoustie SE, Eisenberg DL, Crane L, Hirsch G, Arcenas R, Marlowe EM. Evaluation of the Performance of the Cobas CT/NG Test for Use on the Cobas 6800/8800 Systems for Detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in Male and Female Urogenital Samples. J Clin Microbiol. 2019;57(4):e01996-18. Epub 2019/01/18. doi: 10.1128/JCM.01996-18. PMID: 30651389; PMCID: PMC6440774.
141. Xiao L, Waites KB, **Van Der Pol B**, Aaron KJ, Hook EW, 3rd, Geisler WM. *Mycoplasma genitalium* Infections With Macrolide and Fluoroquinolone Resistance-Associated Mutations in Heterosexual African American Couples in Alabama. Sex Transm Dis. 2019;46(1):18-24. Epub 2018/07/07. doi: 10.1097/OLQ.0000000000000891. PMID: 29979336; PMCID: PMC6289787.
142. Chavez PR, Soehnlén MK, **Van Der Pol B**, Gaynor AM, Wesolowski LG, Owen SM. Highlights From the 2019 HIV Diagnostics Conference: Optimizing Testing for HIV, STIs, and HCV. Sex Transm Dis. 2020;47(5S Suppl 1):S2-S7. Epub 2019/12/06. doi: 10.1097/OLQ.0000000000001107. PMID: 31804298.
143. Felsher M, Bellamy S, Piccara B, **Van Der Pol B**, Laurano R, Roth AM. Applying the Behavioral Model for Vulnerable Populations to Pre-Exposure Prophylaxis Initiation among Women Who Inject Drugs. Aids Education and Prevention. 2020;32(6):486-92. doi: 10.1521/aeap.2020.32.6.486. PMID: WOS:000618983800003.

144. Footman A, Dionne-Odom J, Aaron KJ, Raper JL, **Van Der Pol B**. Performance of 4 Molecular Assays for Detection of Chlamydia and Gonorrhea in a Sample of Human Immunodeficiency Virus-Positive Men Who Have Sex With Men. *Sex Transm Dis*. 2020;47(3):158-61. Epub 2020/02/08. doi: 10.1097/OLQ.0000000000001115. PMID: 32032316; PMCID: PMC7393578.
145. Gettinger J, Van Wagoner N, Daniels B, Boutwell A, **Van Der Pol B**. Patients Are Willing to Wait for Rapid Sexually Transmitted Infection Results in a University Student Health Clinic. *Sex Transm Dis*. 2020;47(1):67-9. Epub 2019/12/20. doi: 10.1097/OLQ.0000000000001083. PMID: 31856075.
146. Gragg SD, Gupta KA, Olson KM, **Van Der Pol B**, Xiao L, Waites KB, Geisler WM. *Mycoplasma genitalium* Infection in Young Women Without Urogenital Symptoms Presenting to a Community-Based Emergency Department in Birmingham, Alabama. *Sexually Transmitted Diseases*. 2020.
147. **Van Der Pol B**. A profile of the cobas® TV/MG test for the detection of *Trichomonas vaginalis* and *Mycoplasma genitalium*. *Expert Rev Mol Diagn*. 2020(just-accepted).
148. **Van Der Pol B**. A profile of the cobas(R) CT/NG assay on the cobas(R) 6800/8800 system for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. *Expert Rev Mol Diagn*. 2020;20(4):375-80. Epub 2020/02/06. doi: 10.1080/14737159.2020.1724093. PMID: 32008410.
149. **Van Der Pol B**, Taylor SN, Mena L, Lebed J, McNeil CJ, Crane L, Ermel A, Sukhija-Cohen A, Gaydos CA. Evaluation of the performance of a point-of-care test for chlamydia and gonorrhea. *JAMA Netw Open*. 2020;3(5):e204819. Epub 2020/05/15. doi: 10.1001/jamanetworkopen.2020.4819. PMID: 32407506; PMCID: PMC7225902.
150. **Van Der Pol B**, Torres-Chavolla E, Kodsi S, Cooper CK, Davis TE, Fife KH, Taylor SN, Augenbraun MH, Gaydos CA. Clinical performance of the BD CTGCTV2 assay for the BD MAX™ System for detection of *Chlamydia trachomatis*, *Neisseria gonorrhoeae* and *Trichomonas vaginalis* infections. *Sexually Transmitted Diseases*. 2020.
151. **Van Der Pol B**, Waites KB, Xiao L, Taylor SN, Rao A, Nye M, Chavoustie S, Ermel A, Kaplan C, Eisenberg D, Chan PA, Mena L, Pacheco S, Krishnamurthy S, Mohan R, Bertuzis R, McGowin CL, Arcenas R, Marlowe EM. *Mycoplasma genitalium* Detection in Urogenital Specimens from Symptomatic and Asymptomatic Men and Women by Use of the cobas TV/MG Test. *J Clin Microbiol*. 2020;58(6):1-9. Epub 2020/03/28. doi: 10.1128/JCM.02124-19. PMID: 32213558; PMCID: PMC7269414.
152. Young S, Vaughan L, Yanson K, Eckert K, Li A, Harris J, Ermel A, Williams JA, Al-Ghoul M, Cammarata CL, Taylor SN, Luff R, Cooper CK, **Van Der Pol B**. Analytical and Clinical Sample Performance Characteristics of the Onclarity Assay for the Detection of Human Papillomavirus. *J*

Clin Microbiol. 2020;59(1):e02048-20. Epub 2020/10/23. doi: 10.1128/JCM.02048-20. PMID: 33087435; PMCID: PMC7771472.

153. Aaron KJ, Brill I, Causey-Pruitt Z, Murphy K, Augenbraun M, Kassaye S, Milam JE, Seidman D, French AL, Gange SJ, Adimora AA, Sheth AN, Fischl MA, **Van Der Pol B**, Marrazzo J, Kempf MC, Dionne-Odom J. Factors associated with syphilis seroprevalence in women with and at-risk for HIV infection in the Women's Interagency HIV Study (1994-2015). *Sex Transm Infect.* 2021. Epub 2021/01/08. doi: 10.1136/sextrans-2020-054674. PMID: 33408096.
154. Arumugam A, Markham C, Aykar SS, **Van Der Pol B**, Dixon P, Wu M, Wong S. PrintrLab incubator: A portable and low-cost CO2 incubator based on an open-source 3D printer architecture. *PloS one.* 2021;16(6):e0251812.
155. Dionne-Odom J, **Van Der Pol B**, Boutwell A, Biligowda N, Schmid DG, Hook EW. Limited utility of reverse algorithm syphilis testing in HIV clinic among men who have sex with men. *Sexually Transmitted Diseases.* 2021;48(9):675-9. doi: 10.1097/OLq.0000000000001386. PMID: WOS:000686747700016.
156. Exten C, Pinto CN, Gaynor AM, Meyerson B, Griner SB, **Van Der Pol B**, Board of Directors of the American Sexually Transmitted Diseases A. Direct-to-Consumer sexually transmitted infection testing services: A position statement from the American Sexually Transmitted Diseases Association. *Sex Transm Dis.* 2021;48(11):e155-e9. Epub 2021/05/25. doi: 10.1097/OLQ.0000000000001475. PMID: 34030157; PMCID: PMC8505153
157. Footman A, Dagama D, Smith CH, **Van Der Pol B**. A systematic review of new approaches to sexually transmitted infection screening framed in the Capability, Opportunity, Motivation, and Behavior Model of implementation science. *Sex Transm Dis.* 2021;48(8S):S58-S65. Epub 2021/05/04. doi: 10.1097/OLQ.0000000000001461. PMID: 33938515; PMCID: PMC8284379
158. Gupta K, Harrison SA, Davis NA, Culp ML, Hand SC, Simpson T, **Van Der Pol B**, Galbraith JW, Van Wagoner NJ, Morrison SG, Morrison RP, Geisler WM. Prevalence of *Chlamydia trachomatis* Infection in young women and associated predictors. *Sex Transm Dis.* 2021;48(8):529-35. Epub 2021/06/11. doi: 10.1097/OLQ.0000000000001372. PMID: 34110759.
159. Olson E, Gupta K, **Van Der Pol B**, Galbraith JW, Geisler WM. *Mycoplasma genitalium* infection in women reporting dysuria: A pilot study and review of the literature. *Int J STD AIDS.* 2021:09564624211030040.
160. Pinto CN, Niles JK, Kaufman HW, Marlowe EM, Alagia DP, Chi GQ, **Van Der Pol B**. Impact of the COVID-19 pandemic on chlamydia and gonorrhea screening in the US. *American Journal of*

Preventive Medicine. 2021;61(3):386-93. doi: 10.1016/j.amepre.2021.03.009. PMID: WOS:000693070000015.

161. Robinson ML, Gaydos C, **Van Der Pol B**, McFall S, Hsieh Y-H, Clarke W, Murphy RL, Widdice LE, Hirschhorn LR, Rothman R. The Clinical Review Committee: impact of the development of in vitro diagnostic tests for SARS-CoV-2 within RADx Tech. IEEE Open Journal of Engineering in Medicine and Biology. 2021;2:138-41.
162. Roth AM, Tran NK, Felsher M, Gadegbeku AB, Piecara B, Fox R, Krakower DS, Bellamy SL, Amico KR, Benitez JA, **Van Der Pol B**. Integrating HIV Preexposure Prophylaxis with community-based syringe services for women who inject drugs: results from the Project SHE demonstration study. J Acquir Immune Defic Syndr. 2021;86(3):e61-e70. Epub 2020/11/06. doi: 10.1097/QAI.0000000000002558. PMID: 33148998; PMCID: PMC7878321.
163. Tran NK, Felsher M, **Van Der Pol B**, Bellamy SL, McKnight J, Roth AM. Intention to initiate and uptake of PrEP among women who injects drugs in a demonstration project: an application of the theory of planned behavior. Aids Care-Psychological and Socio-Medical Aspects of Aids/HIV. 2021;33(6):746-53. doi: 10.1080/09540121.2021.1874267. PMID: WOS:000610175600001.
164. **Van Der Pol B**, Gaydos CA. A profile of the binx health io® molecular point-of-care test for chlamydia and gonorrhea in women and men. Expert Rev Mol Diagn. 2021 :1-8. Doi: 10.1080/14737159-2-21.1952047.
165. **Van Der Pol B**, Rao A, Nye MB, Chavoustie S, Ermel A, Kaplan C, Eisenberg D, Chan PA, Mena L, Pacheco S. *Trichomonas vaginalis* detection in urogenital specimens from symptomatic and asymptomatic men and women using the cobas TV/MG test. Journal of Clinical Microbiology. 2021:JCM. 00264-21.
166. **Van Der Pol B**, Chernesky M, Gaydos CA, Hook EW, 3rd, Joseph AM, Christensen K, Arcenas R, Boutwell A, Wiesenfeld HC, Taylor SN, Mayer KH, Golden MR, Moncada J, Jang D, Schachter J, ExGen Study Group. Multicenter comparison of nucleic acid amplification tests for the diagnosis of rectal and oropharyngeal *Chlamydia trachomatis* and *Neisseria gonorrhoeae* infections. J Clin Microbiol. 2022;60(1):e0136321. Epub 2021/11/04. doi: 10.1128/JCM.01363-21. PMID: 34731020.
167. Mbah CE, Jasani A, Aaron KJ, Akoachere J-F, Tita AT, Geisler WM, **Van Der Pol B**, Dionne-Odom J, Ngeudia JCA. Association between *Chlamydia trachomatis*, *Neisseria gonorrhoea*, *Mycoplasma genitalium*, and *Trichomonas vaginalis* and Secondary Infertility in Cameroon: A case-control study. PLoS One. 2022;17(2):e0263186.
168. Baldanti F, Ganguly NK, Wang G, Möckel M, O'Neill LA, Renz H, dos Santos Ferreira CE, Tateda K, **Van Der Pol B**. Choice of SARS-CoV-2 diagnostic test: challenges and key considerations for the future. Crit Rev Clin Lab Sci. 2022:1-15. doi: 10.1080/10408363.2022.2045250.

169. Tran NK, **Van Der Pol B**, Shrestha R, Bazzi AR, Bellamy SL, Sherman SG, Roth AM. Limited risk compensation among women who inject drugs: Results from the Project Sexual Health Equity preexposure prophylaxis demonstration study in Philadelphia. *Sex Transm Dis*. 2022; 49(5):e64-e6. doi: 10.1097/olq.0000000000001577. PMID: 00007435-202205000-00010.
170. Eloppe L, Boutwell A, Gordon B, Johnson B, Marrazzo J, **Van Der Pol B**, Mugavero MJ. PrEP service delivery preferences of black Cis-gender women living in the Southern United States. *AIDS Behav*. 2022;1-11. Doi: 10.1007/s10461-022-03691-9
171. Van Gerwen O, Griner S, Davis A, Footman A, Pinto CN, Melendez JH, Tuddenham S, Exten C, Soge OO, Chakraborty P, Nenninger A, Marlowe EM, Joseph AM, McGowin CL, Seña AC, Fortenberry JD, Ghanem KG, **Van Der Pol B**. Summary of the fourth annual American Sexually Transmitted Diseases Association Workshop on improving Sexually Transmitted Infection control efforts through cross-sector collaboration. *Sexually Transmitted Diseases*. 2022;49(8):588-93. doi: 10.1097/olq.0000000000001651. PMID: 00007435-202208000-00011.
172. Kilgore JR, Johnston JR, **Van Der Pol B**, Li P, Wilson M, Curry W, Selleck C. Use of a Screening Protocol to Identify Asymptomatic COVID-19 in a Free Community Health Clinic in Shelby County, Alabama, October 2020–February 2021. *Pub H Rep*. 2022. pp 1-6. Doi: 10.1177/00333549221110289
173. McCollum CG, Creger TN, Rana AI, Matthews LT, Baral SD, Burkholder GA, Curry W, Eloppe L, Fletcher FE, Grooms S, Levitan E, Michael M III, **Van Der Pol B**, Mugavero MJ. COVID Community-engaged testing in Alabama (COVID COMET AL): Reaching underserved rural populations through collaboration. *Am J Pub H*. 2022 112(10):1399–1403
174. Griner SB, Footman A, **Van Der Pol B**. Mentoring relationships in the field of sexually transmitted infections: Experiences, observations, and recommendations. *H Behav Res*. 2022; 5:1-9. doi.org/10.4148/2572-1836.1142
175. Gupta K, **Van Der Pol B**, Press CG, Geisler WM. *Chlamydia trachomatis* infection and seropositivity in women reporting sexual contact to a chlamydia-infected partner. *Sex Transm Dis*. 2022;49(9):e97-e9. doi: 10.1097/olq.0000000000001613. PMID: 00007435-202209000-00012.
176. Footman A, Kanney N, Niccolai LM, Zimet GD, Overton ET, Davies SL, **Van Der Pol B**. Parents' acceptance of COVID-19 compared to Human Papillomavirus vaccines. *J Adol Health*. 2022; on-line-ahead of print. Doi: 10.1016/j.jadohealth.2022.07.015
177. Footman A, Kanney N, Niccolai LM, Zimet GD, Overton ET, Davies SL, **Van Der Pol B**. Perceived need and acceptance of a future chlamydia vaccine among healthcare providers. *Sex Transm Dis* 2022; 49:740-744 DOI: 10.1097/olq.0000000000001663.
178. Footman A, Kanney N, Niccolai LM, Zimet GD, Overton ET, Davies SL, **Van Der Pol B**. Chlamydia vaccination: Parent opinions and implications for future promotion programs. *Sex Tranm Dis* 2022; 49:745-749. DOI: 10.1097/olq.0000000000001692.



179. Hu M, Souder JP, Subramaniam A, **Van Der Pol B**, Xiao L, Gupta K, Dionne-Odom J, Geisler WM. Prevalence of *Mycoplasma genitalium* infection and macrolide resistance in pregnant women receiving prenatal care. *Int J Gynecol Obstet.* 2023; 341-344. Doi: 10.1002/ijgo.14443
180. Lillis RA, Parker RL, Ackerman R, Ackerman J, Young S, Weissfeld A, Trevino E, Nachamkin I, Crane L, Brown J, Huang C, Liu X, **Van Der Pol, B**. Clinical evaluation of a new molecular test for the detection of organisms causing vaginitis and vaginosis. *J Clin Microbiol.*2023; e01748-22. doi: doi:10.1128/jcm.01748-22.
181. Aaron KJ, Griner S, Footman A, Boutwell A, and **Van Der Pol B**. Vaginal swab vs urine for detection of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Trichomonas vaginalis*: A meta-analysis. *Ann Fam Med.* 2023;21:172-179.
182. Kahn M, **Van Der Pol B**. Advances in diagnostics of sexually transmitted infections. *Infect Dis Clin N Am.* 2023:381-404. doi: 10.1016/j.idc.2023.02.002.
183. Toh E, Xing Y, Gao X, Jordan SJ, Batteiger TA, Batteiger BE, **Van Der Pol B**, Muzny CA, Gebregziabher N, Williams JA, Fortenberry LJ, Fortenberry JD, Dong Q, Nelson DE. Sexual behavior shapes male genitourinary microbiome composition. *Cell Rep Med.* 2023;4(3):100981. doi: <https://doi.org/10.1016/j.xcrm.2023.100981>.
184. Manca E, **Van Der Pol B**, Exten C, Pinto CN. A review of the scope of direct-to-consumer sexually transmitted infection testing services offered on the internet. *Sex Transm Dis.* 2023; 50(6):p 323-328. doi:10.1097/OLQ.0000000000001783
185. Camino AF, Whitfield M, Pridgen K, **Van Der Pol B**, Van Wagoner N. Embedding a dedicated sexual health clinic in a university's health services expands STI screening options. *Sex Transm Dis.* 2023; 50: 462-466. doi: 10.1097/olq.0000000000001804
186. Pinto, C. , Jung, M. , Wimmer, M. , Goldblatt, C. , Sweeney, N. , Broache, M., **Van Der Pol, B**. Differential screening for non-viral sexually transmitted infections by type of vaginitis testing. *Sex Transm Dis.* 2023 50: 531-535. doi: 10.1097/OLQ.0000000000001820
187. Muzny CA, Cerca N, Elnaggar JH, Taylor CM, Sobel JD, **Van Der Pol B**. State of the art for diagnosis of Bacterial Vaginosis. *J Clin Microbiol.* 2023:e00837-22.
188. **Van Der Pol B**. Testing technologies as enhancers of disease intervention specialist activities: applying lessons from COVID-19. *Sex Transm Dis.* 2023;50(8S):S53-S6. doi: 10.1097/olq.0000000000001732.
189. Chitneni P, Owembabazi M, Muyindike W, Asimwe S, Masete G, Mbalibulha Y, Nakku-Joloba E, Manabe YC, Haberer J, Matthews L, **Van Der Pol B**. Sexually transmitted infection point-of-care testing in resource-limited settings: a narrative review guided by an implementation framework. *Sex Transm Dis.* 2023; 50:e11-e16 doi: 10.1097/olq.0000000000001848.

190. Totten AH, Xiao L, **Van Der Pol B**, Szychowski J, Subramaniam A, Geisler WM. Retrospective evaluation of *Mycoplasma genitalium* prevalence and macrolide resistance in a study cohort of pregnant women in Birmingham, Alabama from 1997-2001. *Sex Transm Dis.* 2023; 50:642-644 doi: 10.1097/olq.0000000000001843.
191. Sohail M, Boutwell A, Johnson B, **Van Der Pol B**, Marrazzo J, Mugavero M, Chapman-Lambert C, Elope L. Factors associated with willingness to use PrEP among Black cis-gender women residing in rural and urban areas: A cross-sectional study. *Sex Transm Dis*, 2023 On line ahead of print,. doi: 10.1097/olq.0000000000001858. PubMed PMID: 00007435-990000000-00235.
192. D'Amico M, Mbah JCE, Gupta K, Dionne JA, Akoachere JF, Assob Nguedia JC, **Van Der Pol B**, Geisler WM. *Chlamydia trachomatis*-specific antibody responses in women in Cameroon with secondary infertility. *Sex Transm Dis.* 2023 on-line ahead of print. DOI: 10.1097/OLQ.0000000000001866
193. Irie WC, Mahone A, Johnson B, Marrazzo J, Mugavero MJ, **Van Der Pol b**, Elope L. “Just the stigma associated with PrEP makes you feel like its HIV itself”: Exploring PrEP stigma, skepticism and medical mistrust among Black cis-gender women in urban and rural communities in the US Deep South. *Arch Sex Behav.* 2024. epub Doi: 10.1007/s10508-028-02769-2
194. Gleeson B, Piton J, Mazzola L, McHugh S, Bender J, Lear M, Gavrikova T, **Van Der Pol B**, Daniels B, Osborn J, Dailey P, Ferreyra C. Development of a Novel Fluorescent-Based Lateral Flow Assay for the Detection of *Neisseria gonorrhoeae* at the Point of Care. *Sexually Transmitted Diseases.* 2024;51(3):186-91. doi: 10.1097/olq.0000000000001913. PubMed PMID: 00007435-202403000-00008.
195. Tucker JD, Chikwari CD, Tang W, Jarolimova J, Gravett R, Goense CJD, Matoga MM, Tan RKJ, Niaupari S, Morroni C, **Van Der Pol B**. A Conference Designathon to Spark Innovation: Actionable Ideas to Enhance STD Control. *Sex Transm Dis.* 2024. 51:e31-e35 doi: 10.1097/OLQ.0000000000001965.
196. Gravett RM, Tan RK, Tang W, Niapauri S, **Van Der Pol B**, Tucker JD. Catching lightning in a bottle: the STI and HIV World Congress Participatory Designathon. 2024. *Sex Health*; 21. Online-ahead-of-print doi:10.1071/SH23205
197. Dionne JA, Anchang-Kimbi J, Hao J, Long D, Apinjoh T, Tih P, Mbah R, Ngah EN, Juliano JJ, Kahn M, Bruxvoort K, **Van Der Pol B**, Tita ATN, Marrazzo J, Achidi E. Trimethoprim-Sulfamethoxazole plus Azithromycin to Prevent Malaria and Sexually Transmitted Infections in Pregnant Women with HIV (PREMISE): A Randomized, Double-Masked, Placebo-Controlled, Phase IIB Clinical Trial. *Open Forum Infectious Diseases.* 2024.
198. Gottlieb SL, Spielman E, Abu-Raddad L, Aderoba AK, Bachmann LH, Blondeel K, Chen XS, Crucitti T, Camacho GG, Godbole S, Ponce de Leon RG, Gupta S, Hermez J, Ishikawa N, Klausner JD, Kurbonov F, Maatouk I, Mandil A, Mello MB, Miranda AE, Mosha FS, Okeibunor JC, Ong JJ, Peters RPH, Pérez F, Seguy N, Seib KL, Sharma M, Sladden T, **Van Der Pol B**, White PJ, Wi T,

Broutet N. World Health Organization global research priorities for sexually transmitted infections. 2024 Lancet Global, on-line-ahead of print

### **Reviews, Reports, Editorials & Letters**

1. **Van Der Pol, B.** Forward, in Chlamydia: The Silent Disease. T. Moss, A. Woodland, Editors, **2007**, Merit Publishing International: Weybridge, Surrey.
2. Moss TR, **Van Der Pol B.** Dual infection with *Neisseria gonorrhoeae* and *Chlamydia trachomatis*. Int J STD AIDS. **2009**;20(2):143-4. Epub 2009/02/03. doi: 10.1258/ijsa.2008.008408. PMID: 19182067.
3. Roth AM, JG Rosenberger, J Waters, B **Van Der Pol.** Marion County Syphilis Elimination Project: understanding sex workers health-related issues. Indianapolis: Report for the Marion County Public Health Department; **2010**.
4. **Van Der Pol, B.** Laboratory Systems Evaluation. Prepared for the University of Zimbabwe-University of California San Francisco Program Executive Committee. **2011**
5. **Van Der Pol, B.** *Trichomonas vaginalis*: It's out there and it's coming your way! Med Lab Obs. **2013**.
6. **Van Der Pol B.** Chlamydia point-of-care diagnostics: caveat emptor. Sex Transm Infect. **2014**;90(3):176-177. Epub 2014/04/11. doi: 10.1136/sextrans-2013-051445.
7. **Van Der Pol B.** Overcoming Barriers to STD Testing. Advance/Laboratory pp.18-20. [www.advanceweb.com](http://www.advanceweb.com) April **2015**
8. **Van Der Pol, B.** New testing options fo *Trichomans vaginalis*respond to growing awareness. Medical Laboratory Observer. **2016**; 6:1-14.
9. **Van Der Pol B.** Sexually Transmitted Infections and Human Immunodeficiency Virus: Are We Applying the Lessons Learned? *Sex Transm Dis.* **2017**;44(3):141-2. doi: 10.1097/olq.0000000000000588. PMID: 00007435-201703000-00002.
10. **Van Der Pol B.** We Have the Technology, but Should We Build the Test? Expert Rev Mol Diagn. **2018**. doi: 10.1080/14737159.2018.1535905.
11. **Van Der Pol, B.** The case for universal STI screening. Clinical Lab Prodcuts. **2018**; pp20-25
12. **Van Der Pol B.** Making the most of Point-of-Care testing for sexually transmitted diseases. Clin Inf Dis. **2020**. 70:1874-1875
13. **Van Der Pol B.** When is Any Test Better than No Test for Chlamydia? On-line Ahead of Print. Sex Transm Dis. **2021**; 48: 521-522

14. Zhong G, Chernesky M, Hook EWI, **Van Der Pol B**. Celebrating 60 years of Research at the 15th International Symposium on Human Chlamydial Infections. *Sex Transm Dis.* **2022.** 50:129-130. doi: 10.1097/olq.0000000000001753. PMID: 00007435-990000000-00126.
15. **Van Der Pol B**. An overview of the BD MAX Vaginal Panel assay on the BD COR System for molecular detection of causes of vaginitis. *touchRevin Infect Dis.* 2024; 3. Online ahead of print.
16. **Van Der Pol B**. Opportunities and challenges of point of care testing paradigms in the post-COVID era. *Expert Rev Mol Diagn.*1-3. doi: 10.1080/14737159.2024.2330774.

#### **BOOKS/BOOK CHAPTERS/EDITOR, SPECIAL EDITIONS**

1. **Van Der Pol B**. The diagnosis of *Chlamydia trachomatis* genital infection, in International Handbook of Chlamydia, T. Moss, Editor. 2006, Alden Press: Halsemere, Surrey. 2nd ed. p. 39-54.
2. **Van Der Pol B**. The diagnosis of *Chlamydia trachomatis* genital infection, in International Handbook of Chlamydia, T. Moss, Editor. 2007, Alden Press: Halsemere, Surrey. 3rd Ed.
3. Thorton A, Stevich B, Arno J, **Van Der Pol B**. Sexually Transmitted Diseases. In: Mainous AI, Pomeroy C, editors. Management of Antimicrobials in Infectious Diseases: Humana Press; 2010.
4. **Van Der Pol B**. The diagnosis of *Chlamydia trachomatis* genital infection, in T. Moss, Editor. International Handbook of Chlamydia, 4th end, Alden Press: Halsemere, Surrey. 2010.
5. **Van Der Pol B**. *Trichomonas vaginalis* Infections, in: Somesh G, Bhushan K, eds. Sexually Transmitted Infections 2<sup>nd</sup> Ed. New Delhi, India: Elsevier, 2012;pages 602-609
6. **Van Der Pol B**, Unemo M. Chapter 5: Chlamydial Infections. In: Unemo M, Ballard R, Ison C, Lewis D, Ndowa F, Peeling R, eds. Laboratory Diagnosis of Sexually Transmitted Infections including Human Immunodeficiency Virus. Geneva, WHO Publications. 2013
7. Adu-Sarkodie Y, Unemo M, **Van Der Pol B**. Chapter 6: Trichomoniasis. In: Unemo M, Ballard R, Ison C, Lewis D, Ndowa F, Peeling R, eds. Laboratory Diagnosis of Sexually Transmitted Infections including Human Immunodeficiency Virus. Geneva, WHO Publications. 2013
8. **Van Der Pol B** and Nelson DE. Chapter 13. Microbial Communities of the Male Urethra. In: “Molecular Microbiology: Diagnostic Principles and Practices.” Eds. Persing DH, et. al. 3<sup>rd</sup> Edition 2016: pages 146-155
9. **Van Der Pol B**, Gaydos CA. Chapter 38. Chlamydiae. In: Clinical Virology Manual”. Eds. Loefflholz MJ, Hodinka RL, Young SA, Pinsky BA. Fifth Edition 2016: pages 545-559
10. **Van Der Pol B**. Chapter 17. *Trichomonas vaginalis* In: Diagnostics to Pathogenomics of Sexually Transmitted Infections. Eds. Singh SK. 2018: pages 341-356

11. Proceedings of the 14<sup>th</sup> International Symposium on Human Chlamydial Infections. Eds. Chernesky M, Clarke I, Gaydos C, Hook EW III, Moore S, Ouburg S, Paavonen J, Schachter J, Starnbach M, Sary A, Stephens R, Timms P, **Van Der Pol B**, Zhong G. 2018
12. Proceedings of the 15<sup>th</sup> Julius Schachter International Symposium on Human Chlamydial Infections. Zhong, Brunham, Chernesky, Clarke, Darville, de Vries, Gaydos, Geub, Hook, Mabey, Moncada, Morre, Paavonen, Sary, Valdivia, **Van Der Pol**, West. (Eds) 2022.
13. International Society for STD Research World Congress: Local Engagement/Global Impact Abstract Publication. Sex Transm Dis 2024; 1(S1). Editors Barclay L, Wilson JD, **Van Der Pol, B**.

## **PUBLISHED ABSTRACTS**

### **Extended Abstracts (4-page, Peer-reviewed, Indexed)**

1. Jones, R and B **Van Der Pol**. *Chlamydia trachomatis* isolates resistant to multiple antibiotics. in Seventh International Symposium on Human Chlamydia Infections. 1990. Harrison Hot Springs, British Columbia, Canada: Cambridge University Press.
2. Peeling, R, W Bowie, J Dillon, R Jones, B **Van Der Pol**, D Low, et al. Standardization of antimicrobial susceptibility testing for *Chlamydia trachomatis*. in Eighth International Symposium on Human Chlamydial Infections. 1994. Chantilly, France
3. Batteiger, BE, P Lin, B **Van Der Pol**, and R Jones. Epitope mapping of the major outer membrane protein (omp1) of *Chlamydia trachomatis* serovar E. in Eighth International Symposium on Human Chlamydial Infections. 1994. Chantilly, France
4. Jones, R and B **Van Der Pol**. Lack of correlation between acquisition of infection and ability of serum to neutralize chlamydial infectivity in vitro. in Eighth International Symposium on Human Chlamydial Infections. 1994. Chantilly, France
5. Katz, BP, MJ Blythe, B **Van Der Pol**, and R Jones. Evaluation of a chlamydial control program among adolescent women. in Eighth International Symposium on Human Chlamydial Infections. 1994. Chantilly, France
6. **Van Der Pol**, B, JA Williams, and R Jones. Competitive expansion of serovars E and F combined in tissue culture. in Ninth International Symposium on Human Chlamydial Infections. 1998. Napa Valley, CA.
7. **Van Der Pol**, B, JA Williams, and NJ Smith. Reproducibility of three commercially available nucleic acid-based assays for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* from urine. in Tenth International Symposium on Human Chlamydial Infections. Schachter, Christiansen, Clarke, et al. (Eds) 2002. p. 401-404

8. Batteiger, BE, **B Van Der Pol**, DR Stothard, BP Katz, and D Fortenberry. Early natural history of treated and incident genital *Chlamydia trachomatis* infections in young women. in Tenth International Symposium on Human Chlamydial Infections. Schachter, Christiansen, Clarke, et al. (Eds) 2002. p. 169-172
9. Batteiger, BE, W Tu, BP Katz, M Temkit, L Meyer, **B Van Der Pol**, et al. Application of *Chlamydia trachomatis* diagnostic PCR to test multiple serial vaginal samples in a longitudinal study of adolescent women. in Eleventh International Symposium on Human Chlamydial Infections. Chernesky, Caldwell, Christiansen, et al. (Eds) 2006. p.513-516
10. Marshall, R, **B Van Der Pol**, JA Williams, J Schachter, J Moncada, S Ho, et al. New automated real time PCR technology for the detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. in Eleventh International Symposium on Human Chlamydial Infections. Chernesky, Caldwell, Christiansen, et al. (Eds) 2006. p.517-520
11. **Van Der Pol**, B, U Reischl, M Alberdi, O Landt, A Herring, and R Peeling. Distribution of *Chlamydia trachomatis* organism load in urogenital specimens determined using quantitative PCR. in Eleventh International Symposium on Human Chlamydial Infections. Chernesky, Caldwell, Christiansen, et al. (Eds) 2006. p.485-488
12. Jones, R, JA Williams, and **B Van Der Pol**. Variation in ratio of EB to IFU among laboratory strains and patient isolates of *Chlamydia trachomatis*. in Eleventh International Symposium on Human Chlamydial Infections. Chernesky, Caldwell, Christiansen, et al. (Eds) 2006. p.265-268
13. **Van Der Pol**, B, JA Williams, S Taylor, W Tu, BP Katz, BE Batteiger, et al. Chlamydia shedding during the weeks following infection in adolescent women. in Twelfth International Symposium on Human Chlamydial Infections. Schachter, Byrne, Caldwell, et al. (Eds). 2010 p.383-396
14. **Van Der Pol B**, Davis A, Dodge B, Zimet G. Chlamydia positivity rates and knowledge among men within the social networks of STD clinic attendees. in Thirteenth International Symposium on Human Chlamydial Infections. Schachter, Byrne, Chernesky, et al. (Eds) 2014. p.433-436
15. Hook EW III, **Van Der Pol B**, Gaydos CA, Taylor SN, Bachmann LH, Horner P, Birkmeir J, Persing D. Towards molecular diagnosis of nongonococcal urethritis: The sample adequacy control. in Thirteenth International Symposium on Human Chlamydial Infections. Schachter, Byrne, Chernesky, et al. (Eds) 2014. p. 221-224
16. Geisler W, Bakshi R, Aaron K, **Van Der Pol B**, Hook EW III. Factors influencing urogenital *Chlamydia trachomatis* clearance after treatment. in Proceedings of the Fourteenth International Symposium on Human Chlamydial Infections. Chernesky M, Clarke I, Gaydos C, et al. (Eds) 2018. p. 383-387
17. **Van Der Pol B**, Boutwell A, Daniel G, Hardy K, Gavrikova T, Aaron K. Distribution of *Chlamydia trachomatis* organism load in specimens determined using real-time PCR. in Proceedings of the Fourteenth International Symposium on Human Chlamydial Infections. Chernesky M, Clarke I, Gaydos C, et al. (Eds) 2018. p. 371-374

18. Aaron KJ, Griner S, Footman A, Boutwell A, **Van Der Pol, B.** Meta-analysis of CT and NG assay sensitivity for female vaginal swabs versus urine. in Proceedings of the Fifteenth Julius Schachter International Symposium on Human Chlamydial Infections. Zhong, Brunham, Chernesky, et al. (Eds) 2022. p.263-267
19. Footman A, Nicolai LM, Zimet GD, **Van Der Pol B.** Parents opinions on a future adolescent chlamydia vaccine. in Proceedings of the Fifteenth Julius Schachter International Symposium on Human Chlamydial Infections. Zhong, Brunham, Chernesky, et al. (Eds) 2022. p. 366-370
20. Griner SB, Johnson KC, Kinard A, Neelamegam M, Kline N, **Van Der Pol B.** Perceptions and adoption of evidence-based prenatal chlamydia screening guidelines. in Proceedings of the Fifteenth Julius Schachter International Symposium on Human Chlamydial Infections. Zhong, Brunham, Chernesky, et al. (Eds) 2022. p. 258-252
21. Gupta K, **Van Der Pol B,** Press C, Geisler WM. *Chlamydia trachomatis* infection and detection of chlamydia antibodies in women reporting sexual exposure to a chlamydia-infected partner. in Proceedings of the Fifteenth Julius Schachter International Symposium on Human Chlamydial Infections. Zhong, Brunham, Chernesky, et al. (Eds) 2022. p. 70-74
22. Hu M, Souder J, Subramaniam A, **Van Der Pol B,** Xiao L, Gupta K, Dionne-Odom J, Geisler W. *Mycoplasma genitalium* infection and associated macrolide resistance in pregnant women seen at an urban US medical center. in Proceedings of the Fifteenth Julius Schachter International Symposium on Human Chlamydial Infections. Zhong, Brunham, Chernesky, et al. (Eds) 2022. p. 41-45
23. **Van Der Pol B,**. The current landscape of chlamydia diagnostics. in Proceedings of the Fifteenth Julius Schachter International Symposium on Human Chlamydial Infections. Zhong, Brunham, Chernesky, et al. (Eds) 2022. p. 225-237

#### **Abstracts with Posters Presented at International Meetings**

1. **Van Der Pol B,** RB Jones and M Shepard. Recovery of *Chlamydia trachomatis* from the upper genital tract of infertile women. 8th International Society for STD Research, September 10-13, 1989, Copenhagen, Denmark.
2. Jones RB, B **Van Der Pol** and B Katz. Prevalence in *Chlamydia trachomatis* of heterotypic tetracycline (TCN) resistance and lack of association with short term treatment failures. 9th International Society for Sexually Transmitted Diseases, Banff, Alberta, Canada, October 6-9, 1991.
3. Jones RB, B **Van Der Pol,** B Katz. Lack of correlation of serum neutralizing antibodies to *Chlamydia trachomatis* with protection from recurrent infection. ISSTD-3, Helsinki, Finland, Aug. 29-Sept. 1, 1993.

4. **Van Der Pol B**, JA Williams, RB Jones. Comparison of Kodak sure-cell, Syva DFA and cell Cultures for the detection of endocervical chlamydial infection. ISSTD-93, Helsinki, Finland. Aug 29-Sept.1, 1993.
5. Peeling RW, JR Dillon, C Black, RB Jones, **B Van Der Pol**, DE Low, DH Martin, J Schachter, J Moncada. Standardization of antimicrobial susceptibility testing (AST) for *Chlamydia trachomatis*. 11th Meeting of the International Society for STD Research, New Orleans, Louisiana, USA. August 1995
6. Jones RB, **B Van Der Pol**, K Wools. *Chlamydia trachomatis* infection of the female urethra in the absence of detectable cervical infection. 3rd European *Chlamydia* Meeting. Vienna Austria. September 11-14, 1996.
7. **Van Der Pol B**, JA Williams, RB Jones. Distribution of serovars of *Chlamydia trachomatis* from cervical and urethral specimens. 12th Meeting of the International Society for Sexually Transmitted Diseases Research. Seville, Spain 1997
8. Williams JA, **B Van Der Pol**, RB Jones. Evaluation of combined PCR for the detection of *C. trachomatis* and *N. gonorrhoeae*. 12th Meeting of the International Society for Sexually Transmitted Diseases Research. Seville, Spain 1997
9. Smith NJ, RB Jones, K Smith, CJ Lenderman, EW Hook, TC Quinn, CA Gaydos, **B Van Der Pol**. Evaluation of The Becton Dickinson ProbeTec Thermophilic Strand Displacement Assay for the simultaneous amplification and detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. 13th Meeting of the International Society for Sexually Transmitted Diseases Research. Denver, CO July, 1999
10. Schillinger J, A Zaidi, K Hutchins, **B Van Der Pol**, RB Jones, C Black, R Johnson, L Markowitz, M St Louis. Can the urine ligase chain reaction be used to quantify organism load in men infected with *Chlamydia trachomatis*? 13th Meeting of the International Society for Sexually Transmitted Diseases Research. Denver, CO July, 1999
11. Tumwesigye E, **B Van Der Pol**, F Kambugo, T Tenywa, S Rwambuya, C Walker, C Whalen, S Spinola, R Salata. The prevalence of laboratory-confirmed STDs at the National STD Referral Centre, Kampala, Uganda. Presented at the XIII International AIDS Conference, Durban, South Africa, July 2000. Abstract WePeC4378.
12. Williams JA, **B Van Der Pol**, NJ Smith, RB Jones. Comparison of the sensitivity of *Chlamydia* culture and PCR in a male population with a high prevalence of multiple sexually transmitted infections. 4th European *Chlamydia* Meeting Helsinki, Finland August, 2000
13. Schillinger JA, **B Van Der Pol**, J Lin, T Brown, J Williams, X-H Su, A Zaidi, B Katz, P Rice, B Batteiger, L Markowitz, CM Black. Comparison of results of quantitative chlamydial culture performed at three different laboratories. 4th European *Chlamydia* Meeting Helsinki, Finland August, 2000



14. **Van Der Pol B**, JA Williams, NJ Smith, BE Batteiger, AP Cullen, T Edens, K Davis, H Salim, VW Chou, L Searce, J Blutman J, WJ Payne. Comparison of the Semi-Automated Digene Rapid Capture System™ with the Manual System for the Hybrid Capture 2 *Chlamydia* Assay Using Endocervical Samples. 14th meeting of the International Society for Sexually Transmitted Diseases Research. Berlin, Germany June, 2001
15. Williams JA, NJ Smith, **B Van Der Pol**. Comparison of two commercially available nucleic acid amplification tests for the detection of *Neisseria Gonorrhoeae* using female urine. 14th meeting of the International Society for Sexually Transmitted Diseases Research. Berlin, Germany June, 2001
16. **Van Der Pol B**, L Thompson, JD Fortenberry, DP Orr. Validation of Gram's stain for the detection of *Neisseria Gonorrhoeae* infection in asymptomatic men. 14th meeting of the International Society for Sexually Transmitted Diseases Research. Berlin, Germany June, 2001
17. **Van Der Pol B**, V Gindi, E Tumwesigye, F Kambugu, C Whalen. Prevalence of Selected Sexually Transmitted Infections in Women Attending the National STD Referral Centre in Kampala, Uganda. 14th meeting of the International Society for Sexually Transmitted Diseases Research. Berlin, Germany June, 2001
18. Williams JA, NJ Smith, **B Van Der Pol** and the Center for Mental Health Services - Project Shield Collaborators. Evaluation of female urine diluted in Fuji medium for the detection of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Trichomonas vaginalis* by PCR. 14th meeting of the International Society for Sexually Transmitted Diseases Research. Berlin, Germany June, 2001
19. Kendrick CS, JA Williams, **B Van Der Pol**. Evaluation of a modified Amplicor PCR assay for the detection of *Trichomonas vaginalis* DNA using female endocervical and urine specimens. 14th meeting of the International Society for Sexually Transmitted Diseases Research. Berlin, Germany June, 2001
20. Schmid G, **B Van Der Pol**, RB Jones, R Johnson. Further investigating the clinical importance of heterotypic resistant *Chlamydia trachomatis*. 14th meeting of the International Society for Sexually Transmitted Diseases Research. Berlin, Germany June, 2001
21. Batteiger BE, JD Fortenberry, **B Van Der Pol**, DR Stothard, BP Katz. Patterns of *Chlamydia trachomatis* infection in adolescent women by repeated sampling. 14th meeting of the International Society for Sexually Transmitted Diseases Research. Berlin, Germany June, 2001
22. Madico G, PA Rice, B Batteiger, PG Braslins, LA Shrier, **B Van Der Pol**, J Papp, CM Black, LE Markowitz, JA Schillinger. Quantification of *Chlamydia trachomatis* in clinical specimens using a touchdown enzyme time release asymmetric PCR (TETRA-PCR). 15th meeting of the International Society for Sexually Transmitted Diseases Research. Ottawa, Canada July, 2003
23. Madico G, PA Rice, B Batteiger, **B Van Der Pol**, PG Braslins, LA Shrier, TE Breen. *Trichomonas vaginalis* infection in sexual partnerships. 15th meeting of the International Society for Sexually Transmitted Diseases Research. Ottawa, Canada July, 2003

24. Schillinger JA, J Chapin, K Hutchins, P Braslins, L Shrier, G Madico, PA Rice, **B Van Der Pol**, T Breen, B Katz, D Orr, B Batteiger, J Papp, LE Markowitz. Transmission of *Chlamydia trachomatis* between heterosexual sex partners; preliminary results from a concordance study. 15th meeting of the International Society for Sexually Transmitted Diseases Research. Ottawa, Canada July, 2003
25. Kahn A, **B Van Der Pol**, TE Breen, JD Fortenberry, DP Orr, BE Batteiger. Sexually transmitted infections frequently differ between partners in sexual dyads. 15th meeting of the International Society for Sexually Transmitted Diseases Research. Ottawa, Canada July, 2003
26. Williams JA, **B Van Der Pol**, BP Katz, BE Batteiger, DP Orr, JD Fortenberry. *Chlamydia trachomatis* and Mycoplasma genitalium co-infection in the young women's project cohort. 5th Meeting of the European Society for *Chlamydia* Research. Budapest, Hungary September 2004.
27. **Van Der Pol** B, JA Williams, BE Batteiger, DP Orr, JD Fortenberry. Infection history and in vitro neutralizing antibodies against *Chlamydia trachomatis*. 5th Meeting of the European Society for *Chlamydia* Research. Budapest, Hungary September 2004.
28. Lenderman C, D Fuller, J Talbott, R Buckner, **B Van Der Pol**, J Williams, CL Cammarata, EW Hook. . Evaluation of the BD ProbeTec Urine Preservative Transport (UPT) for use with the BD ProbeTec ET *Neisseria Gonorrhoeae* Amplified DNA Assay. Presented at the 16th Biennial meeting of the International Society for Sexually Transmitted Diseases Research in Amsterdam 2005.
29. Morrison CS, C Kwok, **B Van Der Pol**, A Rinaldi, T Chipato, F Mmiro, R Mugerwa, C Cohen, RA Salata. Incident Sexually transmitted Infections Among HIV-Infected Women in Uganda and Zimbabwe. Presented at the 16th Biennial meeting of the International Society for Sexually Transmitted Diseases Research in Amsterdam 2005.
30. Williams J, **B Van Der Pol**, RB Jones, D Fuller, T Davis, CL Cammarata, CJ Lenderman, CA Aycock, EW Hook. Evaluation of the BD ProbeTec Urine Preservative Transport (UPT) for use with the BD ProbeTec ET *Chlamydia trachomatis* Amplified Assay. Presented at the 16th Biennial meeting of the International Society for Sexually Transmitted Diseases Research in Amsterdam 2005.
31. **Van Der Pol** B, JA Williams, B E Batteiger. Comparison of Liquid Cytology Medium to Digene Specimen Transport Medium in the Digene Hybrid Capture Ct-GC Assay for detection of *C. trachomatis* and *N. gonorrhoeae*. Presented at the 16th Biennial meeting of the International Society for Sexually Transmitted Diseases Research in Amsterdam 2005.
32. Williams J, JC Elkas, DK Kmak, BE Batteiger, **B Van Der Pol**. Comparison of the Manual Method and the Rapid Capture System using the Digene Hybrid Capture-2 HR HPV Assay for Detection of High-Risk HPV. Presented at the 16th Biennial meeting of the International Society for Sexually Transmitted Diseases Research in Amsterdam 2005.
33. **Van Der Pol** B, RA Salata, T Chipato, F Mmiro, R Mugerwa, NS Padian, B Richardson, CS Morrison. Performance of an HIV Diagnostic Algorithm on Identification of Incident Infection.

Presented at the 16th Biennial meeting of the International Society for Sexually Transmitted Diseases Research in Amsterdam 2005.

34. **Van Der Pol B**, JA Williams, BP Katz, BE Batteiger, DP Orr, JD Fortenberry. Mycoplasma genitalium Infection Within Sexual Partnerships. Presented at the 16th Biennial meeting of the International Society for Sexually Transmitted Diseases Research in Amsterdam 2005.
35. Williams J, B **Van Der Pol**, BE Batteiger, DP Orr, JD Fortenberry. The Natural History of Mycoplasma genitalium Infection in a Longitudinal Cohort of Adolescent Women in the Young Women's Project. Presented at the 16th Biennial meeting of the International Society for Sexually Transmitted Diseases Research in Amsterdam 2005.
36. **Van Der Pol B**, G Zimet, M Temkit, B Katz, D Orr, JD Fortenberry. Effect of Vaginal Moisturizer Use on Performance of PCR for Detection of *C. trachomatis* and *N. gonorrhoeae*. Presented at Microbicides 2006. 23rd April - 26th April 2006, Cape Town
37. **Van Der Pol B**, C Kwok, A Rinaldi, RA Salata, F Mmiro, R Mugerwa, T Chipato, CS Morrison. *Trichomonas vaginalis* as a Risk Factor for HIV Acquisition. Platform presentation at the XVI International AIDS Conference, 13-18 August, 2006, Toronto
38. **Van Der Pol B**, AM Roth, BM Dodge, JD Fortenberry. A qualitative assessment of men's preferences for accessing STI-screening services. Presented at the 18th Biennial meeting of the International Society for Sexually Transmitted Diseases Research in London 2009.
39. Williams JA, B **Van Der Pol**. High reproducibility of the Aptima Combo 2 CT/GC assay. Presented at the 18th Biennial meeting of the International Society for Sexually Transmitted Diseases Research in London 2009
40. Roth AM, B **Van Der Pol**, JM Brand, JN Arno, JD Fortenberry, GD Zimet, K Fife. Uptake of a rapid HSV-2 serology test in an urban STD clinic. Presented at the 18th Biennial meeting of the International Society for Sexually Transmitted Diseases Research in London 2009
41. Dodge BM, J Rosenberger, B **Van Der Pol**, M Reece. Acceptability of rectal self-sampling among MSM in community venues: a qualitative study. Presented at the 18th Biennial meeting of the International Society for Sexually Transmitted Diseases Research in London 2009
42. Rosenberger J, B **Van Der Pol**, BM Dodge, M Reece. Awareness of risk: rectal self-sampling for STD diagnostics. Presented at the 18th Biennial meeting of the International Society for Sexually Transmitted Diseases Research in London 2009
43. Roth AM, B **Van Der Pol**, NW Stupanski, JD Fortenberry. Assessing the psychometric properties of the perceived STD threat scale among young adults. Presented at the 18th Biennial meeting of the International Society for Sexually Transmitted Diseases Research in London 2009

44. Williams JA, B **Van Der Pol**. Evaluation of the Uri Swab sponge collection device for the detection of *Chlamydia trachomatis* in urine. Presented at the 18th Biennial meeting of the International Society for Sexually Transmitted Diseases Research in London 2009
45. Rosenberger J, B **Van Der Pol**, JA Williams, MA Ott. Acceptability of urine sample collection using a sponge-based device in a population of young men. Presented at the 18th Biennial meeting of the International Society for Sexually Transmitted Diseases Research in London 2009
46. Dodge B, B **Van Der Pol**, M Reece, O Martinez, D Malebranche, D Herbenick, JD Fortenberry. An exploratory study of sexual health among bisexual Black, White, and Latino men in the Midwestern United States. International Academy of Sex Research, Prague, Czech Republic. 2010
47. Zhou X, D Beck, M Settles, J Erb, MA Hansmann, AM Roth, C Robbins, B **Van Der Pol**, JD Fortenberry, LJ Forney. Preliminary characterization of the vaginal and vulva microbiota in pre-menarcheal girls and their mothers based on deep 16S rRNA sequencing. Presented at the International Human Microbiome Research Conference, St Louis, MO. August 2010
48. **Van Der Pol** B, JA Williams, EC Toh, W Van Der Pol, Q Dong, X Gao, KV Revanna, JD Fortenberry, DE Nelson. The urethral microbiome in health and STI: All urethritis is not created equal. Presented at the International Human Microbiome Research Conference, St Louis, MO. August 2010
49. Dong Q, X Gao, KV Revanna, DE Nelson, EC Toh, JA Williams, JD Fortenberry, B **Van Der Pol**. Urine specimen microbiomes are similar to those of paired urethral swabs. Presented at the International Human Microbiome Research Conference, St Louis, MO. August 2010
50. Nelson DE, B **Van Der Pol** , Q Don, E Sodergren, GM Weinstock, JD Fortenberry. The urethral and coronal sulcus microbiome of adolescent males. Presented at the International Human Microbiome Research Conference, St Louis, MO. August 2010
51. Nelson D, B **Van Der Pol**, Q Dong, D Mi, B Katz, E Sodergren, G Weinstock, JD Fortenberry. Association of sexual exposures and the microbial composition of the urethral and coronal sulcus microbiota in adolescent males. Presented at the International Human Microbiome Congress. Vancouver, Mar 2011
52. Nelson D, Q Dong, B **Van Der Pol**, D Mi, B Katz, G Weinstock, JD Fortenberry, E Sodergren. Stability of urethral microbiota in adolescent males. Presented at the International Human Microbiome Congress. Vancouver, Mar 2011
53. Dong Q, B **Van Der Pol**, D Nelson, D Mi, B Katz, E Sodergren, G Weinstock, JD Fortenberry. Comparison of the coronal sulcus and urethral microbiota in adolescent males. Presented at the International Human Microbiome Congress. Vancouver, Mar 2011
54. Huang M, L Corey, B **Van Der Pol**, E Hook, B Body, M Nye, S Taylor, M Martens, P Fine, S Ginde, J LeBed, L Mena, T Warren. Comparison of the BD ProbeTec HSVQx assays, ELVIS viral culture system, and TaqMan real-time PCR assays in herpes simplex virus detection of external

anogenital lesions. Presented at the 21st meeting of the European Congress on Clinical Microbiology and Infectious Diseases, Milan, May 2011

55. **Van Der Pol B**, BA Body, M Nye, C Eisenhut, SN Taylor, O Liesenfeld. Vaginal swabs are the optimal sample for screening women for *Chlamydia* and gonorrhea infection using the Roche cobas 4800 system. Presented at the 21st meeting of the European Congress on Clinical Microbiology and Infectious Diseases, Milan, May 2011
56. Rosenberger J, B **Van Der Pol**, D Herbenick, D Novak, M Reece, JD Fortenberry. Bacterial STI Testing Among Men who have Sex with Men in the United States. Presented at the 19th biennial meeting of the International Society for STD Research. Quebec City, July, 2011
57. Rosenberger J, B **Van Der Pol**, D Herbenick, D Novak, M Reece, JD Fortenberry. Examining Risk in High Risk" Populations: Measuring Sexual behavior among Men who have Sex with Men. Presented at the 19th biennial meeting of the International Society for STD Research. Quebec City, July, 2011
58. Rosenberger, JG, B **Van Der Pol**, D Herbenick, D Novak, M Reece, JD Fortenberry. Exploration of enema behaviors among men who have sex with men in the US. Presented at the 19th biennial meeting of the International Society for STD Research. Quebec City, July, 2011
59. Roth AM, B **Van Der Pol**, M Reece, B Dodge, G Zimet. Predictors of HSV-2 seroprevalence and willingness to accept a prescription for suppressive therapy among recently incarcerated women. Presented at the 19th biennial meeting of the International Society for STD Research. Quebec City, July, 2011
60. Brand JE, B **Van Der Pol**, K Fife, GD Zimet. A qualitative longitudinal study of post-diagnosis reactions among HSV-2 serologic positive women. Presented at the 19th biennial meeting of the International Society for STD Research. Quebec City, July, 2011
61. Roth AM, JG Rosenberger, J Waters, JN Arno, B **Van Der Pol**. Integrating public health into the sex worker community in Indianapolis. Presented at the 19th biennial meeting of the International Society for STD Research. Quebec City, July, 2011
62. **Van Der Pol B**, L Hires, SN Taylor, R Lillis, BA Body, MB Nye. Evaluation of the Roche cobas 4800 for the detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* using minimally invasive samples in women. Presented at the 19th biennial meeting of the International Society for STD Research. Quebec City, July, 2011
63. Pantone A, SN Taylor, R Lillis, BA Body, MB Nye, B **Van Der Pol**. Evaluation of the Roche cobas 4800 for the detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* using endocervical specimens. Presented at the 19th biennial meeting of the International Society for STD Research. Quebec City, July, 2011

64. Taylor SN, R Lillis, BA Body, MB Nye, JA Williams, B **Van Der Pol**. Evaluation of the Roche cobas 4800 for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in men. Presented at the 19th biennial meeting of the International Society for STD Research. Quebec City, July, 2011
65. **Van Der Pol B**, LJ Hires, JA Williams, L Corey, EW Hook, M Nye, SN Taylor, M Martens, L Mena, T Warren. Clinical evaluation of the BD HSV2 Qx assay for the direct qualitative testing of HSV 2 as compared to viral culture and a laboratory-based PCR assay using male and female external anogenital lesions. Presented at the 19th biennial meeting of the International Society for STD Research. Quebec City, July 2011
66. **Van Der Pol B**, A Pantone, JA Williams, L Corey, EW Hook, B Body, SN Taylor, P Fine, S Ginde, J LeBed. Clinical evaluation of the BD HSV1 Qx assay for the direct qualitative testing of HSV 1 as compared to viral culture and a laboratory-based PCR assay using male and female external anogenital lesions. Presented at the 19th biennial meeting of the International Society for STD Research. Quebec City, July 2011
67. Williams JA, A Pantone, B **Van Der Pol**. *Chlamydia trachomatis* detection by nucleic acid amplification using rectal swabs. Presented at the 19th biennial meeting of the International Society for STD Research. Quebec City, July 2011
68. **Van Der Pol B**, JA Williams, A Pantone. Using organism load of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in clinical specimens as an epidemiologic tool. Presented at the 19th biennial meeting of the International Society for STD Research. Quebec City, July, 2011
69. **Van Der Pol B**, Pantone A, Williams JA. Evaluation of three different diagnostic systems for the detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* from oral specimens. Presented at the 20<sup>th</sup> biennial meeting of the ISSTD, Vienna Austria July 2013
70. Schwebke JR, **Van Der Pol B**, Taylor SN, Smith B, Lebed J, Gaydos C, Fuller DD, Rivers CA, Aycock C, Nye MB. Comparison of specimen type for the diagnosis of *Trichomonas vaginalis* (TV) using the BD Viper™ System in Extracted Mode. Presented at the 20<sup>th</sup> biennial meeting of the ISSTD, Vienna Austria July 2013
71. Taylor SN, Smith B, Schwebke J, Lebed J, Fuller D, Lillis R, Gaydos CA, **Van Der Pol B**, Nye M, Body B. Evaluation of female urine and vaginal swabs using the BD ProbeTec™ *Trichomonas vaginalis* Qx Amplified DNA Assay on the BD Viper™ System in Extracted Mode and a cleared NAAT TV Assay as compared to PIS. Presented at the 20<sup>th</sup> biennial meeting of the ISSTD, Vienna Austria July 2013
72. **Van Der Pol B**, Williams JA, Eddleman L, Fuller D, Taylor SN, Schwebke J, Lebed J, Smith B, Nye M, Gaydos CA. Evaluation of a new amplified DNA assay on the Becton Dickinson Viper System in Extracted Mode for the detection of *Trichomonas vaginalis* from vaginal specimens. Presented at the 20<sup>th</sup> biennial meeting of the ISSTD, Vienna Austria July 2013
73. Gaydos CA, **Van Der Pol B**, Jett-Goheen M, Barnes M, Quinn N, Clark C, Daniel GE, Dixon P, Hook EW II. An easy to use real time PCR test for *Chlamydia trachomatis* and *Neisseria*

gonorrhoeae providing results that can guide treatment choices before the patient leaves the clinic. Presented at the 20<sup>th</sup> biennial meeting of the ISSTD, Vienna Austria July 2013

74. Williams JA, Eddleman LJ, LeMonte A, **Van Der Pol B**. Evaluation of a laboratory developed test for the detection of *Trichomonas vaginalis* using a modification of the Abbott m2000 Realtime System. Presented at the 20<sup>th</sup> biennial meeting of the ISSTD, Vienna Austria July 2013
75. Meyerson BE, **Van Der Pol B**, Arno JN, Zimet GD, Barclay L, Rivera I. Can STD clinics ride the cervical cancer screening bike? Experiences from an urban STD clinic. Presented at the 20<sup>th</sup> biennial meeting of the ISSTD, Vienna Austria July 2013
76. Schick V, Bell A, Neal C, Carberry J, **Van Der Pol B**, Dodge B, Fortenberry JD. STI screening and diagnosis history among women who have sex with women and men (WSWM). Presented at the 20<sup>th</sup> biennial meeting of the ISSTD, Vienna Austria July 2013
77. Schick V, Bell A, Neal C, Carberry J, **Van Der Pol B**, Dodge B, Fortenberry JD. Sexual behaviors and safety strategies of women who have sex with women and men (WSWM). Presented at the 20<sup>th</sup> biennial meeting of the ISSTD, Vienna Austria July 2013
78. Hubach R, Dodge B, Davis A, Smith AD, Zimet G, **Van Der Pol B**. Bacterial STD rates and preferred methods of STD service delivery among a sample of underserved Midwestern men. Presented at the 20<sup>th</sup> biennial meeting of the ISSTD, Vienna Austria July 2013
79. Williams JA, Weaver B, **Van Der Pol B**, Mi D, Fortenberry JD. *Mycoplasma genitalium* DNA detected from adolescent males in a longitudinal cohort. Presented at the 20<sup>th</sup> biennial meeting of the ISSTD, Vienna Austria July 2013
80. Gorwitz R, Sereday K, **Van Der Pol B**, Kwok C, Morrison CS, Papp J, Xu F, Markowitz L. Development and persistence of anti-chlamydial antibodies in women with incident chlamydial infections in Uganda and Zimbabwe. Presented at the 20<sup>th</sup> biennial meeting of the ISSTD, Vienna Austria July 2013
81. **Van Der Pol B**, Davis A, Smith AD, Williams JA, Zimet GD. Men's preferences for STD screening programs: initial prevalence of STD in the study population. Presented at the 20<sup>th</sup> biennial meeting of the ISSTD, Vienna Austria July 2013
82. **Van Der Pol B**, Williams JA, Daniel G, Hook EW III, Taylor SN. Performance of the BD MAX<sup>TM</sup> CT/GC/TV Assay for Detection of Chlamydia, Gonorrhea and Trichomonas. Presented at the Spring meeting of the British Association for Sexual Health & HIV. Glasgow, UK June 2015
83. Elope E, Van Wagoner N, **Van Der Pol B**, Whitfield M, Hook EW. Factors Associated with Acceptance of Genital Herpes Testing for Black Patients Presenting for Care at an STD Clinic. . Presented at the 21<sup>st</sup> biennial meeting of the ISSTD, Brisbane Australia Sep 2015

84. Dixon P, **Van Der Pol B**, Swerdlow J, Cammarata S, Sun E, Hook EW. Antimicrobial Susceptibilities of Persons with Gonorrhea at Multiple Sites are Accurately Reflected by Urogenital Specimens. Presented at the 21<sup>st</sup> biennial meeting of the ISSTD, Brisbane Australia Sep 2015
85. Young S, **Van Der Pol B**, Taylor S, Fife K, Hook EW, Patel R, Ding K, Hemyari P, Duncan J, Tang S, Liesenfeld O, Osiecki J, Lewinski M. Comparison of the cobas® HSV1/2 Test, Quidel Lyra™, BD ProbeTec™ HSV ½ Qx Assay and Sanger Sequencing using Clinician-collected Anogenital Lesion Swabs. Presented at the 21<sup>st</sup> biennial meeting of the ISSTD, Brisbane Australia Sep 2015
86. Geisler WM, Gorwitz R, Papp J, **Van Der Pol B**. Influence of *Chlamydia trachomatis* Organism Load on Reinfection Risk. Presented at the 21<sup>st</sup> biennial meeting of the ISSTD, Brisbane Australia Sep 2015
87. Dionne-Odom J, Aaron K, Daniels B, Hook EW, **Van Der Pol B**. Optimizing STI screening in HIV-infected men who have sex with men (MSM). Presented at the 22<sup>nd</sup> biennial meeting of the ISSTD, Rio de Janeiro July 2017
88. Xiao L, Waites KB, **Van Der Pol B**, Ratliff AE, Geisler W. Macrolide- and Fluoroquinolone-Resistant *Mycoplasma genitalium* in African Americans in Alabama. Presented at the 22<sup>nd</sup> biennial meeting of the ISSTD, Rio de Janeiro July 2017
89. Bruce J, Van Wagoner N, Culver A, Aaron K, **Van Der Pol B**. Offering STI testing in a community-based HIV prevention outreach program. Presented at the 22<sup>nd</sup> biennial meeting of the ISSTD, Rio de Janeiro July 2017
90. Roth AM, Aumaier B, Piecara BL, Szep Z, Chavis M, **Van Der Pol B**. Pre-exposure prophylaxis (PrEP) eligibility and barriers to uptake among persons who inject drugs recruited from a Syringe Exchange Program (SEP). Presented at the 22<sup>nd</sup> biennial meeting of the ISSTD, Rio de Janeiro July 2017
91. Dionne-Odom J, Westfall AO, Napravnik S, **Van Der Pol B**, Mugavero M, Kitahata M, Moore R, Rodriguez B, Karris M, Geng E, Mayer K, Marrazzo JM. Prevalence of chlamydia, gonorrhea and risk behaviors among women living with HIV in the United States; 2007-2016. Presented at the 2018 International Union Against STI World Conference, Dublin June 2018
92. Dionne-Odom J, Westfall AO, Napravnik S, **Van Der Pol B**, Mugavero M, Kitahata M, Moore R, Rodriguez B, Karris M, Geng E, Mayer K, Marrazzo JM. HIV status is associated with incident and prevalent sexually transmitted infection during pregnancy in Alabama: 2000-2014. Presented at the 2018 International Union Against STI World Conference, Dublin June 2018
93. **Van Der Pol B**, Daniel G, Kodosi S, Paradis S, Cooper C. Detection of co-infections with Sexually Transmitted Infections among women seeking care for Vaginitis. Presented at the 2018 International Union Against STI World Conference, Dublin June 2018



94. Pinninti S, **Van Der Pol B**, Daniel G, Fowler K, Boppana S. P242 Co-infections with cytomegalovirus (CMV) and sexually transmitted infections (STIs) in pregnant women. *Sex Transm Infect.* 2019;95(Suppl 1):A149-A. doi: 10.1136/sextrans-2019-sti.376.
95. Elope L, McDavid C, Johnson B, Gordon B, **Van Der Pol B**, Marrazzo J, et al. P420 Understanding PrEP service delivery preferences among black women in urban and rural counties in the US deep south. *Sex Transm Infect.* 2019;95(Suppl 1):A200-A1. doi: 10.1136/sextrans-2019-sti.506.
96. Dionne-Odom J, Long D, Westfall AO, **Van Der Pol B**, Mugavero M, Napravnik S, Crane H, Kitahata M, Moore R, Ridriguez B, Karris M, Geng E, Mayer K, Marrazzo J. A new prediction model for chlamydia and gonorrhea screening in women with HIV. Presented at the Conference on Retroviruses and Opportunistic Infections. Boston, March 2019
97. Balkus J, Proll S, Holm J, Srinivasan S, Dinwiddie D, **Van Der Pol B**, et al. P588 A multi-site comparative study to understand sources of variability in studies of the vaginal microbiota. *Sex Transm Infect.* 2019;95(Suppl 1):A262-A3. doi: 10.1136/sextrans-2019-sti.659. Presented at the 23<sup>rd</sup> meeting of the International Society for STD Research, Vancouver, July 2019
98. **Van Der Pol B**, Hardy K, Boutwell A. P600 *Mycoplasma genitalium* positivity rates in the US. *Sex Transm Infect.* 2019;95(Suppl 1):A266-A. doi: 10.1136/sextrans-2019-sti.668. Presented at the 23<sup>rd</sup> meeting of the International Society for STD Research, Vancouver, July 2019
99. **Van Der Pol B**, Daniel G, Engowei C, Dionne-Odom J. P604 Platform-agnostic reagents for detection of *Mycoplasma genitalium*. *Sex Transm Infect.* 2019;95(Suppl 1):A267-A8. doi: 10.1136/sextrans-2019-sti.672. Presented at the 23<sup>rd</sup> meeting of the International Society for STD Research, Vancouver, July 2019
100. Hardick J, Tan L, Ingles C, Denver C, **Van Der Pol B**, Jensen J, et al. P620 Inclusivity, exclusivity, stability and prospective testing of two real-time PCR assays for *Mycoplasma genitalium*. *Sex Transm Infect.* 2019;95(Suppl 1):A274-A. doi: 10.1136/sextrans-2019-sti.688. Presented at the 23<sup>rd</sup> meeting of the International Society for STD Research, Vancouver, July 2019
101. Aaron K, Brill I, Causey Z, Murphy K, Augenbraun M, Kassaye S, **Van Der Pol B**. P728 Correlates of syphilis in women living with and without HIV in the US women's interagency HIV study (WIHS). *Sex Transm Infect.* 2019;95(Suppl 1):A315-A. doi: 10.1136/sextrans-2019-sti.789. Presented at the 23<sup>rd</sup> meeting of the International Society for STD Research, Vancouver, July 2019
102. Taylor S, Daniel G, Torres-Chavolla E, Cooper C, Kodsí S, **Van Der Pol B** P787 *Trichomonas vaginalis* positivity rates by HIV status among women in a clinical study. *Sex Transm Infect.* 2019;95(Suppl 1):A336-A. doi: 10.1136/sextrans-2019-sti.842. Presented at the 23<sup>rd</sup> meeting of the International Society for STD Research, Vancouver, July 2019
- 103.

### **Abstracts with Posters Presented at National Meetings**

1. Jones RB, B **Van Der Pol**. Isolation of *Chlamydia trachomatis* from clinical specimens after prolonged passage in tissue culture. American Society for Microbiology, 86th Annual Meeting, March 23-28, 1986, Washington, D.C. Abst. No. C24.
2. Smith JW, RE Rogers, BP Katz, JF Braickler, PL Lineback, B **Van Der Pol**, RB Jones. Comparison of semi-quantitative culture with MicroTrak and Chlamydiazyme for diagnosis of chlamydia, 26th ICAAC, 9-3-86, New Orleans, LA.
3. Laughton BE, JM Ehret, HH Handsfield, RB Jones, FN Judson, T Tanino, B **Van Der Pol**. Fluorescent monoclonal antibody for confirmation of *Neisseria Gonorrhoeae* cultures. American Society for Microbiology, annual Meeting, March 10-6, 1987, Atlanta, GA.
4. Nettleman MD, B **Van Der Pol**, RB Jones. Evaluation of serological tests for diagnosis of *Chlamydia trachomatis* infection in low risk women. 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, NY, October 4-7, 1987, Abst. No. 730.
5. Jones RB, B **Van Der Pol**, BE Batteiger. Prevalence of heterotypic resistance among isolates of *C. trachomatis* (Ct) from selected populations. 30th ICAAC meeting, October 22-24, 1990, Atlanta, Georgia.
6. Williams JA, B **Van Der Pol**, RB Jones. Comparison of a chemiluminescent EIA assay on urine specimens to cell culture for the detection of chlamydia. 95th General Meeting of the American Society of Microbiology. May 21-25, 1995. Washington, D.C.
7. **Van Der Pol** B, JA Williams, RB Jones. Improved sensitivity of PCR for the detection of *Chlamydia trachomatis* using Chlamydia transport medium. 95th General Meeting of the American Society of Microbiology. May 21-25, 1995. Washington, D.C.
8. Birch ME, M Goldman, AI Hartstein, B **Van Der Pol**, CA Gaydos, RB Jones. Recovery of *Chlamydia pneumoniae* in culture of bronchoalveolar lavage specimens from immunosuppressed patients with pulmonary infiltrates. 1995 Meeting of the Infectious Diseases Society of America. San Francisco, CA. September, 1995
9. **Van Der Pol** B, RB Jones. In Vitro activity of cp99,219-27 against *Chlamydia trachomatis* . 35th Meeting of the Interscience Conference on Antimicrobial Agents & Chemotherapy. San Francisco, CA. September, 1995
10. **Van Der Pol** B, RW Pool, RB Jones. Use of a blocking assay for confirmation of *Chlamydia* infection identified by the Vidas antigen assay from swab & urine samples. 96th General Meeting of the American Society for Microbiology. New Orleans, Louisiana. May 19-23, 1996.
11. Ortiz L, K Demick, J Peterson, R Rudersdorf, M Angevine, R Jones, B. **Van Der Pol**, R DeMars. *Chlamydia trachomatis* "MOMP": human T cell epitopes and HLA class II restriction elements. 96th General Meeting of the American Society for Microbiology. New Orleans, Louisiana. May 19-23, 1996.

12. Leister SL, KA Crotchfelt, B **Van Der Pol**, RB Jones, K Smith, C Lenderman, EW Hook, TC Quinn and CA Gaydos. Comparison of the BD ProbeTec ET system to Ligase Chain Reaction (LCR) for the detection of *Chlamydia trachomatis* (CT) and *Neisseria Gonorrhoeae* (GC). 99th Annual Meeting of the American Society for Microbiology. Chicago, IL May, 1999
13. Lenderman CJ, KR Smith, EW Hook, S Leister, C Gaydos, T Quinn, RB Jones and B **Van Der Pol**. Evaluation of the BD ProbeTec ET System for *Neisseria Gonorrhoeae* and *Chlamydia trachomatis* diagnosis using urine or swab specimens from females attending STD clinics. 99th Annual Meeting of the American Society for Microbiology. Chicago, IL May, 1999.
14. Salim H, T Edens, K Davis, AP Cullen, H Erdman, VW Chou, L Scarce, J Blutman, WJ Payne, B **Van Der Pol**, JA Williams, NJ Smith, BE Batteiger. Comparison of Semi-Automated and Manual Hybrid Capture® 2 CT/GC DNA Test Methods on Cervical Specimens. 101st Annual Meeting of the American Society for Microbiology. Orlando FL May 2001
15. **Van Der Pol** B, JA Williams, BE Batteiger, JD Fortenberry, DP Orr. Multiple sexually transmitted infections within sexual dyads. 2002 National STD Prevention Conference. San Diego, CA March, 2002
16. **Van Der Pol** B, BE Batteiger, DP Orr, JD Fortenberry. Early incident STI in adolescent women. 2002 National STD Prevention Conference. San Diego, CA March, 2002
17. Tosh A, B **Van Der Pol**, BP Katz, BE Batteiger, JA Williams, DP Orr, JD Fortenberry. Mycoplasma genitalium infections among adolescent women and their partners. Presented at the 2005 Annual Meeting of the Society for Adolescent Medicine in Los Angeles, CA.
18. Marshall RL, J Robinson, J Yu, B **Van Der Pol**, JA Williams, SY Ho, JF Welk, J Lai-Zhang, KS Otis, and EM Webb. Detection of *Chlamydia trachomatis* and *Neisseria Gonorrhoeae* in clinical samples by the Abbott m2000 Automated Magnetic Sample Preparation Instrument combined with Multiplex Homogeneous Real-Time PCR and performance correlation to an on-market assay. Presented at the 106th ASM meeting, Orlando, Florida May 2006.
19. Morrison CS, C Kwok, K Demers, L Murphy, A Rinaldi, B **Van Der Pol**, PL Chen, T Chipato, F Mmiro, E Arts, R Salata. Predictors of high HIV-1 cervical viral loads during early HIV-1 infection among women in Uganda and Zimbabwe. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, 25-28 Feb, 2007, Los Angeles
20. **Van Der Pol** B, D Brooks, K Curd, JN Arno. *Trichomonas vaginalis* in a population at high risk for other STI and HIV. Presented at the CDC STD Prevention Conference, March 10-13 2008, Chicago
21. Wolfe D, Hook EW, Mena L, Taylor S, **Van Der Pol** B, Eckert K. Evaluation of the BD Viper™ System in Extracted Mode to Detect *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in Male Swab and Urine Specimens. Presented at the Clinical Virology Symposium. Daytona Beach, April 2008

22. Lebed J, D Fuller, S Ginde, EW Hook, W LeBar, M Martens, W McCormack, L Mena, S Taylor, B **Van Der Pol**, C Meyers. Performance of Surepath® preservative fluid specimens with the BD ProbeTec CT/GC Qx amplified DNA assays on the BD Viper™ System with XTR™ technology. Presented at Clinical Virology Symposium, 17-22 April 2009, Daytona Beach
23. Rosenberger JG, B Dodge, B **Van Der Pol**, M Reece, A Roth, D Herbenick, JD Fortenberry. A qualitative exploration of experiences with self-sampling for rectal sexually transmitted infections (STI) among men who have sex with men (MSM). American Public Health Association, Philadelphia, PA. 2009
24. Blakely W, J Arno, C Campbell, B **Van Der Pol**. Characteristics of African American MSM attending an STD clinic 2004-2009. Presented at the 7th Biennial CDC STD Prevention Conference in Atlanta, GA 2010
25. Wiehe S, J Arno, M Rosenman, B **Van Der Pol**, JD Fortenberry. Missed opportunities for *Chlamydia* testing: A look into (non) overlapping clinical and public health data. Presented at the 7th Biennial CDC STD Prevention Conference in Atlanta, GA 2010
26. Robertson C, A Smith, J Arno, J Madlem, J Brand, B **Van Der Pol**, K Fife. The integration of HSV2 serologic testing in a public health STD clinic. Presented at the 7th Biennial CDC STD Prevention Conference in Atlanta, GA 2010
27. Roth A, G Zimet, B Dodge, B **Van Der Pol**. Low acceptance of HSV-2 testing among high-risk women. Presented at the 7th Biennial CDC STD Prevention Conference in Atlanta, GA 2010
28. Curd K, B **Van Der Pol**, C Knochel. Home collection test kits for Gonorrhea and *Chlamydia* at alternative venues, pharmacy pilot project. Presented at the 7th Biennial CDC STD Prevention Conference in Atlanta, GA 2010
29. Madlem J, C Campbell, B **Van Der Pol**, J Arno. A longitudinal evaluation of Quinolone Resistant N. *Gonorrhoeae* and effects of treatment change. Presented at the 7th Biennial CDC STD Prevention Conference in Atlanta, GA 2010
30. Roth A, J Rosenberger, B **Van Der Pol**, M Reece. Condom negotiation during transactional sexual exchanges. Presented at the 7th Biennial CDC STD Prevention Conference in Atlanta, GA 2010
31. Waters J, J Arno, B **Van Der Pol**, M Arnold, A Roth, K Curd. Integrating public health into the sex worker community in Indianapolis. Presented at the 7th Biennial CDC STD Prevention Conference in Atlanta, GA 2010
32. Rosenberger J, A Roth, M Reece, B **Van Der Pol**. Acceptability of STI testing among women and men engaging in transactional sex. Presented at the 7th Biennial CDC STD Prevention Conference in Atlanta, GA 2010

33. Smith A, C Robertson, B **Van Der Pol**. Streamlining services to increase patient capacity at an urban STD clinic. Presented at the 7th Biennial CDC STD Prevention Conference in Atlanta, GA 2010
34. Roth AM, JG Rosenberger, M Reece, B **Van Der Pol**. Risk negotiation in transactional sexual exchanges. Annual Meeting of the Desiree Alliance, Las Vegas. 2010
35. Roth A M, JD Fortenberry, G Zimet, B Dodge, B **Van Der Pol**, M Reece. Community-based participatory research with the justice system to enhance STI testing and treatment. Annual Meeting of the American Public Health Association, Denver. 2010
36. Dodge B, R Nix, O Martinez, M Reece, B **Van Der Pol**, PW Schnarrs, D Malebranche, JD Fortenberry. Connecting hidden communities for research collaboration: a community-based study of sexual health among bisexual men. Annual Meeting of the American Public Health Association, Denver. 2010
37. Roth AM, B Dodge, B **Van Der Pol**, M Reece, G Zimet. Court-based herpes simplex 2 point-of-care testing: collaborating with the judicial system to improve access to sexual health screening. Presented by Roth at the Society for Adolescent Health & Medicine Conference, Seattle, WA, April 2011.
38. **Van Der Pol** B, JA Williams, A Pantone, SN Taylor. Reproducibility of the BD HSV Qx assays using universal transport medium and Qx swab diluent or Qx swab diluent for detection of HSV-1 and 2. 27th annual meeting of the Clinical Virology Society. Daytona Beach, May, 2011
39. Hires LJ, JA Williams, A Pantone, B **Van Der Pol**. Time-motion analysis of three automated and one semi-automated platforms for the detection of *Chlamydia trachomatis* and *Neisseria Gonorrhoeae* by NAAT. 111th annual meeting of the American Society for Microbiology, New Orleans, May, 2011
40. Pantone A, JA Williams, LJ Hires, B **Van Der Pol**. Reproducibility of *Chlamydia trachomatis* and *Neisseria Gonorrhoeae* quantification standards using a commercially available assay. 111th annual meeting of the Society for Microbiology. New Orleans, May, 2011
41. Farrell M, P Fine, C Cammarata, SN Taylor, EW Hook, B **Van Der Pol**, B Body, M Nye, M Martens, S Ginde, J LeBed, L Mena, L Corey, T Warren. Clinical evaluation of the BD ProbeTec HSV1 and HSV2 Qx amplified DNA assays for the direct qualitative testing of HSV 1 & 2 from lesions collected with the Qx swab from men and women. 111th annual meeting of the Society for Microbiology. New Orleans, May, 2011
42. Dodge B, P Schnarrs, G Goncalves, M Reece, O Martinez, D Malebranche, R Nix, B **Van Der Pol**, JD Fortenberry. Administering Sexual Health-Related Services to Bisexual Men: Privacy, Trust, and Appropriate Messaging. Annual Meeting of the American Public Health Association, Washington DC. Nov 2011 [Winner Best Overall Abstract, NIV/AIDS Section]

43. Rosenberger, J.G., Schick, V., **Van Der Pol, B.**, Herbenick, D., Novak, D.S., & Fortenberry, J.D., and Reece, M. (November, 2011). Enema Attitudes and Behaviors among Gay and Bisexual Men in the United States. Presented at the annual meeting of the Society for the Scientific Study of Sexuality. Houston, Texas.
44. Dodge B, Schnarrs P, Goncalves G, Reece M, Martinez O, Malebranche D, Nix R, **Van Der Pol B**, Fortenberry JD. Subjective experiences of behaviorally bisexual men: Attraction, behaviors, and condom use, 140<sup>th</sup> Annual meeting of the American Public Health Association, San Francisco, CA November 2012
45. Schick, V., Bell, A., Neal, C., Carbery, J., Bay-Cheng, L., Dodge, B., **Van der Pol, B.**, Fortenberry, D. (November, 2012). The Sexual Event History Calendar (SEHC) Database: The Development of a New Tool to Capture Detailed Data for Complex Sexual Events. Society for the Scientific Study of Sexuality Anna Meeting. Tampa, Florida.
46. Gaydos CA, Williams JA, Quinn N, Eddleman LJ, Fuller D, Taylor SN, Schwebke J, Lebed J, Smith B, Nye M, **Van Der Pol B.** Performance of a new amplified DNA assay on the BD Viper System in Extracted Mode for the detection of *Trichomonas vaginalis* in women from cervical, vaginal and urine specimens. Presented at the 29th annual Clinical Virology Symposium, Daytona Beach, FL April 2013
47. Fuller D, Taylor SN, Schwebke J, Lebed J, Smith BK, **Van Der Pol B**, Body B, Nye M, Gaydos CA, Davis T. PPA and NPA for ProbeTec™ *Trichomonas vaginalis* (TV) Qx Amplified DNA Assay as compared to the Aptima TV Assay. Presented at the 113<sup>th</sup> Annual meeting of the American Society for Microbiology, Denver CO May 2013
48. **Van Der Pol B**, Taylor SN, Schwebke J, Lebed J, Fuller D, Smith BK, Body B, Nye M. A new molecular assay for detection of *T. vaginalis* on the BD Viper System. Presented at the 113<sup>th</sup> Annual meeting of the American Society for Microbiology, Denver CO May 2013
49. Baldwin, A., Dodge, B., Hubach, R., Schick, V., Gonclaves, G., Schnarrs, P., Martinez, O., Reece, M., **Van Der Pol, B.**, Malebranche, D., Fortenberry, J.D. Sexual identity among behaviorally bisexual men: Implications for HIV/STI and sexual health. American Public Health Association Annual Meeting. Boston, Massachusetts. November, 2013
50. Schick, V., Bell, A., Neal, C., Carbery, J., Dodge, B., **Van Der Pol, B.**, Fortenberry, D. Experiences of Three(or More)Somes Reported by Women Who Have Sex With Women and Men. Society for the Scientific Study of Sexuality Annual Meeting. San Diego, CA. November 2013
51. Barnhart K, Dodge BM, Hubach RD, **Van Der Pol B**, Reece M. Impact of re-entry programs on substance use and sexual risk trends among men recently released from incarceration. Presented at the 141<sup>st</sup> Annual Meeting of the American Public Health Association, Boston, MA. November 2013
52. Baldwin A, Dodge BM, Hubach RD, Goncalves G, Schnarrs P, Martinez O, Reece M, **Van Der Pol B**, Malebranche D, Fortenberry, JD. Sexual identity among behaviorally bisexual men:

Implications for HIV/STI and sexual health. Presented at the 141<sup>st</sup> Annual Meeting of the American Public Health Association, Boston, MA. November 2013

53. **Van Der Pol B**, Hubach R, Zimet GD, Dodge B. Preferred methods of STI service delivery among an urban sample of underserved Midwestern men. Presented at the 141<sup>st</sup> Annual Meeting of the American Public Health Association, Boston, MA. November 2013
54. Lewinski M, Duncan J, Krevolin M, Nye M, **Van Der Pol B**, Eisenhut C, Taylor S, Young S, Hook E, Butcher A, Leisenfeld O, Osiecki J. Performance of the Roche cobas CT/NG v2.0 test for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in urogenital swabs, urine and cervical samples collected in PreservCyt solution from asymptomatic women. Presented at the 114<sup>th</sup> annual meeting of the American Society for Microbiology. Boston, MA May 2014
55. Lewinski M, Duncan J, Krevolin M, Butcher A, Nye M, **Van Der Pol B**, Eisenhut C, Taylor S, Young S, Hook E, Leisenfeld O, Osiecki J. Evaluation of cervical samples collected in PreservCyt solution with the cobas CT/NG v2.0 test before and after processing on the ThinPrep 2000 system to assess sample contamination in a large clinical trial study.. Presented at the 114<sup>th</sup> annual meeting of the American Society for Microbiology. Boston, MA May 2014
56. Meyerson BE, **Van Der Pol B**, Davis A, Zimet GD, Arno JN. Can STD Clinics Reach Women in Need of Cervical Cancer Screening? If They Can, Does It Matter? Presented at the 2014 CDC STD Prevention Conference. Atlanta, GA June 2014
57. Davis A, Meyerson BE, Sayegh MA, Zimet GD, Arno JN, Barclay L, **Van Der Pol B**. “I’ve had a Pap, but I haven’t been screened for Cervical Cancer:” HPV health literacy among women screened for Cervical Cancer at an urban STD clinic: If They Can, Does It Matter? Presented at the 2014 CDC STD Prevention Conference. Atlanta, GA June 2014
58. Meyerson BE, **Van Der Pol B**, Davis A, Zimet GD, Arno JN. Can STD clinics reach women in need of cervical cancer screening? If they can, does it matter? Presented at the 2014 CDC STD Prevention Conference and 15<sup>th</sup> World IUSTI Meeting. Atlanta, Georgia June 2014
59. Schick, V., Dodge, B., Bay-Cheng, L., **Van der Pol, B.**, Fortenberry, D. Sexual Behaviors, Sex Toy and Condom Use Reported by Women who have Sex with Women and Men (WSWM). 2014 Annual Meeting of the American Public Health Association. New Orleans, LA. November 2014
60. Bowling, J., Schick, V., Dodge, B., Baldwin, A., Neal, C. Hubach, R., Bay-Cheng, L., **Van der Pol, B.**, Fortenberry, D. Behaviorally Bisexual Women's Experiences of Perceived Discrimination from Heterosexual and Gay/Lesbian Individuals. 2014 Annual Meeting of the American Public Health Association. New Orleans, LA. November 2014
61. Baldwin, A. M., Schick, V., Dodge, B., Bay-Cheng, L., **Van Der Pol, B.**, Fortenberry, J. D. Complexity in sexual identification among women who have sex with women and men. Presented at the 2014 meeting of the Society for the Scientific Study of Sexuality. Omaha, NE Nov 2014

62. Davis A, Meyerson B, Sayegh A, Zimet GD, Arno JN, Barclay L, **Van Der Pol B**. Incongruence between reported Pap test history and cervical cancer screening history as an indicator of patient HPV-related literacy. Presented at the 142<sup>nd</sup> Annual Meeting of the American Public Health Association, New Orleans, LA. November 2014
63. Williams JA, Fife KH, **Van Der Pol B**. Reproducibility of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* quantification standards using two commercially available assays. Presented at the 115<sup>th</sup> Annual meeting of the American Society for Microbiology. New Orleans, LA. May 2015
64. Aumeir B, Szep Z, Martinez-Donate AP, **Van Der Pol B**, Wells S, Chavis M, Roth AM. Acceptability of pre-exposure prophylaxis (PrEP) among persons who inject drugs. Presented at: Building HIV Research Collaborations in Philadelphia Conference; Philadelphia, PA. January 2016
65. Goldshear JL, **Van Der Pol B**, Wells S, Martinez-Donate AP, Williams R, Roth AM. Prevalence and correlates of chlamydia and gonorrhea among persons who inject drugs in Camden, New Jersey. Presented at: Building HIV Research Collaborations in Philadelphia conference. Philadelphia, PA. January 2016
66. Aumeir B, Szep Z, Martinez-Donates A, **Van Der Pol B**, Wells S, Chavis M, Roth A. Facilitators and barriers to PrEP for persons who inject drugs. Presented at the 2016 APHA Annual Meeting in Denver, CO Oct 2016
67. Goldshear J, **Van Der Pol B**, Wells S, Martinez-Donates A, Roth A. Provision of STD control services at a syringe exchange increases chlamydia/gonorrhea case finding in persons who inject rugs. Presented at the 2016 APHA Annual Meeting in Denver, CO Oct 2016
68. Roth A, Goldshear J, Martinez-Donate A, Welles S, Chavis M, **Van Der Pol B**. Pairing STI control and syringe exchange services increases case finding among persons who inject drugs. Presented at the 2016 CDC STD Prevention Conference. Atlanta, GA Sep 2016
69. Roth A, Aumaier B, Gross R, Martinez-Donate A, Szep Z, **Van Der Pol B**. Towards understanding factors impacting pre-exposure prophylaxis (PrEP) among persons who inject drugs. Presented at the 2016 CDC STD Prevention Conference. Atlanta, GA Sep 2016
70. Gupta K, **Van Der Pol B**, Press C, Gorwitz R, Papp J, Geisler W. *Chlamydia trachomatis* reinfection is associated with lower organism load. Presented at the 2016 CDC STD Prevention Conference. Atlanta, GA Sep 2016
71. Dionne-Odom J, Aaron K, Banasiewicz M, Dougherty S, Daniels B, Raper J, Hook EW III, **Van Der Pol B**. Screening for extragenital CT/GC among HIV-infected MSM: a comparison of 4 NAATs. Presented at the 2018 Conference on Retroviruses and Opportunistic Infections. Boston, MA Mar 2018
72. Dionne-Odom J, Westfall AO, Napravnik S, **Van Der Pol B**, Mugavero M, Kitahata M, Moore R, Rodriguez B, Karris M, Geng E, Mayer K, Marrazzo JM. Chlamydia and Gonorrhea Screening in



Women with HIV in a Multisite US Cohort; 2007-2016. Presented at the 2018 ASTDA/CDC STD Prevention Conference, Washington, DC Aug 2018

73. Daniels B, Boutwell A, Daniel G, **Van Der Pol B**. Real world assessment of willingness to wait for rapid STI screening. Presented at the 2018 ASTDA/CDC STD Prevention Conference, Washington, DC Aug 2018
74. Dionne-Odom J, Westfall AO, Naparvnik S, **Van Der Pol B**, Mugavero M, Kitahata M, Moore R, Rodriguez B, Karris M, Geng E, Mayer K, Marrazzo JMM. Prevalence of chlamydia and gonorrhea and risk behaviors among women living with HIV in the United States; 2007-2016. Presented at the Infectious Diseases Society of America annual conference, San Francisco, CA Oct 2018
75. Dionne-Odom J, Long DM, Westfall A, **Van Der Pol B**, Mugavero MJ, Napravnik S, Crane HM, Kitahata M, Moore RD, Rodriguez B, Karris MY, Geng E, Mayer KH, Marrazzo JM. A new prediction model for chlamydia and gonorrhea screening in women with HIV. Presented at the Conference on Retroviruses and Opportunistic Infections. Seattle, WA Mar 2019
76. Roth AM, Piecara BL, Felsher M, Gadegbeku A, Krakower D, Amico R, Katumkeeryil E, **Van Der Pol B**. Towards Understanding Pre-Exposure Prophylaxis Adherence among Women who Inject Drugs. Poster presentation at: 14th International Conference on HIV Treatment and Prevention Adherence; June 2019; Miami, Florida, USA.
77. Felsher M, Piecara B, Krakower D, Bellamy S, Laurano R, **Van Der Pol B**, Roth A. Offering PrEP care within a community-based syringe exchange facilitates uptake among women who inject drugs. Presented at the American Public Health Association Annual Conference, Nov 2019, Philadelphia PA
78. Griner S.B., **Van Der Pol, B.**, Yockey, R.A., Kline, N., & Thompson, E.L. (2021). Self-collected, mailed samples for sexually transmitted infection screening: Costs, pricing, and payment options among young women. American Public Health Association Conference, Denver, CO
79. Griner, S.B., Allison, W., Nelsen, M., **Van Der Pol, B.**, Johnson, K., Kinard, A., & Lemuz, T. (2022). Gonorrhea Vaccine Acceptability among Young Adults and Parents of Adolescents. American Public Health Association 2022 Annual Meeting. Boston, MA. (Submitted).
80. Lemuz, T., Johnson, K., Kinard, A., Kline, N., **Van Der Pol, B.**, & Griner, S.B., (2022). Gender non-conforming young adults: Perceptions of chlamydia and gonorrhea vaccines. American Public Health Association 2022 Annual Meeting. Boston, MA. (Submitted).
81. Kinard, A., Johnson, K.C, Lemuz, T., **Van Der Pol, B.**, & Griner, S.B. (2022). Young adult acceptance and perceived barriers to future chlamydia vaccines. American Public Health Association 2022 Annual Meeting. Boston, MA. (Submitted).

## **ORAL PRESENTATIONS**

### **Scientific Papers Presented at National & International Meetings**

1. **Van Der Pol B, JA Williams, RB Jones.** Amplification using culture transport medium to resolve discrepancies between urine PCR and urethral swab culture for *Chlamydia trachomatis*. 11th Meeting of the International Society for STD Research, New Orleans, Louisiana, USA. August 1995
2. **Van Der Pol B, JA Williams, RW Pools, K Wools, RB Jones.** Amplification by PCR & LCR of specimens collected in culture transport medium for the detection of *Chlamydia trachomatis*. 3rd European *Chlamydia* Meeting. Vienna, Austria. September 11-14, 1996.
3. **Van Der Pol B, JA Williams, RB Jones.** Multiplex amplification of *Chlamydia trachomatis*, *Neisseria Gonorrhoeae*, and *Trichomonas vaginalis* in genital specimens. Congress on Sexually Transmitted Diseases in a Changing Europe. Rotterdam, The Netherlands April, 2000
4. **Van Der Pol B, JA Williams, RB Jones.** Multiplex amplification of *Chlamydia trachomatis*, *Neisseria Gonorrhoeae*, and *Trichomonas vaginalis* in genital specimens. Congress on Sexually Transmitted Diseases in a Changing Europe. Rotterdam, The Netherlands April, 2000
5. **Van Der Pol B, JA Williams, NJ Smith, RB Jones.** Stability of vaginal swabs for the detection of chlamydia, gonorrhea and *Trichomonas* by polymerase chain reaction. 4th European *Chlamydia* Meeting Helsinki, Finland August, 2000
6. **Van Der Pol B, JA Williams, Center for Mental Health Services/Project Shield Collaborators.** Distribution of *Trichomonas vaginalis* infection in females at high risk for STI. 2002 National STD Prevention Conference. San Diego, CA March, 2002
7. **Van Der Pol B, JA Williams, BE Batteiger, DP Orr, JD Fortenberry.** Mycoplasma genitalium in Adolescent Women Participating in the Young Women's Project. BASHH/ASTDA Spring Meeting. Bath, UK May 2004.
8. **Van Der Pol B, C Kwok, A Rinaldi, RA Salata, F Mmiro, R Mugerwa, T Chipato, CS Morrison.** *Trichomonas vaginalis* as a Risk Factor for HIV Acquisition. Platform presentation at the XVI International AIDS Conference, 13-18 August, 2006, Toronto
9. **Van Der Pol B, EW Hook, S Taylor, CA Gaydos, L Mena.** Performance of the BD ProbeTec CT/GC Qx amplified DNA assays on the BD Viper™ System with XTR™ technology using male urine samples. Presented at Clinical Virology symposium, 17-22 April 2009, Daytona Beach
10. **Van Der Pol B, DE Nelson, JA Williams, A. Berger, JD Fortenberry.** Urogenital tract microbial communities in male STD clinic patients. Presented as a Platform at the 18th Biennial meeting of the International Society for Sexually Transmitted Diseases Research in London 2009
11. **Van Der Pol B, C Campbell, D Nguyen, B Dodge.** Addition of rectal amplified DNA testing improves *Chlamydia* case finding. Presented at the 25th International Union against STI – Europe Meeting, Tbilisi, Georgia, Sep 2010

12. **Van Der Pol B**, Mi D, Dong Q, Katz B, Rong R, Denski C, Nelson DE, Fortenberry JD. Impact of chlamydial infection on male urethral microbiota. Presented at the 7<sup>th</sup> meeting of the European Society for Chlamydia Research, Amsterdam, July 2012
13. **Van Der Pol B**, Williams JA, Daniel G, Hook EW III, Taylor SN. Performance of the BD MAX<sup>TM</sup> CT/GC/TV Assay for Detection of Chlamydia, Gonorrhea and Trichomonas. Presented at the Spring meeting of the British Association for Sexual Health & HIV. Glasgow, UK June 2015
14. **Van Der Pol B**. Incorporating Trichomonas Screening with CT/GC Testing Using the Multi-Plex BD MAX<sup>TM</sup> CT/GC/TV Assay. Presented at Clinical Virology symposium, Daytona Beach. May 2016
15. **Van Der Pol B**, Daniel G, Aaron K, Cooper CK, Kodosi S, Paradis S. Testing of BD MAX<sup>TM</sup> vaginal panel residual specimens using the BD MAX<sup>TM</sup> CT/GC/TV assay. Presented at the 22<sup>nd</sup> biennial meeting of the ISSTD, Rio de Janeiro July 2017
16. **Van Der Pol B**. Diagnostics for Women with Discharge. Presented at the 23<sup>rd</sup> meeting of the International Society for STD Research, Vancouver, July 2019
17. **Van Der Pol B**. Clinical Performance of the cobas TV/MG Assay for Detection of *Mycoplasma genitalium*. Presented at the 23<sup>rd</sup> meeting of the International Society for STD Research, Vancouver, July 2019